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ABSTRACT OF THESIS 
 
CHANGES TO THE EQUINE HINDGUT MICROFLORA IN  
RESPONSE TO ANTIBIOTIC CHALLENGE 
 
 
Antibiotics are important to equine medicine, but can cause detrimental side-
effects including reduced feed intake, allergic reactions, and diarrhea. Antibiotic-
associated diarrhea (AAD) is attributed to disruption of the hindgut microflora, 
permitting proliferation of pathogenic microbes. The objectives were to evaluate the 
effects of antibiotics on beneficial fecal bacteria, AAD-associated pathogens, microbial 
species richness and fermentation. Horses were assigned to treatment groups: control (no 
antibiotics, n=6), trimethoprim-sulfadiazine (oral, n=6), or sodium ceftiofur (IM, n=6). 
Fecal samples were taken during adaptation (3 wk), antibiotic challenge (1 wk), and 
withdrawal (1 wk). Fecal cellulolytics decreased by >99% during challenge and did not 
recover during withdrawal (P < 0.0001).  Lactobacilli decreased by >60% during 
challenge (P = 0.0453). Salmonella spp. increased 94% with trimethoprim-sulfadiazine 
challenge (P = 0.0115). There was no detectable Clostridium difficile during adaptation 
or in any control horse. C. difficile increased (P < 0.0001) when horses were challenged, 
and remained elevated 7 d after withdrawal. There was no effect of challenge on in vitro 
digestibility or microbial species richness as evaluated by denaturing gradient gel 
electrophoresis (P > 0.05).  These results indicate that antibiotics can disrupt the normal 
flora and allow proliferation of pathogens, even without affecting digestibility and 
causing AAD.  
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Chapter 1: Introduction 
Antibiotic therapy is commonly used in horses to treat and prevent undesirable 
bacterial infections.  Data on the economic importance of antibiotics to the equine 
industry are not currently available. However, it can be speculated that antibiotic 
treatment can decrease infection rates, death loss, recovery time and loss of performance 
(Gustafson and Bowen, 1997).  Unfortunately, there are also detrimental effects of 
antibiotic therapy such as reduced feed intake, allergic reactions, and diarrhea (Wilson, 
2001). Antibiotic associated diarrhea (AAD) can range in severity from mild transient 
diarrhea to severe acute diarrhea which can be life threatening (Gustafsson, 2004). In a 
retrospective study of horses in a veterinary hospital with acute diarrhea, it was 
demonstrated that horses that had been treated for AAD were 4.5 times less likely to 
survive than horse treated for non-antibiotic associated diarrhea (Cohen et al., 1999).  
The underlying mechanism of AAD is believed to be disruption of the normal 
microflora by antibiotics, allowing overgrowth of potentially pathogenic bacteria 
(Dethlefsen et al., 2008).  However, very little research has been done to date to 
document the effects of antibiotic administration on the normal microflora and 
consequent pathogen proliferation in the horse.  In a study by White and Prior (1982), 
when horses were treated with oxytetracycline there was a decrease in Veillonella spp. 
which was coincident with an increase in the pathogen Clostridium perfringens.  The 
pathogens most commonly implicated in equine AAD are Clostridium perfringens, 
Clostridium difficile and Salmonella spp. (Weese et al., 2001; Hillyer, 2004).  The results 
of White and Prior (1982) are consistent with the hypothesis that antibiotic treatment 
leads to disruption of the normal flora allowing colonization of pathogens. However, the 
effects of antibiotics on other mutualistic normal flora and overall microbial species 
richness have not been explored.  
The normal flora of humans and food-animals, like ruminants, are well 
characterized in existing literature. However, less research has been performed to study 
t     r     qu         ut   r    r   S v r   ― u  t       r ups‖  r  u   s   v       
identified in the equine hindgut (De Fombelle et al., 2003).  These include the lactate-
utilizers (e.g. Veillonella spp.), saccharolytic bacteria, proteolytic bacteria, cellulolytic
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bacteria, etc. These guilds are composed of many ecological niches that are responsible 
for utilization of specific su str t s    t     rs ‘s    t   For example, horses primarily 
consume fibrous plant material and the enzymes required to metabolize plant structural 
carbohydrates (e.g. cellulose and hemicellulose) are strictly microbial.  Thus, the 
cellulolytic bacteria, which produce the enzyme cellulase, are arguably the most 
important mutualist guild in the equine hindgut. Additionally, lactobacilli are known to 
occupy niches within the saccharolytic guild in healthy horses (Al Jassim et al., 2006). 
Therefore, the presence of a stable microflora in the hindgut plays a critical role in 
determining the nutrients that are available to the horse for utilization.  Furthermore, if 
these guilds are disrupted by antibiotic treatment, even without diarrhea onset, there 
could be consequences in microbial fermentative digestion and feed utilization by the 
horse.  
 The objectives of the current study were to determine the effects of two common 
antibiotics on 1) the lactobacilli, cellulolytic bacteria, AAD-associated pathogens and 
overall microbial species richness in healthy horses and 2) microbial fermentative 
digestion and the production of energetic end-products (volatile fatty acids). The 
hypotheses of this study were 1) that one or both of the mutualist groups would decrease 
after antibiotic challenge, and there would be a concomitant increase in C. perfringens, C. 
difficile or Salmonella spp., 2) microbial species richness would be altered with antibiotic 
challenge and 3) microbial fermentative digestion would be compromised by antibiotic 
challenge leading to a decrease in digestibility and energetic end-product production 
(volatile fatty acids).  
Not all horses that are administered antibiotics develop AAD, so it is important to 
understand why some horses are able to maintain a healthy microflora while others 
cannot.  In addition, understanding the severity and duration of microbial disturbances 
that occur with antibiotic treatment and its effects on digestion of feedstuffs, could aid in 
devising intervention strategies to mitigate these disturbances.  Some prospective 
prevention or intervention options could include: supplemental antimicrobials, 
vaccinations, dietary interventions, probiotics, prebiotics, etc.   
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Chapter 2: Literature Review 
Gastrointestinal Anatomy  
Horses are classified as herbivores, which means their diet primarily consists of 
plant material and is extremely fibrous.  To ensure that the fibrous diet provided to horses 
 s    qu t  t    t t     rs ‘s    r y r qu r    ts  t    qu      str   t st     tr  t 
(GIT) has evolved to meet their specific digestive needs.   The equine GIT is considered 
monogastric, which means horses only have one simple single-chambered stomach, as 
opposed to other herbivores like ruminants that have stomachs with multiple 
compartments.  Furthermore, horses have a functional cecum (fermentation vat) and a 
large colon containing an active population of microbes that through their symbiotic 
relationship with the horse, aid in digestion and nutrient utilization of their diet.  For this 
reason horses are classified as hindgut fermenters.   
T    tur    rs ‘s GIT  s  v r 50              s sts    t    ut    s p   us  
stomach, small intestine (duodenum, jejunum and ileum), cecum, large colon, small colon 
and rectum.  The stomach of the horse is relatively small when compared to the capacity 
of the entire GIT (~8% capacity; Colin, 1871 as cited by Hintz and Cymbaluk, 1994). In 
fact, the stomach capacity of an adult horse (mature BW ~500 kg) is only about double 
t   s z        tur  p  ‘s st      (mature BW ~165 kg; Stevens, 1977).  This small 
stomach size is in result of their evolution as continuous grazers, designed to utilize small 
frequent meals.  
   The small intestine of the horse is ~20 m long and has a capacity of ~64 L when 
fully distended. It is the longest section of the equine GIT at 75% of the total length and 
is second in capacity only to the large colon (Colin, 1871 as cited by Hintz and 
Cymbaluk, 1994; Smyth, 1988). The equine small intestine is very similar in structure 
and function to the small intestine in other domestic animals. It is the primary site of 
absorption of amino acids from protein digestion, fatty acids from digestion of the lipid 
component of the diet, sugars from digested starch, vitamins A, D, E and K and some 
minerals including Ca and P.  
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The most unique portion of the equine GIT is the hindgut, consisting of the cecum 
and large colon.  The cecum accounts for 15% of the horse‘s total GIT and has a holding 
capacity of 26 – 33 L.   The large colon accounts for 38% of the horse‘s GIT with a 
holding capacity of 81 L (Colin, 1871 as cited by Hintz and Cymbaluk, 1994).  All 
material not digested in the foregut passes into the hindgut where it undergoes microbial 
fermentation. The cecum and large colon are described as being functionally analogous to 
the rumen and reticulum, containing billions of bacteria, fungi, archaea and protozoa that 
serve in a symbiotic relationship with the horse. These microflora enable the horse to 
digest cellulose and other fibrous fractions of the feed that would otherwise not be 
ut   z    I     t  w        rs   s    su         y    t  57%    t     rs ‘s t t         
glucose is from propionate produced by microbial fermentation in the cecum and colon 
(Ford and Simmons, 1985; Simmons and Ford, 1991).   
The hindgut of the horse is also unique in its structural characteristics. The colon 
is sacculated, which reduces the passage rate allowing for prolonged exposure of the 
digesta to microbial fermentation. This anatomical characteristic also allows for a greater 
holding capacity and surface area for absorption of nutrients (Hintz and Cymbaluk, 
1994). These sacculations probably evolved when horses were primarily maintained on 
pasture, spending the majority of their time grazing. Therefore, they ensure that the 
microflora of the hindgut receive a steady supply of fermentable material at all times, 
maintaining the health and stability of the hindgut microflora. However, not all modern 
horses are provided with the opportunity to primarily and continuously consume forage. 
Some horses are subjected to meal-feeding practices consisting of large amounts of feed 
high in starch and low in fiber provided usually in one to three meals a day. Because of 
this, digestive disturbances are of great concern with modern feeding and management 
practices.  
Mutualistic Fermentative Digestion 
The Normal Intestinal Microflora 
 The equine microflora include protozoa, fungi, archaea and bacteria (Julliand, 
1992).  It has been demonstrated that microflora are present in the stomach (De Fombelle 
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et al., 2003), small intestine (Mackie and Wilkins, 1988), cecum (Kern et al., 1973) and 
colon (Kern et al., 1974) of the horse. However, activity and composition varies between 
segments of the GIT.   These microflora are essential for digest       t     rs ‘s   r    
diet.  Equine diets ideally are high in structural carbohydrates (cellulose and 
hemicellulose) which are not susceptible to mammalian enzymes, and require microbial 
enzymes for utilization. It has been demonstrated, that 70% to 80%    t     rs ‘s t t   
energy absorbed are from volatile fatty acids (VFAs; Ford and Simmons, 1985; Simmons 
and Ford, 1991; Al Jassim and Andrews, 2009).  These VFAs are produced by hindgut 
microbial fermentation activity (Vermorel and Martin-Rosset, 1997).  The equine 
microflora also play a role in both immunological function (Macpherson and Harris, 
2004) and in pathogen defense (Vollaard and Clasener, 1994).  However, mechanistically 
these functions remain unclear and require further research.  Therefore, understanding 
composition and function of the microbial population, as well as managing the horse to 
maintain microbial stability, is essential to ensure equine health.  
Newborn foals have a sterile gastrointestinal tract.  It has been demonstrated that 
by 4 days of age, foals are already colonized by many bacterial species that are similar to 
their dam and continue to become more similar over time (Earing et al., 2012; Strasinger 
et al., 2012).  By adulthood the equine microflora is vast and complex with hundreds of 
     r  t    t r    sp    s    upy      y      r  t      s  ss  t    t  t     rs ‘s 
normal digestive function (Jones, 2000; Garrett et al., 2002).  In humans more than 500 
different enteric bacterial species have been isolated and greater than 99% of these 
species are anaerobic (Kerr, 1991; Vollaard and Clasener, 1994).   Although, there has 
been minimal research performed to characterize the equine microflora, horses are 
probably similar to humans having a wide variety of microbial species present with a 
large percentage consisting of anaerobic bacteria (Jones, 2000).   
The equine stomach is small in capacity and although rarely empty due to 
continuous consumption, the digesta passage rate is quick with little retention. There is 
continuous secretion of HCl in this organ, leading to a low pH which slows microbial 
fermentation and increases pepsin activity for proteolysis. However, some fermentative 
activity, although minimal in comparison to the hindgut, does occur in the equine 
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stomach. The stomach has been shown to have the highest anaerobic bacteria count of all 
GIT sections of ~1.45 x 10
9 
c.f.u. mL
-1
 (De Fombelle et al., 2003).  However, due to 
limitations in culture recovery, it is postulated that uncultivable anaerobic bacteria in the 
hindgut could make up for the differences observed between the stomach and other GIT 
compartments (Edwards et al., 2009).    The microflora of the stomach are primarily 
composed of Lactobacillus spp., Streptococci and lactate-utilizing bacteria. 
 Concomitantly, gastric fermentation is also believed to contribute to gastric 
malfunction. In a study by Nadeau and colleagues (2000), increasing concentrations of 
VFAs, were associated with increasing severity of gastric ulcers in horses. In a later 
study, it was demonstrated that this observed increase in severity was in result of the 
VFAs penetrating cells in the non-glandular region of the equine gastric mucosa, causing 
acidification of cell contents, inhibition of sodium transport and consequent cellular 
swelling (Nadeau et al., 2003).  A relationship between microbial changes in the foregut 
and the development of laminitis has also been indicated (Coenen et al., 2006).  
Additionally, microbial fermentation can lead to a large amount of gastric gas production 
which the horse has limited capacity to alleviate from the stomach due to its one-way 
esophagus (Moore et al., 2001). However, little research has been done to elucidate and 
characterize these detrimental effects as well as fermentative activity in the stomach of 
healthy horses.  
The small intestine, like the stomach, is a site of minimal fermentation.  However, 
the three sections of the small intestine (duodenum, jejunum and ileum) have been shown 
to have progressively larger cultivable numbers of bacteria when approaching the cecum 
(2.9 x 10
6 
c.f.u. g
-1
 to 3.84 x 10
7 
c.f.u. g
-1
; Mackie and Wilkins, 1988).   The small 
intestine is primarily responsible for enzymatic digestion and absorption of starch, lipids 
and protein.  Only 5-15% of cell wall carbohydrates are fermented in the small intestine 
(Van Weyenberg et al., 2006), therefore the majority of structural carbohydrates are 
subjected to hindgut fermentation. In addition, a significant portion of starch and protein 
can escape small intestinal digestion, making it to the hindgut. The amount of starch and 
protein in the diet that escapes small intestinal digestion is dependent on diet 
composition, amount fed, and feeding intervals.  
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The hindgut including the cecum and colon, are the primary sites of fermentation 
in the horse. These segments of the horse‘s GIT have the best characterized microflora. 
Bacteria in the hindgut can be classified into the following guilds; cellulolytic, 
proteolytic, glycolytic, lactate-utilizing, etc. It has been estimated that 80% of the bacteria 
present in the cecum and colon are strictly anaerobic (Kern et al., 1974) and total 
anaerobes have been demonstrated at concentrations of 2.59 x 10
9 
c.f.u. g
-1
 in the cecum 
and 6.1 x 10
8 
c.f.u. g
-1
 in the colon (Mackie and Wilkins, 1988). Furthermore, when using 
molecular analysis techniques, it was discovered that 89% of recovered sequences from 
the equine hindgut were not previously described. This finding indicates that the equine 
hindgut microflora may contain many novel bacterial species that are most likely 
overlooked when concentrations are based on strictly culture techniques (Daly et al., 
2001).   The predominant bacterial genera in the large intestine of horses include: 
members of the family Spirochaetaceae, the Cytophaga-Flexibacter-Bacteroides genera, 
Eubacterium rectal-Clostridium coccoides species and an unknown cluster of 
clostridiaceae. Each of these bacterial genera were found to represent between 10% to 
30% of the total microflora. Other bacterial genera identified included: the Bacillus-
Lactobacillus-Streptococcus and Fibrobacter each accounting for 1% to 10% of the 
normal flora (Daly and Shirazi-Beechey, 2003).   
Cellulolytic bacteria numbers have been shown to be higher in the cecum then in 
the lower portions of the hindgut (De Fombelle et al., 2003). The concentration in the 
cecum can be attributed to the unique structure of the organ.  The cecum of the horse is a 
large blind sac with both its entrance and exit opening located on the dorsal side of the 
organ. Therefore, in the cecum there is a longer retention time of particulate matter, 
allowing for a greater degree of cellulolysis in this organ because cellulolytic bacteria 
directly associate with particulate material when performing their metabolic function 
(Weimer, 1996).  Conversely, starch-utilizing bacteria (lactobacilli and streptococci) and 
lactate-utilizing bacteria tend to be lower in the cecum in comparison to the colon (De 
Fombelle et al., 2003).  This observation is because rapidly fermentable carbohydrates 
are most commonly associated with the liquid phase of digesta, allowing carbohydrates to 
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evade retention in the cecum, therefore causing starch and lactate-utilizing bacteria to be 
more prevalent in the colon.   
Animal-Microflora Symbiotic Relationship 
 Animal-microbial relationships are very complex, highly variable, and are 
dependent on the animal of interest and the degree to which the animal is able to utilize 
its diet independently (Hungate, 1984).  All animals and humans have been shown to 
possess microbial populations. Furthermore, each host species has evolved to compete or 
cooperate with their resident microbial populations.  For instance, carnivores typically 
have a competitive relationship with their microflora, in which host and microbes are in 
competition for the same food source. This competition occurs because most nutrients in 
    r  v r ‘s    t  r  r     y  v        t  t          t r u     zy  t       st    s  t  y 
do not require microbial fermentation. Therefore, the resident microflora compete with 
their host for these readily available nutrients. Contrastingly, most ruminant animals have 
a cooperative relationship with their microflora. This cooperative relationship occurs 
because the ruminant diet consists mainly of structural carbohydrates (cellulose and 
hemicellulose) that are indigestible by the animal alone, but can be made available by 
microbial fermentation. The ruminant diet is first exposed to the microflora in the rumen 
before becoming available to the host animal. This digestive set up allows for 
fermentation of the indigestible fiber component of the diet making these nutrients 
available for absorption in the foregut and later in the GIT (Hungate, 1984; Russell et al., 
1992; Varga and Kolver, 1997). One downside to this relationship is that the animal is 
forced to sacrifice a large amount of dietary protein to the microflora. However, the 
animal is able to utilize residual microbial protein which can be more beneficial to the 
ruminant when consuming low quality protein sources. This can be beneficial because the 
microflora are able to ferment and utilize low quality protein sources that the animal itself 
cannot digest. As a by-product of this fermentation, microbial protein is produced that the 
host is able to utilize (Tamminga, 1979).                                                                                                             
Horses have a combined competitive and cooperative relationship with their 
microbial population. This combined relationship is because the host is first able to 
compete with microflora in the foregut, subjecting the feed to its own enzymes and 
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  s r      utr   ts   r    y t     st‘s       t   T    t   p rt       t          t     st   
in the foregut is transported to the hindgut for microbial fermentation.   The hindgut is 
where the cooperative portion of their relationship takes place in which the microflora 
make available nutrients that are not otherwise available to the host by microbial 
fermentation. The horse is then able to absorb and utilize these fermentation end-products 
to meet their energy requirements. The disadvantage of this type of relationship is that 
unlike ruminants, horses cannot utilize the microbial cells and residual microbial protein 
themselves for a protein source (Martin-Rosset and Tisserand, 2004).  However, to 
overcome this deficiency, other animals that possess this type of relationship with their 
microflora have evolved to practice coprophagy or cecotrophy. Although this has not 
been documented to occur in adult horses, foals are known to practice coprophagy, 
although the primary reason for which is still being explored (Strasinger et al., 2012).  
Methods for Examining Microbial Functionality 
 As mentioned previously, the equine microflora is extremely complex and plays 
an important role in energy balance of the horse. In order to best understand microbial 
fermentation and functionality, in vitro fermentation procedures have become 
increasingly popular in equine nutrition research (Lattimer et al., 2005, 2007). These 
methods are often employed when studying diet digestibility, microbial activity, the 
kinetics of microbial metabolism and microbial fermentation end-products.  In vitro dry 
matter digestibility (IVDMD) has been demonstrated to yield similar results to what is 
found in vivo (Malestein et al., 1982).  Many methods, including a method developed by 
Tilley and Terry (1963) have been employed and modified over the years to estimate 
IVDMD of feedstuffs.  A more recent method for measuring IVDMD that is increasingly 
utilized in equine research is the Daisy II apparatus (ANKOM Technology Corp, 
Macedon, NY).  This method has been demonstrated to give comparable digestibility 
results to the Tilley and Terry method for both forage and grain sources (Holden, 1999). 
In addition, Daisy II allows for multiple feed samples to be analyzed for IVDMD 
concurrently which can increase labor efficiency and potentially improve precision of the 
assay itself.  This method employs continually agitated incubation vessels that contain a 
buffer solution mimicking the in vivo environment. More than 100 filter bags with pre-
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weighed feedstuffs (forage or grain sources) can be placed in the vessel (ANKOM Daisy 
II Incubator, 120v Domestic, product bulletin). The disappearance of material within 
these bags during incubation is considered the digestible portion. Equine feces are 
typically used as the microbial inoculum in the incubation jars.  Researchers have 
demonstrated that the use of equine feces as an inoculum with varying grain and forage 
substrates produce valid in vitro estimates of DM, NDF and ADF digestibility (Earing et 
al., 2010).   
Another method of interest is the measurement of fermentative gas production. A 
commercially available system for measuring gas production is the ANKOM RFS Gas 
Production Kit (ANKOM Technology Corp., Macedon, NY).  This system allows for the 
evaluation of fermentation kinetics as well as the measurement of microbial fermentation 
by-products.  Gas production has been used to measure biodegradability (Basalan et al., 
2011), rumen microbial digestion (Getachew et al., 2005; Hervás et al., 2005), yeast 
activity (Woodward, 1998), etc. In this system individual gas incubation vessels are filled 
with a pre-weighed substrate (forage or grain) and an incubation buffer that simulates the 
in vivo environment.  These vessels are also inoculated with a microbial rich substance.  
For horses, feces have been demonstrated to produce similar gas production profiles as   
gas concentrations reported when rumen fluid was employed as the inoculum for both 
grain and forage substrates (Macheboeuf, 1997; Lowman et al., 1999).  Incubation 
vessels are capped with pressure sensor modules that measure ambient pressure and 
temperature in the vessels at selected intervals, and are placed in an incubator. Also, each 
module is designed to allow for gas sampling and liquid sampling during the incubation 
period.  
In addition, there are non-commercial methods for measuring gas production. For 
instance, Menke and Ehrensvärd (1974) developed an in vitro procedure for determining 
the rate of gas production. This technique employs large (100 mL capacity) ground glass 
syringe barrels containing a feedstuff of interest suspended in an anaerobic medium that 
is inoculated with a microbial source (rumen fluid, feces, etc.).  As the substrate is 
fermented, gases are produced and the syringe plunger is forced to rise in the syringe 
barrel.  The rate of gas production (fermentation) is determined by monitoring the rate of 
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plunger movement.  This procedure has been successfully employed in many studies in 
the past (Krishnamoorthy et al., 1990; Theodorou et al., 1994; Blümmel et al., 1997). 
Culture Methods for Microbial Ecological Analysis 
In addition to understanding the kinetics of microbial fermentation, knowing the 
composition of the microflora is also important to better design diets that complement the 
microflora and to maximize dietary energy utilization. Both culture and molecular 
methods have been developed and used in humans and animals to better characterize 
complex microbial communities.  Microbiological culture includes methods that are used 
to multiply microbial organisms by allowing them to reproduce in culture media under 
controlled laboratory conditions.  Microbial culture is one of the primary diagnostic 
methods for many infectious diseases and also is useful in identifying specific bacterial 
species and determining bacterial abundance.  Growth media can be liquid or solid and 
can be classified into four different categories: nutrient media, minimal media, selective 
media and differential media.   
 Nutrient media is an undefined media type. It is non-selective and contains all of 
the components necessary for bacterial growth.  Typically, nutrient media is useful for 
the cultivation of bacterial pure cultures that were previously isolated for maintenance in 
culture collections. Although nutrient media is not typically used for isolation or 
enumeration purposes, it has been employed to isolate bacteria that previously were 
considered uncultivable (Kaeberlein et al., 2002). This approach was used because the 
   t r  ‘s  utr t      r qu r    t   r  r wt  w s u    w     Pur   u tur    r       y 
is an important tool for examining individual microbial functionality. This tool relies on 
asceptic technique to allow for isolation and to avoid contamination of the culture (Smith 
and Hamilton, 1969).  Pure cultures can be used to study physiological, metabolic and 
growth requirements of a specific microbial species of interest (Flythe and Russell, 
2004).  In addition, pure cultures can also be used to elucidate and characterize both 
competitive and cooperative relationships between multiple microbial species and have 
been essential for bacterial pathogen research conducted to date in vitro (Wilson and 
Freter, 1986; Daube et al., 1994; Fooks and Gibson, 2002; Edrington et al., 2003).  
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  Minimal media is a defined media type and contains the minimum nutrients 
necessary for bacterial growth.  Minimal media is much more selective than nutrient 
           s typ     y us   t   u t v t  ―w    typ ‖    t r        t     tur     r        
organism (Demain, 1958; Mayberry et al., 1968; Rowe et al., 1975). In addition, this 
media type can also be supplemented with a single selective agent, usually a nutrient 
(amino acid or sugar) which is useful when isolating auxotrophic bacteria.  
 The media types most commonly used for isolation and enumeration purposes in 
the laboratory and diagnostically include selective and differential media.  Selective 
media, in addition to all of the necessary nutrients for bacterial growth, contain a 
selective agent or multiple selective agents that allow or limit the growth of specific 
microorganisms.  Selective agents typically used in these media types include antibiotics 
that select against undesired bacteria and specific nutrients (amino acids, sugars) that are 
essential for the growth of desired bacteria (Harmon et al., 1971; Chapman et al., 1990).  
Differential media types use the biochemical characteristics of the desired 
microorganism, growing in the presence of specific nutrients or indicator agents (phenol 
red, methylene blue, etc.), to visibly indicate the defining characteristic of the 
microorganism of interest.  Media can be both selective and differential (Aguirre et al., 
1990; Talwalkar and Kailasapathy, 2004; Nerandzic and Donskey, 2009). These media 
types allow not only for isolation and identification of bacteria of interest, they also can 
allow differentiation between species.    
Although, culture methods are useful in cultivation, isolation and enumeration of 
bacteria, these methods depending on the degree of selectivity can be used in conjunction 
with other supplemental analyses.  Commonly, microscopic evaluation is employed to 
confirm the identity of the microorganism, as well as other biochemical tests to help in 
identification of the bacteria cultivated.  
Molecular Methods for Microbial Ecological Analysis 
As mentioned previously, culture techniques and microscopic evaluation are often 
employed together to estimate the total cultivability of a bacterial species or functional 
group. However, in some instances comparisons of microscopic counts and total viable 
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counts have been demonstrated to be different. Originally, this difference was thought to 
be due to the number of dead cells present in a sample. In fact, dead bacteria in a fecal 
sample may account for one third of the total bacterial community (Apajalahti et al., 
2003).  More recent studies have shown that there are also dissimilarities found in culture 
vs. nucleic acid based methods for a large majority of bacteria from multiple ecosystems 
(Pace, 1997). Therefore differences found between microscopic evaluation and culture 
techniques could be attributed to many bacteria being uncultivable. Bacterial culture 
media are designed to be selective and contain compounds that promote growth of 
desired bacteria and deter growth of other bacteria. Due to the selectivity of these media 
types and the lack of knowledge of the specific bacteria present in the host and their 
growth requirements, a large portion of the bacteria present are currently undetectable by 
culture methods alone.  This finding has led to the development and use of culture-
independent methods to comprehensively study complex microbial ecosystems. 
Sequencing of small subunit (SSU) rRNA from bacteria and archae species is a 
helpful tool and has been used in horses to look at bacterial diversity within different 
segments if their GIT (Daly et al., 2001).  Sequencing can be used to identify individual 
isolates and also allows for phylogenetic classification of each isolate. The Sanger 
sequencing method, was one of the first rapid DNA sequencing methods developed 
(Sanger et al., 1977). It has been employed in many past and current studies and has been 
demonstrated to be a reliable and consistent method. Sanger sequencing relies on 
amplification of the DNA fragment of interest by DNA polymerase and incorporation of 
fluorescent dideoxyneucleotides that are then identified for sequencing purposes.  Sanger 
sequencing has a relatively long read length of approximately 700 to 1,000 base pairs per 
read making it an attractive option for complex sequencing projects (Shendure and Ji, 
2008). Sanger sequencing provides high quality reads but is more expensive and time 
consuming than newer methods. For example, other DNA sequencing methods (i.e. 
pyrosequencing, ion semiconductor sequencing, etc.) have been developed more recently 
that require less work and are more efficient for studying complex microbial communities 
like those that occur in the equine hindgut (Ahmadian et al., 2000; Ronaghi, 2001; Huse 
et al., 2007; Rohde et al., 2011).  
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Pyrosequencing is a DNA sequencing technique that is based on the detection of 
released inorganic pyrophosphate during DNA synthesis. Visible light is produced by a 
series of enzymatic reactions and is proportional to the number of incorporated 
nucleotides (Ronaghi, 2001).  This sequencing technology has been demonstrated to 
increase the efficiency of DNA sequencing and has been used successfully both for de 
novo sequencing and confirmatory sequencing (Huse et al., 2007; Ronaghi, 2001). 
However, there are some limitations to this technique. Pyrosequencing is limited in read 
length (~400 base pairs) in comparison to Sanger sequencing. Therefore, it can make the 
process of genome assembly more difficult, especially for genomes that contain tandem 
repeats, or repetitive sequences. This can also lead to misidentification of genes with 
larger read lengths than the maximal reads in pyrosequencing.  Also, when used to profile 
the phylogenetic diversity within microbial communities, like those found in the equine 
hindgut, the intrinsic error rate of the method can lead to overestimates of the number of 
rare phylotypes. Some of this error can be controlled for by means of applying stringent 
read quality filtering and low clustering thresholds, however, this is not necessarily 
sufficient to ensure accurate estimates of microbial diversity (Kunin et al., 2010).  
Furthermore, pyrosequencing technology can be extremely expensive to employ when 
used for larger genomic sequencing, with a purchase cost of approximately $500,000, a 
minimum unit run cost of $2,000 and a reagent cost per run of approximately $6,500 
(Glenn, 2011). 
Ion semiconductor sequencing has also become increasingly popular as a new age 
sequencing technology. This technology is similar to pyrosequencing but detects 
hydrogen ions (H
+
) released during DNA polymerization.  This method is unique because 
it does not require imaging technology, like those required by pyrosequencing and 
therefore reduces the complexity of the technology and the corresponding unit cost. Ion 
semiconductor sequencing is available for purchase at approximately $50,000 which is 
10% of what a pyrosequencing instrument costs (Glenn, 2011).  In addition, sequencing 
output time and cost is also less than pyrosequencing. However, ion semiconductor 
sequencing has even shorter read lengths than pyrosequencing (~200 base pairs vs. 400 
base pairs), potentially leading to similar drawbacks of the technology in application.  
  
15 
 
These sequencing technologies have demonstrated that a large portion of bacteria 
present in animal GIT segments have not previously been discovered (Whitford et al., 
1998; Pryde et al., 1999; Gong et al., 2002).  Furthermore the majority of the novel 
sequences described were grouped specifically in the low G + C Gram-positive phylum 
which include species from the phylum firmicutes, suggesting that these species are 
particularly unrepresented in culture techniques.  Unfortunately, even though many 
cloned SSU rDNA from the GIT of different animal models have been deposited in 
databases, there are few examples of direct comparisons of sequences obtained and 
colony forming units from culturable bacteria. In addition, only a small fraction of culture 
isolates are sequenced and deposited in databases, limiting the application of these 
molecular sequencing techniques.    
There are several DNA databases (National Center for Biotechnology Information 
and Receptor Database) available that contain 16S rRNA sequences that can be used for 
bacterial identification.  When sequencing metagenomic DNA, bacterial clone libraries 
are created by using rDNA or cDNA from rRNA.  Ribosomal RNA sequences can be 
obtained directly from SSU rRNA or from their encoding genes or directly from SSU 
rDNA by means of reverse transcription PCR (RT-PCR) or regular PCR.  After the 
library is complete the sequences obtained are compared with the database sequences for 
characterization, and is followed by phylogenetic analysis (Altschul et al., 1990; Ludwig 
et al., 2002; Cole et al., 2003).  
SSU rDNA fingerprinting techniques have also been developed for studying 
bacterial communities. These techniques are useful when monitoring community shifts 
and comparing communities from different locations in the GIT.   One such technique is 
denaturing gradient gel electrophoresis (DGGE; Fischer and Lerman, 1979, 1983; 
Muyzer et al., 1993).  DGGE is believed to be sensitive enough to detect bacteria that 
constitute up to 1% of a bacterial community (Zoetendal et al., 1998).  This technique is 
PCR based and generates fingerprint profiles that represent the sequence diversity within 
the measured community. DGGE is based on sequence-specific melting behavior of PCR 
amplicons in a polyacrylamide gel. This melting behavior occurs by denaturation in 
discrete melting domains and the formation of characteristic bands.  Gels are dyed, 
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exposing bands, and are subjected to UV-transillumination and imaging. Gels can then be 
analyzed using a commercially available software and similarities in banding pattern, 
number of bands and curve based analyses can be performed. Bands can also be removed 
and sequenced for identification purposes. In addition, a similar procedure producing 
comparable results can be found using temperature gradient gel electrophoresis (TGGE) 
using a temperature gradient gel (Muyzer and Smalla, 1998).  DGGE/TGGE methods 
have been successfully used in the ecological analysis of microbial communities in 
humans (Zoetendal et al., 1998; Satokari et al., 2001; Favier et al., 2002), cattle 
(Kocherginskaya et al., 2001), pigs (Simpson et al., 2000), horses (Endo et al., 2009; 
Earing et al., 2012) , etc. 
Other finger printing techniques are also available for use including single strand 
conformation polymorphism (SSCP; Schwieger and Tebbe, 1998) and terminal-
restriction fragment length polymorphism (T-RFLP; Liu et al., 1997) analyses. Although 
all of these techniques are PCR-based and can result in an indication of microbial 
diversity and species richness within a selected ecosystem, they differ in band separation. 
DGGE and TGGE are based on sequence specific melting behavior while SSCP is based 
on secondary structure of single stranded DNA and T-RFLP is based on restriction 
enzyme target sites.   SSCP and T-RFLP have also been successfully used to monitor 
environmental microbial communities and GI microflora (Leser et al., 2000; Nagashima, 
2003; Smalla et al., 2007).  Smalla and colleagues (2007) found that although there was 
some variability in fragment amplification when DGGE, T-RFLP and SSCP were 
performed on the same sample, they all had similar findings.   
Normal Flora of Interest 
            There are several different classification systems that can be used for 
characterizing the bacteria present in the hindgut of the horse (Table 2.1). They can be 
classified based on their specific niche within the bacterial community or by functional 
guild (a group of niches) into: cellulolytic, proteolytic, glycolytic, lactate-utilizing, 
lipolytic etc.  Additionally, bacteria can be classified by structure, Gram-positive vs. 
Gram-negative, low vs. high G-C bacteria, metabolically (nutrient requirements,   
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Table 2.1.: Major bacterial species of interest in equine normal flora and AAD-associated pathogens
1 
1 
Van Soest, 1994 
2
A: Aerobic; AN: Anaerobe
Genus/Species Phylum Guild Morphology 
Aerobic vs. 
Anaerobic
2
  
Gram 
Stain 
Substrate Products 
Ruminococcus 
albus
 Firmicutes Cellulolytic Cocci AN + 
cellulose, 
hemicellulose 
formate, acetate, 
ethanol 
Ruminococcus 
flavefaciens
 Firmicutes Cellulolytic Cocci AN + 
cellulose, 
hemicellulose 
formate, acetate, 
succinate 
Fibrobacter 
succinogenes
 Fibrobacteres Cellulolytic Rod AN - cellulose 
formate, acetate, 
succinate 
Streptococcus spp.
 
Firmicutes Saccharolytic Cocci A/AN + sugars lactate 
Lactobacillus spp.
 
Firmicutes Saccharolytic Rod A/AN + sugars lactate 
Veillonella spp.
 
Firmicutes 
Lactic Acid- 
Fermenter 
Cocci AN - lactate acetate, propionate 
Salmonella 
typhimurium
 Proteobacteria Proteolytic Rod A/AN - 
sugars, 
proteins 
formate, acetate, 
lactate, succinate 
Clostridium  
difficile
 Firmicutes Proteolytic Rod AN + 
amino acids, 
sugars 
acetate, formate, 
isobutyrate, butyrate, 
isovalerate, valerate 
isocaproate  
Clostridium 
perfringens
 Firmicutes Proteolytic Rod AN + 
amino acids, 
sugars 
ethanol, formate, 
lactate, acetate, 
butyrate  
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metabolic by-products, etc.) or even based on morphometric characteristics (i.e. rod, 
cocci, diplococci, flagella). 
However, the most well defined and widely accepted classification system is 
bacterial taxonomy.  In this system bacteria are classified based on phenotypic, 
phylogenetic, and genetic analyses. This taxonomic classification system is then based on 
hierarchal taxanomic ranking (kingdom, phylum, class, order, family, genus and species). 
When identifying bacteria based on this ranking system the lowest rank in which the 2 
bacteria are similar demonstrates how closely related the 2 bacterial species are. 
Typically, bacteria are identified in literature by their genus and species (i.e. 
Lactobacillus reuteri) but in some cases they are identified by their functional guild.     
As mentioned previously, the equine hindgut microflora has not been well 
characterized to date, although, certain guilds of bacteria have received more attention 
than others.  For example, work on lactic acid-producing bacteria (Streptococcus spp., 
Lactobacillus spp.) and lactic acid-utilizing bacteria (Veillonella spp.) has been more 
extensive than work performed on cellulolytic bacteria. This is primarily due to the 
relationship of these bacteria with metabolic disorders, fermentative acidosis and 
laminitis in horses (Al Jassim et al., 2005).  Streptococcus bovis and S. equinus are 
known to be the predominant lactic acid-producing bacteria in the hindgut of the horse 
(Al Jassim and Rowe, 1999). In addition, many Lactobacillus spp. are also present in the 
equine hindgut. Lactobacilli are of special interest to researchers due to their prospective 
role in pathogen defense and as beneficial bacteria used in many commercial probiotics.   
Veillonella spp. are part of the lactic acid-utilizing guild of bacteria in the equine hindgut. 
These bacteria are important to horses because they utilize lactic acid produced by lactic 
acid-producing bacterial species to generate important energetic end-products for the 
horse most notably acetate and propionate.   However, it is important to keep in mind that 
these lactic acid bacteria are only present in low numbers in healthy horses under normal 
feeding conditions (high forage diets). Therefore, this review of the normal flora of 
interest in the equine hindgut will focus primarily on cellulolytic bacteria and the lactic 
acid bacteria of special interest, Lactobacillus spp.  
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Cellulolytic Bacteria 
Bacteria 
The cellulolytic bacteria are arguably the most important bacteria in the equine 
hindgut, because the majority of substrates reaching the hindgut are structural 
carbohydrates (plant fiber).   Due to the complexity of structural carbohydrates (cellulose 
and hemicellulose), only cellulolytic bacteria can produce the enzymes needed to break 
these fibers down. These bacteria have been demonstrated to be 6 times more 
concentrated in the cecum than in the colon, with 4.3 x 10
7 
and 7 x 10
6 
c.f.u mL
-1
, 
respectively (De Fombelle et al., 2003). Furthermore, two consecutive studies found that 
56% of blood glucose in horses on a strict hay diet was from propionate produced by 
microbial fermentation in the cecum and colon (Simmons and Ford, 1985; Ford and 
Simmons, 1991).  Although, propionate does not represent the majority of the VFA 
produced when horses are fed a high fiber diet (acetate), propionate is the VFA that 
predominately contributes to blood glucose levels (Argenzio and Stevens, 1975). 
Therefore, even though cellulolytic bacteria are not responsible for the production of 
propionate directly, presumably, a diet consisting only of hay would be high in structural 
carbohydrates.  Therefore, this large contribution of propionate to blood glucose levels 
further reinforces the indispensible role of cellulolytic bacteria in hindgut fermentation 
and dietary energy generation for the horse.  
 The primary cellulolytic bacteria found to exist in the cecum include 
Ruminococcus flavefaciens, Ruminococcus albus and Fibrobacter succinogenes (Julliand 
et al., 1999). Although, these cellulolytic species are similar to what is typically observed 
in the rumen (Hungate, 1966), there are genetic differences between cellulolytics isolated 
from the cecum of the horse, most likely due to environmental differences. Furthermore, 
in a study by Lin and Stahl (1995) two F. succinogenes strains were identified as being 
unique to the horse, further indicating the specificity of the hindgut for fiber-degradation. 
Minimal research has been done looking ecologically at cellulolytic bacteria in 
the hindgut of the horse and no research to date has been done to look at them 
physiologically.  However, it is possible to speculate that because the predominant 
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cellulolytic bacterial species of interest are the same in the rumen and hindgut, their 
mechanism of cellulose digestion may also be similar. Ruminal cellulolytic bacteria 
produce cellulase enzymes.  When cellulose is limited, in a continuous culture chemostat 
system, it has been demonstrated that cellulolytic bacteria adhere to cellulose particles. 
This adherence is facilitated primarily by an extracellular glycocalyx coat and 
secondarily by adhesins and ligands that form with the substrate (Miron et al., 2001; 
Weimer, 1996). The cellulolytic bacteria retain the cellulase enzymes on their cell 
surface, and when they come into contact cellulose, digestion occurs (Weimer, 1996).  
Ruminal cellulolytic bacteria not only compete for common substrates with other 
functional bacterial groups (branched chain VFAs, glucose, etc.), but also fight among 
themselves for both cellulose and cellobiose in vitro (Odenyo et al., 1994; Chen and 
Weimer, 2001).  The outcome of interactions between cellulolytic bacterial species is 
dependent on many factors. These factors include: the rate of adherence to cellulose 
(Koike et al., 2003), bacteriocin production (Chen et al., 2004), and presence of non-
cellulolytic bacteria (Chen and Weimer, 2001).    
Ruminococcus flavefaciens are Gram-positive cocci that are usually found 
microscopically in chains. They are able to ferment cellulose, cellobiose and glucose and 
their primary end-products include: acetic acid, formic acid, succinic acid, some lactic 
acid and H2.  Ruminococcus albus are Gram-positive cocci.  They are able to ferment 
cellulose and cellobiose but cannot utilize glucose.  Their primary end-products of 
fermentation are similar to R. flavefaciens except they produce ethanol instead of succinic 
acid. Fibrobacter succinogenes are Gram-negative rods. They ferment cellulose, 
cellobiose and glucose and produce acetic acid, formic acid and succinic acid. All of 
these cellulolytic bacteria are strict anaerobes and only tolerate a narrow pH range (pH 6 
to 7). In a study by Hiltner and Dehority (1983), low pH (< 6.0) decreased the rate of 
cellulose digestion for both R. flavefaciens and F. succinogenes with little effect on 
subsequent ability to digest cellulose after pH was increased back to normal levels. 
Cellulolytic bacteria also require branched chain VFAs (isobutyrate, isovalerate and 2-
methylbutyrate). They use branched chain VFAs for synthesis of branched chain amino 
acids and branched chain fatty acids (Bryant, 1973). R. flavefaciens, R. albus and F. 
succinogenes are all able to digest cellulose. R. flavefaciens and R. albus can also digest 
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hemicellulose, but F. succinogenes cannot (Russell et al., 2009). Other cellulose 
digesting bacteria of interest that have been described in ruminants but not yet in the 
horse include both Eubacterium cellulosolvens and Butyrivibrio fibrisolvens (Linden et 
al., 1984). 
Culture and Identification 
There are numerous culture and molecular methods that have been developed to 
observe and characterize cellulolytic bacteria in the rumen. To date, many of these 
methods have not been adapted for equine use, but presumably could be in the future.  
Culture methods for ruminal cellulolytic bacteria were first described by Hungate (1969) 
and were further revised by Fonty and colleagues (1995).  These methods employed the 
use of roll tubes and amorphous cellulose with an extremely nutrient dense media type. 
Julliand and colleagues (1999), were the first to adapt this media for horses using these 
previously described ruminal culture methods with minimal adaptation. Adaptations 
included pH adjustment to 7.3 prior to autoclaving the media and the rumen fluid 
addition being replaced with a 1:1 mixture of rumen fluid and equine cecal liquor.  In 
order to most efficiently isolate cellulolytic bacteria, ruminant microbiologists have 
identified key ingredients necessary for bacterial growth. For instance 3-phenylpropanoic 
acid (PPA) has been discovered to be the ingredient accounting for the stimulatory effect 
of rumen fluid on cellulolytic growth and cellulose degradation by Ruminococcus albus 8 
(Hungate and Stack, 1982). Phenylacetic acid (PAA) has also been identified as a 
limiting agent for cellulolytic growth, because cellulose degradation by R. albus 8 is 
limited by phenylalanine biosynthesis (Stack et al., 1983).   Unfortunately, research to 
identify key ingredients specific to the growth and function of cellulolytic bacteria in the 
equine hindgut has not yet been performed. Microscopic analysis is also typically 
employed with culture to further identify, confirm and characterize the presence of 
cellulolytic bacteria in samples. This analysis can be done using wet mount and other 
microscopic techniques or Gram-staining can also be employed.  
Unfortunately, there are some disadvantages to only using culture techniques for 
cellulolytic bacteria.  As mentioned, these bacteria are primarily adherent and therefore 
cannot be accurately quantified by culture techniques. Approximately, 70% of all rumen 
 22 
 
bacteria are firmly attached to feed particles (Forsberg and Lam, 1977) and when cultured 
even particles containing many individual bacteria will only produce a single colony, 
making underestimation of bacterial enumerations inevitable. Therefore, either 
employing broth dilution or molecular techniques can be useful for overcoming this bias. 
As mentioned earlier, PCR can be employed with taxon-specific primers or probes based 
on 16S rRNA genes (Stevenson and Weimer, 2007).  This technique is limited in that the 
16S rRNA genes employed are derived from culture based methods and are therefore not 
necessarily representative of the composition of the true cellulolytic guild. This bias 
allows for the possibility that primer and probe specificity could prevent detection of a 
phylogenetically related group. Studies employing real-time PCR techniques have 
demonstrated this bias. Results of these studies indicated that neither R. albus nor R. 
flavefaciens account for >1% of the total 16S rRNA gene. Furthermore, when 
Ruminococcus as a genus-level primer was used this value increased to 8%. These results 
indicate that not all Ruminococcus spp. are encompassed by R. albus and R. flavefaciens 
(Stevenson and Weimer, 2007; Weimer et al., 2008).   
Lactobacillus spp.  
Bacteria 
Lactobacillus is a genus of facultative anaerobic bacteria that are Gram-positive 
and are typically rod-shaped.  They are known to ferment starch and simple sugars that 
escape small intestinal digestion and produce D- and/or L- lactate. This lactate is then 
used by lactate-utilizing bacteria (i.e. Veillonella spp.) to make propionate.  Lactobacillus 
spp. and other lactic acid-producing bacteria are known to be pioneer species in humans 
and other animals (Ducluzeau, 1993; Steward, 1991). However, little research has been 
done in horses to identify pioneer species in the hindgut. Pioneer species are bacteria that 
are first to colonize locations where there previously were no living bacteria.  They are 
hardy bacteria, and are able to survive in hostile environments.  Furthermore, these 
bacteria produce by-products of metabolism that modify the microenvironment and create 
new potential ecological niches for other bacteria to colonize, concurrently fending off 
pathogenic bacteria (Connell and Slayter, 1977; McFall-Ngai, 1998). Lactobacilli are 
known to inhibit pathogenic bacteria colonization by a variety of mechanisms including: 
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competition for nutrients, production of metabolic by-products that modify the 
microenvironment discouraging pathogenic colonization, competition for adhesion sites 
and by producing antimicrobial compounds. It is important to recognize that one or all of 
these mechanisms could contribute to pathogen resistance.   
The normal microflora utilize nutrients provided to them that are not previously 
  s r     y t   r   st‘s   t st     T   u t tu   of different bacterial species occupying 
niches within the hindgut of the horse when healthy, should guarantee nutrient depletion 
of the majority of nutrients that otherwise could be utilized by pathogenic species to 
      z    T  s t   ry     w   s ‗Fr t r‘s  utr   t-r     yp t  s s‘ st t s t  t     r  r   r 
bacteria to colonize, the bacteria must consume growth-limiting nutrients better than 
other competitors in the microenvironment, and that their growth rate must exceed their 
wash out rate (Freter et al., 1983; Brogden and Clarke, 1997; Fabich et al., 2008).  This 
theory has been demonstrated using Escherichia coli as a model organism and defined 
metabolic pathways in multiple studies (Chang et al., 2004; Leatham et al., 2009).  
Research has not been done in any animal model looking at Lactobacillus spp. and 
competition for nutrients with pathogenic bacteria.  However, the theory is plausible for 
application in this relationship. For example, lactobacilli consume many of the same 
nutrients that are also required for growth of clostridia including: amino acids, simple 
sugars and essential vitamins (Dunn et al., 1947; Morishita et al., 1981; Muhammed et 
al., 1975; Wilson and Perini, 1988).   
   y    t     r       r       u       rt       t              r  t  t     st‘s GI 
epithelial cells to ensure survival and colonization in the GIT (Jankowska et al., 2008). 
This phenomenon has been demonstrated both in vitro (Stickler et al., 2006; Ma et al., 
2006) and in vivo (Chauvière et al., 1992, 1992b).  Some pathogenic bacteria also require 
adhesion to GIT epithelium to allow the release of detrimental enzymes and toxins, 
causing necrosis of the epithelial lining and facilitating invasion of the pathogen 
(Sylvester et al., 1996). For example, Salmonella spp. first require adherence to intestinal 
epithelium before they are able to exert their detrimental effects on the host. In order to 
attach, salmonella rely on their bacterial fimbrae to recognize specific receptors on 
epithelial cells (Lehto and Salminen, 1997).  If Lactobacillus spp. are already present on 
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the epithelium they may block these receptors from detection by salmonella, and 
therefore reduce its pathogenic action. In fact, many studies have demonstrated that 
lactic-acid bacteria can competitively exclude pathogens from adhesion sites on the GIT 
mucosa, and therefore prevent infection (Coconnier et al., 1993a, 1993b; Zárate and 
Nader-Macias, 2006).  In a study performed by Jankowska and colleagues (2008), L. 
paracasei (strain indigenous to humans) was co-incubated with salmonella, and 4-fold 
less salmonella were able to colonize caco-2 cells.  In addition, 7-fold less salmonella 
were able to colonize when caco-2 cells were first incubated with L. paracasei and then 
exposed to salmonella.   
Lactobacillus spp. can also inhibit the growth of other bacteria, including 
pathogens by releasing products of normal metabolism, which make the 
microenvironment unsuitable for pathogenic colonization (De Keersmaecker et al., 
2006).   These inhibitory metabolites can include VFAs (i.e. acetate, butyrate and lactate), 
other organic acids, bio surfactants, hydrogen peroxide etc. (Gupta et al., 1998; Pabich et 
al., 2003).  In a study by Naaber and colleagues (2004), the antagonistic activity of 50 
indigenous intestinal Lactobacillus spp. strains were tested against 23 known pathogenic 
strains of C. difficile.  They found that lactobacilli most antagonistic to C. difficile 
produced higher levels of H2O2 and lactic acid in comparison to other Lactobacillus spp. 
These results indicate that production of metabolic by-products may be an important 
mechanism of colonization resistance for Lactobacillus spp.  Furthermore, in a study by 
Flythe and Russell (2006), Clostridium sporogenes MD1, a relatively close phylogenetic 
relative of the pathogen C. difficile, was inhibited both in rate of growth and 
metabolically (ammonia production) when exposed to high levels of fermentation acids 
(acetate, propionate and lactate).  Furthermore, it has been documented that increasing 
VFA concentrations and their effect on lowering cecal pH in hamsters can inhibit 
colonization of C. difficile (Rolfe, 1984).   
The production of bacteriocins are also commonly implicated in pathogen 
resistance. Bacteriocins are defined as any group of substances produced by a strain of 
bacteria that is harmful to another closely related strain.  It has been demonstrated that 
Lactobacillus spp. produce a variety of different bacteriocins and other antimicrobial 
 25 
 
molecules that can have antagonistic effects against pathogenic bacterial species 
(Savadogo et al., 2004). For example, Lactobacillus acidophilus, a known mutualist in 
the GI microflora of horses (Fujisawa et al., 1993) has been demonstrated to produce two 
different bacteriocins that inhibit C. difficile      t  r p t           t r   (    v č-
  t j ń ć et al., 1998).  
 As mentioned previously lactobacilli can also produce small antimicrobial 
compounds. For example, L. reuteri is an indigenous Lactobacillus spp. in the horse, and 
has been shown to produce an antimicrobial compound reuterin (Valeur et al., 2004).  
This potent cell growth inhibitor is produced via conversion of glycerol or 
dihydroxyacetone phosphate (DHAP), and has activity against Gram-positive and Gram-
negative bacteria as well as fungi and protozoa (Talarico and Dobrogosz, 1989).  In a 
study by Bernard and colleagues (2011), indigenous lactobacilli strains were isolated 
from the equine GIT and were tested for antimicrobial activity against Salmonella.  In 
this study they identified multiple indigenous strains of lactobacilli that had salmonella 
antimicrobial activity (L. reuteri, L. kefiri and L. crispatus).  Studies in humans and other 
animal models have also demonstrated the production of antimicrobial compounds from 
multiple lactobacilli strains (Silva et al., 1987; Asahara et al., 2001).    
  In addition to their ability to prevent colonization of pathogens, more recently 
some Lactobacillus strains have been shown to actually inhibit toxigenic effects of 
pathogenic bacteria both in vitro (Garrote et al., 2000; Banerjee et al., 2009) and in vivo 
(Bekar et al., 2011). In a recent study by Carasi and colleagues (2012), they found that L. 
kefir had the ability to bind C. difficile toxins to their S-layer proteins. Although this 
experiment was performed in vitro, this action of L. kefir potentially could inactivate the 
pathogenesis of C. difficile in vivo and protect the host from its detrimental effects. Due 
to the lack of research to date in this area, this topic warrants further exploration in the 
future.  
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Culture and Identification 
 Lactobacilli enumerations are typically done by plating on a selective media.  
There are many commercial media types available for the cultivation of lactobacilli 
including: Rogosa SL Agar (Rogosa et al., 1953) and Lactobacilli MRS Agar (deMan et 
al., 1960).  Both media types contain a fermentable carbohydrate, amino acids and a 
vitamin source to meet general growth requirements. Sodium acetate and ammonium 
citrate act as selective agents in these media types and inhibit the growth of streptococci, 
molds, and other contaminating microflora. Polysorbate 80 is also included in these 
media types as a surfactant.  Lactobacilli appear on the selective media as white circular 
colonies. Some limitations of these media types include: that some lactobacilli strains 
may grow poorly or fail to grow due to varying nutritional requirements and organisms 
other than lactobacilli can grow.  In order to ensure definitive identification of 
lactobacilli, other molecular methodology can be employed. These methods include using 
lactobacilli species specific primers in DGGE (Walter et al., 2000) and 16S rRNA 
sequencing (Song et al., 2000).   
 
Possible Disruption of the Equine Intestinal Microflora 
Antibiotic therapy has been demonstrated to be the most common cause of 
disruption in the normal human microflora (Nord, 1993).   Antibiotics are also commonly 
administered in horses. However, minimal research has been performed to actually study 
the effect of antibiotic treatment on the stability of the normal equine flora.  One study by 
White and Prior (1982), observed that when horses were treated with the antibiotic 
oxytetracycline there was a significant increase in pathogenic bacteria and a decrease in 
Veillonella spp. (normal flora).  Experimental work in mice has also indicated that with 
antibiotic treatment, colonization resistance of the normal flora decreases allowing for the 
colonization of pathogenic bacteria (van der Waaij et al., 1977).   
Transportation, stress, surgical procedures, episodic feeding, and abrupt changes 
in diet can also have effects on the stability of the normal flora (Clarke et al., 1990). 
These effects are primarily due to effects on pH, increases in acid production, decreases 
 27 
 
in buffering capacity and consequent disruption of the microflora. For example, when a 
horse is in a fasting state (during episodic feeding) they are not receiving feed and 
therefore their hindgut has a decreased buffering capacity which allows for a decrease in 
pH and consequent microbial disruption (Clarke et al., 1990).   
Diet composition can also have effects on the stability of the equine hindgut 
microflora. For instance, diets high in readily fermentable carbohydrates are often fed to 
horses with high energy requirements. However, studies have demonstrated that by 
feeding high starch diets as opposed to high fiber diets, horses are more likely to develop 
GI disease (i.e. colic and laminitis), and this is primarily attributed to disruption of the 
hindgut microflora (Clarke et al., 1990; Bailey et al., 2004).  Many studies have observed 
this relationship by enumerating microbial species and guilds that can be cultivated (De 
Fombelle et al., 2003; Varloud et al., 2007; Respondek et al., 2008).  Due to the many 
normal flora that are uncultivable, Willing and colleagues (2009), utilized molecular 
techniques (T-RFLP and 16S rRNA Sequencing) to look at the changes in hindgut 
microflora when concentrate and forage only diets were provided to performance horses. 
This study found that when feeding a diet that was high in fiber in comparison to high in 
starch, there were lower counts of lactic-acid bacteria most specifically members of the 
Streptococcus bovis/equinus complex. It is important to keep in mind that not all lactic 
acid bacteria are the same. Some lactic acid bacteria play an essential mutualistic role in 
the healthy equine hindgut microflora. However, large numbers of other lactic acid 
bacteria like Streptococcus spp. are typically associated with a disturbed microbial 
population. In previous studies it had been demonstrated that the onset of laminitis is 
characterized by an increase in Streptococcus spp. (Milinovich et al., 2008). This 
relationship is because an increase in streptococci leads to lactate accumulation in the 
hindgut (Medina et al., 2002). This causes a substantial reduction in hindgut pH which 
has been associated with laminitis onset (Julliand et al., 2001). In addition, decreasing pH 
has been shown to trigger the production of vasoactive amines which can be absorbed by 
the host, and can also lead to the development of laminitis (Crawford et al., 2007).  
Therefore, the high fiber diet in the Willing and colleagues (2009) study was considered 
to provide a more stable environment for the normal equine microflora. An increase in 
lactic-acid bacteria has also been associated with the development of other GI 
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disturbances (Garner et al., 1978; Bailey et al., 2003).   For example, diets high in starch 
have been shown to increase microbial disruption and chances of diarrhea while high 
fiber diets can actually reduce microbial disruption and chances of diarrhea (Horner et 
al., 2000; Partanen et al., 2002).   
Antibiotic Associated Diarrhea (AAD)  
Reasons for Antibiotic Use  
 Antibiotic therapy is commonly used in horses both prophylactically and 
therapeutically to treat a variety of undesirable bacterial infections.  It is difficult to 
assess the economic impact of antibiotics on the equine industry because of the enormity 
of its use in animal agriculture. However, it is accepted that antibiotic treatment can 
decrease death loss, suffering and recovery time, loss of performance and the likelihood 
of transmission of infections (Gustafson and Bowen, 1997). The ultimate goal of 
antibiotic treatment is to challenge infecting bacteria sufficiently enough to kill the 
bacterial organism or debilitate it to the point that it is susceptible to host defenses 
(Brumbaugh and Langston, 2002).  Therefore, it is very important to recognize when 
choosing a specific antibiotic therapy, what type of bacteria are involved, if those bacteria 
are susceptible to the antibiotic (mode of action) and adverse effects of treatment 
(Wilson, 2001).  
Definition of AAD 
AAD is generally defined as diarrhea occurrence in close proximity to antibiotic 
treatment, and is probably the most commonly recognized negative effect of antibiotic 
therapy. Clinical signs can range from transient diarrhea to life-threatening colitis. In a 
study by Cohen and colleagues (1999), horses with diarrhea that were treated with 
antimicrobials prior to symptom onset were 4.5 times less likely to survive.  
Unfortunately, true definitive diagnosis of AAD is nearly impossible in a clinical setting. 
This difficulty of diagnosis is because there are many other factors that can occur 
concurrently with antibiotic treatment that also predispose a horse to developing 
enterocolitis. These include: transportation, hospitalization, other medical treatments, 
surgery, stress, changes in diet and feed intake etc. (Chapman, 2009).   For instance, in a 
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study by Gustafsson (2004) it was reported that 62% of horses in a clinical setting with 
colitis had received antimicrobials prior to onset of symptoms. However, 53% of the 
horses with colitis had surgery under anesthesia.  Therefore, it is difficult to distinguish 
the causality of the colitis in this study. For this reason, as well as inconsistencies in the 
case definition of AAD, there is very little information concerning the incidence rate of 
AAD in horses. In hospitalized human patients, AAD occurs at a rate of 1 – 30% 
(Högenauer et al., 1998; Bartlett, 2002).  However, AAD incidence associated with 
specific antimicrobials can vary widely (Bartlett et al., 1996; Wiström et al., 2001; 
Beaugerie et al., 2003).  The percentage of mature horses with diarrhea, in which the 
onset of symptoms was considered to be temporally associated with antimicrobial 
treatment, varies enormously between research studies from 22% (Cohen et al., 1999), 
79% (Gustafsson, 2004) or as high as 94% in one study (McGorum et al., 1998).  In 
addition, the time from antimicrobial treatment to onset of diarrhea symptoms for horses 
with AAD is also highly variable, with some studies reporting values from 24 h to the 
first few days after treatment (Cook, 1973; White and Prior, 1982; Staempfli et al., 1992; 
Gustafsson et al., 1997; Stratton-Phelps et al. 2000) and others reporting an average of 
3.4 days (range 1-11 days; Wilson et al., 1996) or 5.7 days (range 1-7 days; Weese et al., 
2000).  In humans, it has been reported that risk of AAD increases with the length of 
antimicrobial therapy, from 3 to 7 days of treatment (Wiström et al., 2001). However, the 
risk did not increase further when treatment exceeded 7 days. This observation indicates 
that disturbances in the intestinal microflora causing AAD occur soon after the initial 
treatment. Due to lack of research, it is unclear if this is also what is observed in horses.  
Pathogenesis 
 There are multiple proposed mechanisms for the onset of AAD in horses. One of 
the most widely accepted mechanisms depends on the disruption of the normal enteric 
microflora by antibiotics.  As mentioned previously, the normal flora in the GIT of the 
horse are poorly characterized, but are known to play an important role in nutrient 
digestion, nutrient utilization and in colonization resistance (Vollaard and Clasener, 
1994).  The healthy normal microflora prevent opportunistic pathogens from colonizing 
and exerting their detrimental effects on the animal.  This mechanism was demonstrated 
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in a study where mice treated with antimicrobials required a dose of only 100 or less E. 
coli to colonize the intestines while healthy mice required a dose greater than 10
7
 (van 
der Waaij et al., 1997).  There are many ways that the normal flora can fend off 
pathogens.  These include: by out competing pathogens for nutrients (Brogden and 
Clarke, 1997), end-products of fermentation that create microenvironments that are not 
suitable for pathogen growth, stimulation of host immune defenses (Endt et al., 2010), 
and production of antimicrobial substances by indigenous microflora (Liévin et al., 2000; 
Vesterlund et al., 2004).  The opportunistic pathogens most commonly implicated in 
AAD are Clostridium difficile, Clostridium perfringens and Salmonella spp. (Weese et 
al., 2001; Kaltenbach and Heitz, 2004).  Fecal shedding of these pathogens have been 
demonstrated to increase when horses are treated with antibiotics (Ernst et al., 2004; 
Gustafsson et al., 2004).  When niches are available due to normal flora upset (antibiotic 
treatment), these pathogens are able to proliferate, release exotoxins and exert other 
detrimental effects on the host that can result in mucosal damage with consequent 
inflammation. This inflammatory response alters the absorptive and secretory function of 
the large intestine resulting in diarrhea (Valle et al., 2012). However, these pathogens 
only account for 50% of AAD cases in horses, leaving a large proportion undetermined 
(Gustafsson, 2004).  
 Another mechanism of AAD could be attributed to the disruption of normal 
metabolic functioning of the microflora with antibiotic treatment.  During microbial 
digestion, various metabolic by-products are released that are essential for colonization 
and stability of the normal flora. The major energetic by-products of microbial 
fermentation are VFAs. In addition to these by-pr  u ts‘ s                   u  ty 
stability, the microflora also influence fluid and ion transport across enteric epithelium. In 
fact, ion and water content in the lumen of the large intestine are extremely dependent on 
microbial digestion (Argenzio and Stevens, 1975).  Therefore, disruption by 
antimicrobial treatment of fatty acid metabolism, bile acid metabolism, or intestinal 
carbohydrate and VFA metabolism and absorption can lead to the development of AAD 
(Hӧ    u r et al., 1998).  In humans, broad-spectrum antimicrobials decrease intestinal 
concentrations of short chain fatty acids (McFarland, 1998).  Antimicrobials have also 
been shown to have a direct prokinetic effect on toxin production by invasive pathogens. 
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This phenomenon could also contribute to the pathogenesis of AAD.  Erythromycin for 
example has a well-documented prokinetic effect. This antibiotic indirectly stimulates 
acetylcholine release from enteric receptors and directly stimulates smooth muscle 
motility receptors. Potassium penicillin administration has been shown to cause 
immediate defecation in horses (Roussel et al., 2003).  The mechanism by which this 
happens is largely unknown, however, this is probably due to direct effects on stimulation 
of smooth muscle in the small colon and rectum. Gentamicin, clindamycin and 
trimethoprim have all been shown to evoke enteric reflex responses in the guinea pig 
(Brummett, 1981).  Clindamycin and gentamicin have also been shown to evoke reflex 
responses in the rabbit colon (Lees and Percy, 1981). However, hypersensitivity and 
toxicity reactions to antimicrobial compounds are thought to be very uncommon causes 
   AA  (Hӧ enauer et al., 1998).     
Tetracyclines 
 Tetracycline antibiotics are used both therapeutically and prophylactically in 
humans and animals to control undesirable bacterial infections. In addition, sub-
therapeutic amounts of oxytetracyclines are commonly added to feed to promote growth 
in food animals. In result of the extensive application of tetracycline antibiotics in both 
humans and animals, they are produced on the largest scale of all classes of antibiotics 
(Johnson and Adams, 1992; Levy, 1992).  Tetracyclines are active against most common 
pathogens, exhibit little to no toxicity, cause minimal adverse reactions and are relatively 
inexpensive making them an attractive treatment option (Standiford and Aziz, 2005).  
However, despite their common use and proven efficacy, little is known about their 
mechanism of antibiotic action. Tetracyclines exhibit bacteriostatic activity which is 
associated with reversible inhibition of protein synthesis.  Several studies have identified 
tetracycline binding sites on the ribosome (Tritton, 1977; Epe and Woolley, 1984).  It has 
been speculated that when tetracycline binds to the ribosome it weakens the ribosome-
tRNA interaction which inhibits protein synthesis (Epe et al., 1987; Aleksandrov and 
Simonson, 2008; Dönhöfer et al., 2012).  However, further research is necessary to 
confirm a clear correlation between tetracycline binding and inhibition of protein 
synthesis in vivo.  
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 Historically, oxytetracycline has been associated with a higher risk of AAD in 
horses than other antibiotics (Andersson et al., 1971; Baker and Leyland, 1973; Cook, 
1973)  T  s      r r s  pr     y    p rt  s  u  t    ru ‘s  r qu  t            us     t   
past. However, there has been little evidence in more recent research to support or refute 
whether horses treated with oxytetracycline have a higher risk of developing AAD.  The 
first documented cases of AAD in horses followed administration of an intravenous (I.V.) 
single excessive dose of tetracycline (27-40 mg kg
-1
). The antibiotic was dosed 48 to 72 h 
prior to surgery and 2 of the 3 horses with documented AAD died.  This AAD effect was 
then reproduced in 3 of 4 experimental horses that did not undergo general anesthesia or 
surgery (Andersson et al., 1971).   In another study, when horses were subjected to 
general anesthesia and administered oxytetracycline at therapeutic dosing (4 mg kg
-1
), 
severe AAD was observed in 3 horses (Cook, 1973).   Baker and Leyland (1973) also 
reported 4 cases of fatal profuse AAD after horses were given a single dose of 
oxytetracycline (1-2 mg kg
-1
).  Owen (1975) found that when horses were administered 
this antibiotic, 50% (4/8) of horses had AAD and were also shedding salmonella. 
Furthermore, in a later study by Owen and colleagues (1983), when horses were 
administered I.V. oxytetracycline (10 mg kg
-1
 2 x daily) for 5 d, there was a prolonged 
salmonella shedding period. Oral administration of oxytetracycline (10 mg kg
-1
 for 5 d or 
40 mg kg
-1
 for 2 d) caused diarrhea with increases in total coliforms, C. perfringens Type 
A, bacteriodes and Streptococcus spp. with a concomitant decrease in the normal flora 
Veillonella spp. (White and Prior, 1982). Lastly, when horses were fed sweet feed 
contaminated with tetracycline (10 mg kg
-1
 feed) 4 horses developed AAD with 1 dying 
from severe colitis (Moore Keir et al., 1999).   
Macrolides/Lincosamides 
 Macrolides and lincosamide antibiotics have also been associated with diarrhea in 
horses (Staempfli et al., 1992). These classes of antibiotics are functionally similar, but 
differ in structure.  Macrolides and lincosamide antibiotics that have mycarose sugar 
groups (Spiramycin, Josamycin, etc.), act by directly inhibiting the peptidyl transferase 
reaction (Poulsen et al., 2000). This inhibition occurs, because the binding site of these 
antibiotics on the ribosome partly overlaps with the substrates of the reaction (Schlünzen 
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et al., 2001; Hansen et al., 1999). In contrast, macrolides in the erythromycin group do 
not have a mycarose sugar group, and therefore do not inhibit the peptidyl transferase 
reaction but instead block the entrance of the ribosomal subunit tunnel when bound. This 
blockage induces premature dissociation of peptidyl-tRNAs from the ribosomes, 
inhibiting protein synthesis (Otaka and Kaji, 1975; Milligan and Unwin, 1986; Cocito et 
al., 1997; Tenson and Ehrenberg, 2002).   However, due to their site of action, macrolide 
and lincosamide antibiotics are not able to inhibit protein synthesis on ribosomes when 
peptides have reached a critical length, and therefore are only active at, or just after, 
initiation of mRNA translation (Tenson et al., 2003).  
 Following early reports of AAD with administration of tetracycline, macrolides 
and lincosamide antibiotics were also explored.  Raisbeck and colleagues (1981) reported 
that when horses were provided with feed contaminated with lincomycin (0.5 mg kg
-1
) 
for 2 days, all 7 horses exposed developed colitis.  In a following study, colitis was 
induced in 3 experimental ponies that were administered lincomycin (25 mg kg
-1
, 2 x 
daily, 4-7 doses). The same research team also induced colitis in 2 ponies by dosing them 
with clindamycin (10 mg kg
-1
, 2 x daily, 3 doses), followed by treatment with lincomycin 
(25 mg kg
-1
, 2 x daily, 7 doses) and administration of colonic contents from an unrelated 
horse with colitis.  However, ponies that were only dosed with the antibiotics or with 
only the colonic contents did not develop colitis (Prescott et al., 1988). Furthermore, 
Staempfli and colleagues (1992) induced colitis in 8 experimental ponies by 
administering lincomycin (25 mg kg
-1
, 1 dose).  Although, administration of a lower dose 
of lincomycin (10 mg kg
-1
, 1 dose), only induced colitis when administered with colonic 
contents from a horse with colitis.  These results indicate that a major disturbance as well 
as microbial inoculation is necessary to induce AAD in horses treated with lincomycin.   
 Due to the high concentration of active drug that is found in the large intestine 
because of limited absorption, erythromycin administration has also been demonstrated to 
induce AAD (Gustafsson et al., 1997; Gustafsson, 2004).    When foals with pneumonia 
were treated with erythromycin both alone and when combined with rifampin or 
gentamicin there was an 8-fold higher risk of developing AAD in comparisons to foals 
with pneumonia being treated with trimethoprim-sulfamethoxazole or penicillin 
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(Stratton-Phelps et al., 2000).  The effect of erythromycin treatment specifically on 
development of AAD is hard to definitively identify due to other extraneous factors that 
could have contributed to diarrhea in this study (hospitalization, age, etc.). Furthermore, 
erythromycin was administered in combination with other drugs in some foals making it 
difficult to discern whether a single drug or the combination was responsible for the 
AAD.  Gustafsson and colleagues (1997) induced colitis in 50% (2/4) of horses and 
observed enormous disturbances in the hindgut microflora (C. difficile and C. perfringens 
proliferation) in all experimental horses with a very small dose of erythromycin 
ethylsuccinate (0.125 or 1.25 mg kg
-1
 every 8 h).  This study also detected levels of 
erythromycin high enough to inhibit the growth of Gram-positive and anaerobic bacteria, 
even in the horses given the lowest dose of erythromycin.  These results indicate that 
erythromycin administration could potentially cause severe microflora disturbances 
without colitis.  
β – Lactam Antibiotics 
 A t    t  s t  t  r    t   r z    s β- lactam antibiotics all contain a single 
       stru tur      r  t r st      β- lactam ring. These antibiotics include both 
p         s       p    sp r  s        st     y  β- lactam antibiotics have bacteriocidal 
effects, disrupting cell wall synthesis by inhibiting the enzymes that catalyze the cross-
linking reactions of the D-alanyl peptides on peptidoglycan strands of the growing cell 
wall. This inhibition of transpeptidase activity is believed to be in result of the antibiotic 
being structurally analogous to the D-alanyl-D-alanine portion of peptidoglycan (Lee, 
1971; Boyd, 1979). Peptidoglycan is extremely important for cell wall structural 
  t  r ty  T  s   srupt     y β- lactam antibiotics is especially of concern to Gram-
positive organisms because peptidoglycan is the outermost and primary component of the 
cell wall.    
 H    r t s    p                str t    (β- lactam antibiotic) have been 
documented prior to the onset of acute colitis and diarrhea in 3 equine case studies 
(Båverud et al., 1997; McGorum et al., 1998; Weese et al., 2000).  In the first study it 
was reported that of 10 horses diagnosed with C. difficile AAD, all had been previously 
tr  t   w t     y β-lactam antibiotics (Båverud et al., 1997).  In a second case study they 
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  u   t  t 88% (14/16)      rs s w t  AA           tr  t   w t  p             β-lactam 
antibiotic (McGorum et al., 1998).  These horses had also received other antibiotics in the 
study, so there was not a definitive answer if the penicillin specifically was responsible 
for the diarrhea observed. Furthermore, in the aforementioned studies horses were 
exposed to other extraneous factors that could have caused the colitis including: surgery, 
transportation, concurrent disease, etc. further complicating determination of what caused 
the diarrhea.  Weese et al. (2000) similarly reported that 17 of 40 horses diagnosed with 
AAD had received a penicillin treatment alone or in combination with other antibiotics. 
Although, the causality of penicillin in AAD appears to be higher than other antibiotics in 
horses, this incidence could simply be due to the wide use of penicillin.  However, other 
studies have linked penicillin administration with pathogenic bacterial shedding. One 
such study by Gustafsson and colleagues (2004), reported that penicillin treatment 
increased fecal shedding of C. difficile in horses.  It has also been demonstrated that 
concentrations of penicillin in the colonic lumen when horses were administered 
penicillin G sodium (i.v., 10 mg kg
-1
) were high enough to kill a multitude of anaerobic 
bacteria (Horspool and McKellar, 1995).    Penicillin has also been shown to have 
prokinetic effects that could lead to the development of AAD. This antibiotic has been 
demonstrated to increase the myoelectic activity (electricity produced by muscle) in the 
cecum and colon of horses which could alter functioning of the colonic mucosa and 
increase passage rates, leading to diarrhea (Roussel et al., 2003).  
 There have been varying results reported concerning the role of the cephalosporin 
ceftiofur in equine AAD.  Folz and colleagues (1992) reported that when horses were 
treated with ceftiofur sodium (2.2 mg kg
-1
, 1 x daily, 10 days) for respiratory infections, 
no horses (n=28) developed any diarrhea.  Furthermore, in a drug tolerance study by 
Mahrt (1992) when horses were administered ceftiofur sodium at 1, 3, and 5 times the 
suggested dose (2.2, 6.6, 11 mg kg
-1
, I.M.) for 30-31 days, diarrhea was not induced. 
Contrastingly, in other studies ceftiofur has been reported as an antibiotic associated with 
C. difficile  ss    t   AA   w    pr v         x  ss      u   tur r‘s   stru t   s 
(Foreman, 1998; Weese et al., 2000).  For instance, in the aforementioned research by 
Mahrt (1992), another drug tolerance study was cited in which horses developed AAD 
after I.V. administration of ceftiofur sodium at 10 to 25 times the labeled dose for 10 
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days.  In a study by Foreman (1998), the frequency of diarrhea in young horses suffering 
from respiratory infections was compared when they received 1 of 3 treatments: ceftiofur 
sodium (2.2 mg kg
-1
, I.M., 1 x daily, 10 days), ampicillin sodium (6.6 mg kg
-1
, I.M., 2 x 
daily, 10 days) or saline (control).  This study found that horses receiving ceftiofur 
sodium had higher incidence of diarrhea during antibiotic treatment (2% of days) in 
comparison to the control groups (1.5% of days). However, horses in this study were also 
transported before receiving antibiotics which could also contribute to microbial 
disruption.  Furthermore, the ceftiofur horses had higher documented rates of diarrhea 
after transportation and before antibiotic administration, making the significance of the 
previous finding inconclusive. In the same study it was also reported that there was no 
difference in the frequency of diarrhea when horses with strangles (n=18) were treated 
with either ceftiofur sodium (2.2 mg kg
-1
, I.M.) or procaine penicillin G (22,000 IU kg
-1
, 
I.M.) for up to 30 days (Foreman, 1998). Furthermore, Foreman (1998) drew an 
anecdotal positive association between ceftiofur treatment and AAD when ceftiofur was 
administered in connection with general surgery and anesthesia.   
 Lastly, ampicillin and cloxacillin have also been associated with the development 
of equine AAD (Weese et al., 2002). However, in a study by Folz et al. (1992) horses 
treated with ampicillin (6.6 mg kg
-1
, 2 x daily, 10 days) for respiratory infections, did not 
develop AAD.  
Trimethoprim-sulfonamides 
 Trimethoprim and sulfadizine are both bacteriostatic antibiotics that interrupt the 
bacterial folate synthesis pathway. Folic acid is an important precursor in the de novo 
synthesis of DNA both in terms of replication and transcription.  Sulfadiazine 
competitively inhibits the enzyme dihydropteroate synthetase (DHPS) which is required 
in one of the first steps of folate synthesis. Trimethoprim then acts by interfering with the 
action of the enzyme dihydrofolate reductase which inhibits synthesis of tetrahydrofolic 
acid (Bushby and Hitchings, 1968). Trimethoprim and sulfadizine antibiotics have been 
demonstrated to have a greater effect when given together as opposed to when 
administered individually which is why they are typically administered as a combination 
to horses and other animals (Bushby and Hitchings, 1968; Böhni, 1969).  
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The role of trimethoprim-sulfonamide antibiotics in equine AAD has not been 
definitively determined. However, horses treated with these antibiotics are typically 
considered to be at a lower risk for developing diarrhea. This apparent lower risk could 
be due to the effective absorption of this antibiotic when administered orally, from the 
small intestine minimizing microbial and digestive disturbance in the lower gut (White 
and Prior, 1982; Van Duijkeren et al., 1994).  Few studies have demonstrated minor 
changes in intestinal microflora when trimethoprim-sulfonamide antibiotics were 
administered. These microflora disturbances were specifically noted as a decrease in fecal 
coliforms (White and Prior, 1982; Gustafsson et al., 1999). However, these studies were 
limited in normal flora measurements taken and more research is required in this area. 
  In a large case study, it was demonstrated that there were no differences in the 
incidence of diarrhea when comparing horses receiving trimethoprim-sulfonamides (23% 
of horses) and control horses (20% of horses; Wilson et al., 1996). All diarrhea cases in 
the aforementioned studies were resolved when antibiotic treatment was discontinued.  
Conversely, in a study by Ensink and colleagues (1996), they found that horses treated 
with trimethoprim-sulfadiazine had a higher incidence of loose feces and diarrhea in 
comparison to horses treated with pivampicillin.  Lastly, in a retrospective study by 
Cohen and colleagues (1999), trimethoprim-sulfadiazine in combination with another 
antimicrobial was the most commonly administered antibiotic prior to the development of 
diarrhea.    
Pathogenic bacteria associated with AAD 
 As mentioned previously the 3 most common pathogens implicated in equine 
AAD include: Clostridium difficile, Clostridium perfringens and Salmonella spp. (Weese 
et al., 2001). These pathogens are each unique morphologically, physiologically and 
pathologically.   
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Clostridium difficile 
Historical Perspective 
Clostridium difficile was first isolated from human newborn infants in 1935 (Hall 
    O‘T    , 1935).  Upon isolation, C. difficile w s    t    y       ―Bacillus difficilis‖ 
because of how difficult the bacterium was to isolate and cultivate from the healthy 
newborn stool samples.  However, the relationship of C. difficile to human disease was 
  t r      z   u t   t   1970‘s w     t w s  s   t   sp         y  r   u t p     t    t  -
associated pseudo-membrane colitis (PMC) stool samples. After this discovery, many 
studies in humans and corresponding animal models were conducted to better 
characterize C. difficile and its pathogenicity. It was not until 1984, when C. difficile was 
first detected in mature horses in a study of diarrhea in the Potomac River area (Ehrich et 
al., 1984).  Furthermore in 1993, C. difficile was first associated with a case of colitis in a 
horse treated with antimicrobials (Perrin et al., 1993). Since then many studies have 
demonstrated the relationship of cultivable C. difficile and diarrhea in horses (Weese et 
al., 2001; Donaldson and Palmer, 1999) especially with corresponding antimicrobial 
treatment (Madewell et al., 1995; Gustafsson et al., 1997; Båverud et al., 1997; 
Gustafsson et al., 2004; Taha et al., 2007).      
Bacterium 
In humans, C. difficile is the pathogen most commonly implicated in AAD 
(McFarland et al., 1989; Johnson et al., 1990; Riley, 1994).  This pathogen is a spore 
forming, Gram-positive bacteria that grows in anaerobic environments. C. difficile 
requires 5 amino acids for energy metabolism (Leu, Ile, Pro, Trp and Val) and an addition 
of Gly has been shown to increase growth significantly.  In order to generate energy in 
the form of ATP, C. difficile utilizes amino acid fermentation and can also utilize sugars 
(i.e. glucose). The primary fermentation end-products of C. difficile metabolism include: 
acetic, isobutyric, butyric, isovaleric, valeric and isocaproic acids. 
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Pathogenesis 
Although C. difficile has been detected at low transient levels in healthy horses 
(Weese et al., 2001; Båverud et al., 2003; Medina-Torres et al., 2011) it is thought to 
colonize and proliferate opportunistically when the healthy microflora in the host are 
compromised. The healthy hindgut microflora have a protective effect against the 
colonization of pathogens such as C. difficile both when introduced via an exogenous 
source but also when present endogenously in subclinical carriers. The exact 
pathogenesis of C. difficile has not yet been studied in the horse, but in humans it has 
been shown to colonize by the fecal-oral route.  Colonization is typically preceded by 
disruption of the normal flora allowing ingested C. difficile spores that survive the gastric 
acid barrier to be converted to their vegetative form in the distal ileum and multiply in the 
colon (Kelly and LaMont, 1994; Kelly, 1998; Jones, 2000).  Disruption of the healthy 
flora occurs most frequently with antimicrobial treatment but can also occur with 
exposure to antineoplastic or immunosuppressive drugs or in consequence of other stress 
factors (Anand and Glatt, 1993; Sharma and Holder, 1998). Possible stress factors in 
horses can include but are not limited to: dietary changes, environmental changes, 
transportation, starvation, surgery, medical treatment, etc.   Infection with C. difficile can 
range from severe acute diarrhea and life-threatening PMC to asymptomatic carriage.   
Many factors both physiological and toxicological have been implicated in the 
virulence of C. difficile. Physiological factors include: fimbriae (Borriello et al., 1990), 
flagella (Stabler et al., 2006), capsule (Borriello et al., 1990), extracellular enzymes 
(Savariau-Lacomme et al., 2003), adhesins (Waligora et al., 2001) and a paracrystalline 
S-layer (McCoubrey and Poxton, 2001). Unfortunately, although all of these factors have 
been documented to occur in some strains of virulent C. difficile their role in the 
virulence of this organism has not yet been well characterized.  
Furthermore, C. difficile isolates can either be classified as non-toxigenic or 
toxigenic.  Non-toxigenic strains do not produce any toxins and therefore are not able to 
cause disease. Strains are only considered toxigenic strains if they produce toxins. C. 
difficile strains can produce up to 3 secreted protein toxins: Toxin A (TcdA), Toxin B 
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(TcdB) and the binary toxin CDTab. It is important to note that not all strains of toxigenic 
C. difficile produce all of these toxins.  
Many studies have been performed to characterize the mechanism of action of 
TcdA and TcdB. Cells treated with TcdA and TcdB typically have a loss of cytoskeletal 
structure. This is attributed to the ability of both TcdA and TcdB to cause cell rounding 
and cell death in many cell types.  TcdB is considered to be 100 to 10,000 times more 
potent than TcdA in many cell types in its capacity to cause cell rounding (Tucker et al., 
1990; Chaves-Olarte et al., 1997). Both toxins TcdA and TcdB have the ability to modify 
cellular proteins in the Rho family (Dillon et al   1995)  R   pr t   s  r   u   s    5‘ 
triphosphate (GTP)-binding proteins th t  r    v  v      t   r  u  t       t       ‘s 
cytoskeletal structure. With exposure to TcdA and TcdB Rho proteins are disrupted 
impairing the stability between actin filaments in the cell allowing for cell rounding and 
eventual cell death. In addition, the disruption of Rho GTPases can attribute to the 
pathogenesis of C. difficile by the disruption of cell tight junctions increasing epithelial 
permeability and allowing fluid accumulation associated with diarrhea (Johal et al., 
2004).  TcdA and TcdB cell death is often mechanistically attributed to apoptosis as well 
 s    r s s (Q ‘    et al., 2002; Kim et al., 2005; Matarrese et al., 2007).  
TcdA and TcdB have also been shown to induce the secretion of cytokines in both 
immune and epithelial cells (Savidge et al., 2003). The gene encoding IL-8 is specifically 
thought to play a large role in the pathogenesis of C. difficile in that alterations within this 
gene have been associated with susceptibility of subjects to recurrent C. difficile 
associated diarrhea (CDAD).  In addition, IL-8 is involved in the recruitment and 
activation of neutrophils which have been shown to be present specifically at sites of C. 
difficile associated inflammation (Jiang et al., 2006).  
Although TcdA and TcdB have been demonstrated to have similar mechanisms of 
action in terms of cytotoxic effects, these similarities are not as apparent when observing 
effects in the animal model.  Based on early research performed on a variety of species 
TcdA was determined to be an enterotoxin because it was able to induce fluid 
accumulation, inflammation and extensive tissue damage within the intestinal tract 
(Lyerly et al., 1982, 1985, 1988). However, in these studies TcdB had little to no effect 
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on intestinal stability. Due to this observation TcdB was primarily referred to as the 
cytotoxin. These studies led to the hypothesis that TcdA was the primary toxin because it 
alone was responsible for disrupting the intestinal barrier in vivo and causing intestinal 
damage. Thusly, TcdB might only access the tissues to exhibit its cytotoxic effects after 
the action of TcdA and would be inactive if provided alone (Lyerly et al., 1988).  More 
recently a number of pathogenic strains have been identified that produce TcdB and not 
TcdA.  These strains have been demonstrated to cause the same range of symptoms as 
TcdA+ strains therefore discrediting the previous hypothesis of Lyerly and colleagues 
(Sambol et al., 2000; Kuehne et al., 2010).  TcdB also has multiple isoforms that have 
distinctive substrate specificity (Stabler et al., 2009).  The binary toxin CDTab is not 
produced by all pathogenic strains of C. difficile. It has been found to be homologous to 
iota toxin produced by C. perfringens but its pathogenesis still remains unclear (Perelle et 
al., 1997).  
Toxigenic C. difficile strains do not continuously produce toxin, and some strains 
are more toxigenic than others. In a study by Dupuy and Sonenshein in 1998 they 
demonstrated that when sugar i.e. glucose was readily available and C. difficile was in its 
exponential phase of growth, TcdA and TcdB expression was repressed. However, when 
the bacteria were in stationary phase (size of bacterial population remains constant) their 
rate of toxin production increased. By prioritizing growth over toxin production, C. 
difficile is able to grow and colonize as much as possible depending on substrate 
availability and total niche capacity before starting to produce their detrimental toxins. 
This also could indicate a possible catabolite repression of toxin gene expression based 
on the availability of substrate.  Additionally, in a study by Naaber and colleagues 
(2004), relationships were identified between C. difficile toxicity, resistance to antibiotics 
and susceptibility to antimicrobial agents produced by lactobacilli.  Based on their 
observations the researchers speculated that highly-toxigenic C. difficile strains were 
typically antibiotic resistant, but susceptible to antimicrobial activity by the normal flora 
lactobacilli. Consequently, in order for highly toxigenic C. difficile to proliferate, 
lactobacilli must already be deeply suppressed. These results indicate that non-toxigenic 
or less toxigenic strains of C. difficile may be the strains detected in healthy horses or 
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asymptomatic horses that have a slightly compromised microflora, while highly toxigenic 
strains only colonize when the equine microflora are deeply compromised.  
  Much further research is needed in order to elucidate the roles of C. difficile 
t x  s    t      t r u ‘s p t      s s  It  s   p rt  t t  have a complete understanding 
of this role for the development of therapeutic strategies to combat these toxigenic 
effects. 
 Culture and Identification 
In humans, C. difficile infection is primarily nosocomial.  C. difficile and its 
spores have been isolated from the hospital environment and hands of staff in both human 
and veterinary hospitals (Kim et al., 1981; Weese et al., 2000; Båverud et al., 2003).  
Horses can also become infected with vegetative cells or C. difficile spores from contact 
with another infected horse, a contaminated environment, or from human contact. 
Although C. difficile in its vegetative form is easily killed by exposure to an aerobic 
environment, spores may persist for years (Båverud et al., 2003). Due to the hardy nature 
of this pathogen and the detrimental effects it can have on its host, it is important to know 
its prevalence and methods of detection in horses both with and without enteric disorders. 
In order to identify carriers of C. difficile, fecal samples are typically collected 
and inoculated onto a selective and differential medium. In 1979, George and colleagues 
developed a medium called cycloserine-cefoxitin-fructose agar (CCFA) for the selective 
cultivation of C. difficile. CCFA was then further modified to identify the most effective 
concentrations of cycloserine and cefoxitin for C. difficile specific isolation. Cycloserine 
and cefoxitin are selective antimicrobial agents that reduce contaminating bacteria in 
selective culture. Over time different additions were also tested for culturing C. difficile 
including: horse serum, sodium taurocholate and media with mannitol replacing fructose 
(Dezfulian et al., 1981). Clostridium difficile selective agar (CDSA) is a modified 
formulation of the original CCFA that is also differential. CDSA provides amino acids as 
the primary nutrient source and contains mannitol instead of fructose because it is known 
to be utilized by fewer Clostridium spp., increasing selection for C. difficile. CDSA also 
contains a neutral red indicator that turns fluorescent yellow with growth of C. difficile 
 43 
 
and the consequent pH increase allowing for visual selection of C. difficile colonies. 
Plates must be incubated anaerobically and at an optimal temperature of 35 ± 2 ºC for 
growth of C. difficile (BBL, CDSA Technical Bulletin).  
C. difficile can also be identified based on its distinctive odor on agar plates, 
colony appearance and Gram stain results. Vegetative cells may appear motile in broth 
cultures with flagella when viewed microscopically. In addition, spore staining can be 
employed for further identification and characterization purposes. There are also a variety 
of biochemical tests available commercially for identification of C. difficile.  
In addition, to identifying the subject as a carrier in order to definitively diagnose 
C. difficile diarrhea, toxins must also be detected in fecal samples. There are many tests 
available for determining the presence of toxins. Toxin specific microwell enzyme 
   u   ss ys (EIA‘s)  r   v             r     y   r   t  tcdA and tcdA and B 
detection (CD-Tox, Porton; Premier, Meridian Diagnostics Inc.; C.difficile TOX A/B II, 
TechLab Inc.). These assays are typically quick and specific although some kits can vary 
in sensitivity and may give intermediate readings. Toxin sp          r    EIA‘s  r  
also available commercially but only for detection of tcdA and are not as sensitive as 
   r w    EIA‘s (C. difficile Toxin A, Oxoid Inc.).  Another option for detection is tissue 
culture for tcdB (C. difficile Toxin/Antitoxin, TechLab Inc.; Cytoxi, Advanced Clinical 
Diagnostics).  This method is only useful for labs that are already equipped to do tissue 
culture. It is sensitive and specific for tcdB but if performed improperly or if there are 
deviations in proper sample handling, false negative results are possible.  Also, tissue 
culture requires 48 h for definitive diagnosis, which is longer than other aforementioned 
methods.  Most recently enzyme linked immunoabsorbant assays (ELISAs) have been 
developed to detect tcdA and/or tcdB specifically in stool samples.  These tests are very 
rapid and reliable for toxin screening and CDAD diagnosis.  
When testing a horse for CDAD it is important to take many factors into 
consideration. In a study performed by Båverud and colleagues in 2003, within a group of 
horses that developed acute colitis during antibiotic treatment, 42% were found to be 
positive with C. difficile culture and 28% of these were positive in the tissue culture 
cytotoxin B test. Therefore, when choosing diagnostic methods for CDAD it is important 
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to test not only for the presence of C. difficile in culture but also for toxin production. 
Both nontoxigenic C. difficile strains and toxigenic strains that may produce tcdA and/or 
tcdB can be present in the horse at any given time allowing for false positives when only 
using culture methods.  Also, because toxin production can vary between C. difficile 
strains it is possible that one toxin assay is not necessarily sufficient for definitive 
diagnosis. In addition, the degree to which toxins are produced between equine isolates 
can vary enormously and can be down-regulated at times by the equine hindgut 
microflora making multiple samples over time necessary to avoid false negatives. Lastly, 
it is important to keep in mind that healthy horses can be carriers of C. difficile without 
exhibiting any outward signs of enteric illness. The rate of infection of presumably 
healthy horses can range from 0% to 7.59% depending on the study (Weese et al., 2001; 
Båverud et al., 2003; Medina-Torres et al., 2011). 
Clostridium perfringens 
Historical Perspective 
The first association between Clostridium perfringens and veterinary 
  str   t st       s  s  w s    u   t    s   r y  s t   1920‘s (S    r  1996)   It w s   t 
until the mid-1940‘s w    C. perfringens was first suspected in humans to be a cause of 
  str   t st       s  s         t     t  1940‘s C. perfringens was linked to outbreaks of 
  r  r      tt r    w   s ―    r       t     w  ‖  r   t r t s    r t    s    p st-
WWI Germany (Lawrence et al., 1997). Historically, C. perfringens is most commonly 
associated with gas gangrene but also plays a role in enteric disease. The association 
between food poisoning and C. perfringens was confirmed with research performed by 
H   s    t   1950‘s      r   t  t point on, was the main relationship associated with C. 
perfringens and enteric disease (McDonel, 1986).    It was not until decades later in the 
  r y 1980‘s t  t C. perfringens was linked to GI disease in humans that was not directly 
foodborne in origin (Borriello, 1995).   
The relationship between equine enteric disease and C. perfringens was not 
  v st   t   u t   t     t  1970‘s  I  1977 W  rup was able to make a connection between 
high counts of C. perfringens type A in feces and colitis in racehorses (Wierup and 
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DiPietro, 1981). In addition, he also found that healthy racehorses had low transient 
levels of C. perfringens (10
2 
c.f.u g
-1
). With his findings he suggested that intestinal 
disease caused by clostridia was primarily due to infection with C. perfringens type A 
specifically. After this discovery, more research was done to explore this area and C. 
perfringens was further implicated as a cause of severe colitis in horses (Wierup and 
DiPietro, 1981; Donaldson and Palmer, 1999; Weese et al., 2001) and AAD (Herholz et 
al., 1999; Weese et al., 2000).   
Bacterium 
C. perfringens is a rod-shaped, Gram-positive bacterium that requires an 
anaerobic environment for growth. It is a mesophile with an optimal growing temperature 
of 37 ºC and is non-motile with the ability to produce endospores. C. perfringens requires 
 ss  t              s  r    ts   v r     t  u  t  t      t r u ‘s        ty t  p r  r   ts 
own amino acid biosynthesis. However, C. perfringens has many other ways in addition 
to amino acids fermentation of acquiring energy.  Uniquely, C. perfringens can perform 
anaerobic respiration using nitrates allowing an increased yield of energy. In addition, C. 
perfringens has the ability to use anaerobic fermentation to produced gases such as CO2 
to create an anaerobic environment that is essential for growth and survival of the 
organism, and is also able to carry out glycolysis and glycogen metabolism utilizing 
simple sugars. The primary end-products of C. perfringens metabolism include: ethanol, 
lactate, acetate, butyrate and CO2.  
Pathogenesis 
C. perfringens is often referred to as a prolific toxin producer and is able to 
produce at least 15 different toxins (McDonel, 1986). However, not all strains of C. 
perfringens produce all toxins and these differences in toxin production can explain the 
pathogenic versatility of C. perfringens. Four toxins are used for classification purposes 
of C. perfringens into isolate types A-E   T     ur t x  s     u  : α  β  τ     ε t x  s  
Outside of the core typing system there are other toxins that have been associated with 
  t r     s  s      u       t r t x    PE     β2 t x  s  Equ      t r     t s   s      
associated primarily with C. perfringens types A and C (Ochoa and Kern, 1980; Howard-
 46 
 
Martin et al., 1986; Drolet et al., 1990; East et al., 1998).  However, types B, D and E 
have sporadically been implicated in foal enterocolitis (Traub-Dargatz and Jones, 1993). 
Furthermore, C. perfringens has also been specifically implicated in cases of equine AAD 
(Andersson et al., 1971; Weese, 2000).  The toxins of most interest currently in the 
pathogenesis of C. perfringens   t r     t s      rs s  r  t    PE     β2 t x  s   
Currently the role of CPE positive C. perfringens in the pathogenesis of AAD and 
enterocolitis in horses is unclear and requires further experimental investigation. 
However, multiple studies have been performed looking at CPE in the horse making it a 
toxin of interest in equine diarrhea. Ochoa and Kern (1980) found with I.V. injection of 
CPE that ponies demonstrated marked edema, intestinal lesions and hemorrhagic enteritis 
in post-mortem examination. In another study it was shown that 19% of diarrheic adult 
horses and 28.6% of diarrheic foals had detectable levels of CPE, while in control horses 
CPE was undetected (Weese et al., 2001). Furthermore, studies in humans and other 
animals have demonstrated a relationship between the presence of CPE positive C. 
perfringens isolates and the development of enteric disease and AAD (Borriello et al., 
1984; McDonel, 1986; Samuel et al., 1991; Sherman et al., 1994; McClane, 2000; 
Chakrabarti et al., 2003).  
CPE positive C. perfringens isolates can either carry the toxin gene in a 
chromosomal form or a plasmid form.  Typically in food borne illnesses the isolates carry 
chromosomal CPE while more severe enteric disease (AAD) causing isolates carry the 
plasmid form (Cornillot et al., 2006).  Some CPE plasmid isolates have also been 
demonstrated to have the ability to transfer between C. perfringens Type A isolates 
(Brynestad et al., 2001). This transfer could allow for the initiation and establishment of a 
non-foodborne enteric disease with a very low infective dose as previously documented 
(Borriello, 1995).    In addition, the transfer of CPE plasmids to C. perfringens isolates 
that are typically part of the normal flora and therefore continuously present could 
explain why symptoms of non-foodborne enteric disease (AAD) remain for an extended 
period of time.  Isolates carrying the CPE gene typically produce enormous amounts of 
CPE toxin which also contributes to initiation and establishment of disease (Collie et al., 
1998).   
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CPE toxin can act in many different ways to cause detriment to its host.  It is 
believed to have enterotoxic and cytotoxic abilities as well as the ability to cause 
anatomical changes to intestinal tissue. In recent studies it has been demonstrated that 
CPE binds to protein receptors on the surface of cells and prevents claudin binding 
(Katahira et al., 1997; Fujita et al., 2000). Claudins are proteins that are very important in 
maintaining tight junction integrity and specifically establishment of the paracellular 
barrier controlling the flow of molecules between the cells of the epithelium. When this 
barrier is disrupted it allows CPE to damage the gastric epithelium and exert its cytotoxic 
     ts    PE‘s  yt t x        ts  r    s    p     t    t  t w    t         tr t       
CPE in the intestinal lumen increases rapidly more cell death pathways are triggered than 
when the concentrations increase at a slower rate (Chakrabarti et al., 2003)    PE‘s 
effects on tight junction proteins and consequent increases in paracellular permeability 
could contribute to intestinal fluid and electrolyte loss as seen in cases of diarrhea 
(McClane, 2000). Also, high levels of CPE can also have a pro-inflammatory effect 
which could further contribute to diarrhea like symptoms (Chakrabarti et al., 2003).  
Another toxin produced by C. perfringens      t r st    AA   s β2 t x   ( r tt 
and Gilbert, 1997). This toxin has previously been implicated in equine typhlocolitis. In a 
study performed by Herholz and colleagues (1999) 52% of horses diagnosed with 
typ       t s       t  t       v  s    β2 t x  enic C. perfringens in fecal samples while 
no toxin was found in any healthy control horse. In addition, a correlation was found to 
 x st    t  s stu y   tw      rs s tr  t   w t    t    t  s t  t w r  p s t v    r β2 
toxigenic C. perfringens and lethal pr  r ss       t     s  s   T   pr s        β2 t x   
has also been highly associated with enteric disease in other animals including dogs 
(Thiede et al., 2001), calves (Manteca et al., 2002), piglets (Klaasen et al., 1999) and an 
African elephant (Bacciarini et al., 2001).  
R s  r   t    t r     β2 t x   stru tur    u  t              s       t     s 
 urr  t y          β2 t x    s    w  t    v    t r t x   pr p rt  s       s      s  w  
to cause fluid accumulation and necrotic lesions in a guinea pig ileal loop model (Gibert 
et al., 1997). Several cell lines (1407, CaCo-2, Chinese hamster ovary cells etc.) are 
sus  pt     t  t    yt t x        ts    β2 t x   (G   rt et al., 1997; Fisher et al., 2005). 
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W    t  s           s w r  tr  t   w t  β2 t x   t  y  x    ted cell rounding, decoupling 
of the cytoskeleton and the plasma membrane and eventual detachment from the 
cytoskeleton. Further research to investigate the pathogenesis of C. perfringens in AAD 
    t   r         t  t    PE     t   β2 t x    s     ss ry  
Culture and Identification 
Diagnosing C. perfringens as a cause of AAD in horses is difficult due to its 
natural prevalence in the healthy animal although typically in low quantities (Wierup and 
DiPietro, 1981). Therefore usually C. perfringens is investigated as the cause of diarrhea 
after other causes have been ruled out. Upon investigation it has been suggested that 3 
criteria be taken into consideration with diagnosis: finding large numbers of C. 
perfringens (>10
5 
c.f.u g
-1
 of feces), evidence of sporulation and detectable toxins in the 
feces (Modi and Wilcox, 2001; Divers and Ball, 1996).  
  Enumerations of C. perfringens are best done by plating fecal samples on a 
selective and differential medium.  SPS agar (Sulfite Polymyxin Sulfadiazine Agar) is a 
commercially available selective media type that can be used for enumerations of C. 
perfringens from fecal samples. This media type contains caseine peptone, yeast extract, 
ferric citrate, sodium sulfite, sulfadiazine, and Polymyxin B Sulfate. Sulfadiazine and 
Polymyxin B Sulfate are antibiotics and are included in the media to select against 
contaminants and for C. perfringens. Ferric citrate and sodium sulfite are included as H2S 
indicators. When C. perfringens is present on the plate it reduces the sulfite to sulfide 
which reacts with the iron, and forms a black iron sulfide precipitate leading to black 
characteristic colonies.  Plates must be incubated anaerobically and at an optimal 
temperature of 35 ± 2 ºC for best results. 
  C. perfringens can also be identified based on its distinctive odor on agar plates, 
large gas production capacity, colony appearance and Gram stain results (Brazier et al., 
2002). Vegetative cells may appear non-motile in broth cultures and rod shaped when 
viewed microscopically. In addition, spore staining can be employed for further 
identification and characterization purposes. 
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In order to definitively diagnose C. perfringens as a cause of diarrhea it is 
important to screen for enterotoxin. Enterotoxin screening can be done using tissue 
culture assays, enzyme immunoassays, or by detecting toxin genes by PCR isolates. The 
α  β  β2  ɛ  ι       p  t x       s     be identified using PCR (Herholz et al., 1999; 
Goldstein et al., 2012). ELISAs have also been developed to detect C. perfringens toxins 
in stool samples.   
However, because toxin production can vary between C. perfringens strains it is 
possible that 1 toxin assay is not necessarily sufficient for definitive diagnosis. In 
addition, the degree to which toxins are produced and present between equine isolates can 
vary enormously and can be down-regulated at times by the equine hindgut microflora 
making multiple samples over time necessary to avoid false negatives. Lastly, it is 
important to keep in mind that healthy horses can be carriers of C. perfringens without 
exhibiting any outward signs of enteric illness. The rate of infection can range from 0% 
to 8% in the feces of healthy adult horses (Herholz et al., 1999; Weese et al., 2001; 
Waggett et al., 2010). 
 Salmonella spp. 
Historical Perspective 
Salmonella spp. are commonly implicated as a pathogen in 1 of 4 major 
conditions: chronic asymptomatic carriage, typhoid fever, bacteremia and 
enterocolitis/diarrhea. The manifestation of disease is dependent on the salmonella 
serovar present and the susceptibility of the host to infection (Fierer and Guiney, 2001).  
O   st   t r st  s s         ‘s      st t           tr  ut    t    t r     t s     
diarrhea. It is believed that 3 million human deaths occur each year due to non-typhoid 
salmonella.  Furthermore, it has also been reported that 200 million to 1.3 billion human 
cases of intestinal disease on an annual basis are a consequence of Salmonella infection, 
which does not include cases that were not reported (WHO, 2005). Nosocomial infection 
with salmonella has also been of great concern in the equine industry for the past 30 yrs. 
I  t     r y 1980‘s t  r  w s     ut r       s         s s  t t   U  v rs ty          r   -
Davis Vet Med Hospital. This outbreak, in addition to lasting 10 mo, led to temporary 
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closure of the hospital for 3 mo to facilitate disinfection (Hird et al., 1984).  Outbreaks of 
salmonellosis have also occurred in 1995 at Colorado State University resulting in 
$500,000 in lost revenue and facility renovation (Dunowska et al., 2007), and Michigan 
State University in 1996 resulting in closure of the veterinary hospital for 1 mo and an 
extremely high case fatality of 44% (8/18 horses) (Schott et al., 2001).  Furthermore, in 
2000 an outbreak at Purdue University led to hospital closure for 3 mo and $250,000 - 
$300,000 loss for cleaning, renovation, mortality and loss of business (Ward et al., 2005).  
Most recently, in 2004 the University of Pennsylvania Veterinary Teaching Hospital had 
an outbreak closing this hospital for 3 mo and losses included an estimated $4 million in 
renovations, equine patient mortality and a reduced case-load for 10 mo following the re-
opening (Dallap et al., 2010). It is extremely apparent that salmonellosis is of great 
concern in the equine industry, and in the past has led to enormous losses in the hospital 
setting both financially and in terms of mortality. Of most concern is that these losses 
persisted long after cessation of the initial infection. This continuation of losses can be 
attributed to the persistence of this pathogen as well as the ease of transfer from patient to 
patient. Lastly, although the list of losses due to nosocomial infection of salmonella is 
long for the equine industry, these losses do not include other undocumented or 
undiagnosed cases in a clinical setting or cases occurring that are never presented to a 
veterinary hospital. 
Salmonella is implicated in AAD in humans and even more so in animals (Owen, 
1975; Staempfli et al., 1992; Weese et al., 2002; Barr et al., 2012).  It has been shown 
that the inoculum size of salmonella required to induce diarrhea is 10,000-fold less when 
mice are pre-treated with antibiotics (Bohnhoff et al., 1964). Furthermore, many studies 
in horses have demonstrated an association between antimicrobial therapy and 
Salmonella spp. shedding (Baker and Leyland, 1973; Owen et al., 1983; Staempfli et al., 
1992).  In these studies salmonella shedding was preceded by treatment with potassium 
penicillin G, oxytetracycline and lincomycin although this does not rule out the ability of 
other antimicrobial therapies to induce salmonellosis. 
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Bacterium 
Salmonella are Gram-negative, rod-shaped and peritrichous. Unlike Clostridia 
they do not form spores and are facultative anaerobes which means they have the ability 
to both produce ATP by means of aerobic respiration and by fermentation in anaerobic 
environments. Therefore, Salmonella are able to survive for extended periods of time in a 
vegetative state due to their ability to flourish in the presence of oxygen. The genus 
Salmonella is comprised of two species: S. enterica which is subdivided into over 2500 
serovars and S. bongori (Ochman and Groisman, 1994; McClelland et al., 2001).  The 
serotype of particular concern in horses is S .enterica Typhimurium although all 
Salmonella spp. are considered to be pathogenic (Chen et al., 2004). This bacterium is a 
mixed-acid heterofermenter of glucose to produce ATP. The end-products of this 
fermentation include: CO2 , formate, acetate, lactate and succinate. In addition to glucose, 
S. enterica Typhimurium is also able to utilize maltose and maltodextrins for energy by 
using an ATP-binding cassette (ABC) transporter (Bordignon et al., 2010).  
Pathogenesis 
Salmonella spp. have the ability to adhere to intestinal epithelial cells and invade 
these cells causing damage to the outer membrane and villi as well as disrupting 
intracellular processes, allowing proliferation and survival of the pathogen. salmonella 
can also cause apoptosis of the host cell within 18 to 24 h post-invasion (Maaser et al., 
2002). However, the pathogenesis of salmonella in enterocolitis is believed to be 
primarily attributed to inflammation at the site of infection and production of enterotoxin, 
disrupting the absorption/secretion ratios of the intestinal mucosa leading to diarrhea.   
  It has been shown that salmonella adherence is facilitated by their flagella as well 
as multiple genetic factors that are unique to this pathogen.  In order to invade the cell 
and act on an intracellular level, salmonella depends on the function of type III secretion 
system-1 and 2 (TTSS-1, TTSS-2) that are encoded in the salmonella pathogenicity 
islands-1 and 2 (SPI-1, SPI-2) loci, respectively.  
SPI-1 encoded TTSS-1 allows for the transfer of effector proteins into the host 
cells cytoplasm.  TTSS-1 transfers these effector proteins by acting on Rho family 
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GTPases and actin to produce structural and physiological changes in the cytoskeleton 
    ‗    r    ru       ‘     w      r    t r    upt     SPI-1 also has functions that 
relate to the activation of immune pathways. Multiple TTSS-1 translocation effector 
proteins have been shown to induce inflammation by a variety of different mechanisms.  
For instance, the translocation effector sipA which is encoded on SPI-1 has been linked 
with the production of epithelial chemoattractant (PEEC) and consequent activation and 
recruitment of neutrophils to the site of salmonella infection, causing inflammation 
(Gewirtz et al., 1999; Lee et al., 2000). SPI-1 also has the ability to activate mitogen-
associated protein kinases (MAPKs), inducing NF-κβ  y                 t    u t p   
effectors leading to an inflammatory response (Hobbie et al., 1997).  Furthermore, sopE 
w    tr  s    t     t  t     st     ‘s  yt s     s           str t   t    us  t   release 
of pro-inflammatory cytokines IL-1β/I -18 (Hardt et al., 1998; Hapfelmeier et al., 2004).  
Other effectors associated with TTSS-1 (sopA, sopE2 and sptP) and TTSS-2 activity 
have also been implicated in the inflammatory response observed with salmonella 
infection but require further research and exploration. Lastly, Salmonella spp. also 
produce an enterotoxin (S-LT) which affects adenylate cyclase levels (Chopra et al., 
1987; Peterson et al., 1983).  This action inhibits sodium absorption in the intestine and 
stimulates chloride secretion. This allows for consequent fluid secretion into the intestinal 
lumen (Fromm et al., 1974; Rout et al., 1974).   
Culture and Identification 
For diagnosis of salmonella infection, selective and differential agar plates 
inoculated with fecal material are often employed. A chromogenic agar is available 
commercially for salmonella detection (BBL
TM 
CHROMagar
TM
 Salmonella, BD).  This 
media type has been shown to have a 100% sensitivity of salmonella detection and an 
83% specificity of salmonella detection. This is 28% more specific than what was 
observed using other media types (Xylose-Lysine-Desoxycholate Agar and Salmonella-
Shigella Agar; Maddocks et al., 2002). This media also allows for color differentiation 
between cultivable salmonella and contaminants that are not otherwise selected against in 
the media. This differentiation is due to metabolic differences between the bacteria and 
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allows colonies of salmonella species to appear mauve (rose to purple) in color, whereas 
undesired bacteria appear blue-green or colorless.  
 A concern of using culture methods for salmonella detection is that the organism 
may be present in the animal but may not be detected.  This problem can be solved by 
multiple day and sample collection for diagnosis or by utilizing other detection methods. 
Rectal biopsy culture for instance has been shown to be nearly twice as sensitive in 
detecting salmonella off a single fecal culture (Palmer et al., 1985). However, rectal 
biopsy methods are more invasive to the animal and therefore are not commonly used.  
Another option for salmonella detection is PCR. PCR is a more rapid and sensitive test in 
comparison to culture of fecal material (Cohen et al., 1996). It has been recommended 
that a horse with diarrhea be considered negative for salmonella if 2 PCR fecal sample 
tests are negative or if 5 fecal cultures are negative (Cohen and Divers, 1998).  An 
additional complication in the horse is that healthy horses often carry salmonella. In a 
study by McCain and Powell (1990) it was reported that 71.4% (50/70) of horses at 
slaughter were carriers of Salmonella spp.  This can make diagnosis of salmonellosis 
difficult without knowing the carrier status of the patient prior to the appearance of 
clinical symptoms. Therefore, in order to implicate salmonella without a reference level 
of salmonella, you must have a salmonella positive sample and have ruled out the 
possibility of other pathogens and coinciding toxins in the affected horse (Bartlett, 2002).   
Treatment of AAD 
 Typically AAD will resolve when antibiotic treatment is discontinued. However, 
this is not always the ideal option if the indication for a specific antibiotic therapy is 
correct and there are no alternatives available. There is a lot of literature available on the 
treatment of horses with colitis (Palmer and Benson, 1992; Cohen and Divers, 1998; 
Divers, 2002).  Treatments described are primarily supportive excluding a few select 
situations in which other therapies are required.   
 Supportive care is required in horses suffering from diarrhea or colitis and should 
be immediately provided upon onset of symptoms to maintain hydration, electrolyte and 
acid-base balance (Magdesian et al., 1997; Divers, 2002).  Typically a polyionic 
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crystalloid solution is preferred but the alternatives of saline solution or colloids can also 
be used if administered properly and appropriately (Bertone et al., 1990).  Drenching 
w t    u  s         tr  yt s  s r r  y p r  r     r   y     us    rs s‘ GIT t  t  r  
suffering from AAD and colitis are highly disturbed with altered intestinal motility. This 
altered intestinal motility increases passage rate and in rare cases can cause gastric reflux.  
Uptake of fluids from the intestinal lumen in AAD horses is typically compromised due 
to intestinal damage and inflammation depending on the case. Furthermore, nasogastric 
tubing to administer fluids also incur a higher risk of bleeding. Therefore, I.V. 
administration of fluid and electrolyte therapy is preferable.  It is important that fluids 
and electrolytes are administered at a high enough rate to combat endotoxemia and shock.  
This can require several in-dwelling venous catheters which can prove difficult to 
maintain when a horse is in distress. If endotoxemia or shock is already apparent colloids 
or hypertonic saline is typically preferable (Schusser et al., 2007).  Furthermore, a mild 
acidotic state can be corrected by rehydration but in a more severe metabolic acidosis 
cases acid-base balance therapy using a bicarbonate solution is necessary (Aleman et al., 
2001).  Non-steroidal anti-inflammatory drugs are also typically administered to horses 
with colitis to reduce the inflammatory response (Cohen et al., 1995).  These drugs 
should be administered with caution because the altered metabolic state in horses 
suffering from colitis can increase the risk of hyperproteinemia and dehydration in these 
horses.   
 As mentioned previously, the primary recommendation for horses suffering from 
AAD is to discontinue antibiotic treatment.  This can often be effective in eliminating 
AAD symptoms, however there are some circumstances in which antibiotic therapy may 
be necessary for recovery.  One such situation is if the antibiotic therapy causing the 
diarrhea and colitis symptoms were assigned correctly due to an overwhelming pre-
existing condition and there are no viable alternatives available. Antibiotic treatment may 
also be necessary to survival in more severe cases of AAD when the risk of septicemia is 
extremely high. There has been no indication that antibiotic therapy would prove 
beneficial when AAD is due to Salmonella infection.  However, when clostridia are 
suspected or diagnosed with the development of AAD, antibiotic therapy is often 
necessary to alleviate the infection.  Metronidazole has been demonstrated to be effective 
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when treating idiopathic acute colitis as well as C. difficile or C. perfringens associated 
colitis (McGorum et al., 1998; Weese et al., 2000; Weese et al., 2001).  In a previous 
study 8 horses with colitis that were treated with metronidazole survived while 5 of 7 
horses with colitis that were not treated died (McGorum et al., 1998).  
 Vancomycin is another antibiotic alternative used in humans for treatment of 
CDAD (Wenisch et al., 1996).  However, this treatment has been associated with 
antimicrobial resistance in enterococci and staphylococci in humans and is also much 
more costly than metronidazole therapy.  In a study by Magdesian and colleagues (1997), 
horses suffering from CDAD were treated with metronidazole therapy alone or 
vancomycin therapy and metronidazole therapy.  In result, diarrhea was resolved in 12 
out of 14 horses receiving both vancomycin and metronidazole therapy while 
metronidazole therapy alone was successful in 5 out of 7 horses. Therefore, although 
vancomycin therapy is costly, it may be necessary to most successfully treat diagnosed 
cases of CDAD.  Bacitracin is another antibiotic used in humans for the treatment of 
severe cases of CDAD (Wenisch et al., 1996).  This antibiotic, when used in horses with 
CDAD, has also been shown to have beneficial effects (Staempfli et al., 1992).  
However, there has been some evidence of antibiotic resistance in some C. difficile 
strains to bacitracin.  In 1 such study by Jang and colleagues (1997) they found that 40% 
of equine isolated C. difficile isolates were resistant to this antibiotic. Other studies have 
also demonstrated a 95 to 100% resistance of equine C. difficile strains to bacitracin, 
making it an unsuitable antibiotic for the treatment of CDAD in horses (Jang et al., 1997; 
Weese et al., 2001; Båverud et al., 2003).  Many studies have demonstrated susceptibility 
of C. difficile isolates to metronidazole and vancomycin therapy making them viable 
options for the treatment of CDAD (Weese et al., 2001; Båverud et al., 2003; Pituch et 
al., 2005).    
 There have been attempts to design anti-diarrheic products from many different 
pharmacological standpoints.  These include slowing passage rate of digesta, 
administration of binders, compounds that alter the balance favorably from secretion to 
  s rpt         st   t   y   tr  u     ‗    t y    t r  ‘      pr    t  s t  t        ut  
Although, there are many commercially available products that claim to be anti-diarrheic, 
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and are used in different clinical settings, there has been very little research performed to 
investigate the validity of these products. Probiotics assist in pathogen exclusion by 
strengthening the normal flora or reestablishing a disrupted flora (McFarland, 2000; 
Elmer, 2001). Minimal research has been done in humans or other animal models on the 
efficacy of different probiotic strains in the treatment of AAD.  In one study by Katz 
(2006) L. rhamnosus when administered as a probiotic was demonstrated to be effective 
in treatment of AAD in children.  In horses, Saccharomyces boulardii administered to a 
small population of horses (n=14) with AAD resulted in a significant decrease in the 
severity and duration of GI disease in a hospital setting (Desrochers et al., 2005).  
Although, this data supports the potential use of probiotics like S. boulardii for the 
treatment of GI disease (AAD), more research with a larger number of animals is 
necessary to fully evaluate this treatment option. However, probiotics have been 
demonstrated to be much more effective when administered with antibiotic therapy and 
are less effective or completely ineffective when administered after the development of 
AAD in humans (Guandalini, 2011).  This indicates that probiotics may be more useful in 
the prevention of AAD in horses instead of as a treatment option.   
Prevention of AAD 
The threat of AAD development does not warrant elimination of antibiotic use in 
horses.  Antimicrobial therapy is necessary for use in many different clinical applications 
and has numerous benefits to the health and wellbeing of the horse, as mentioned 
previously.  However, the risks of AAD should be taken into consideration when 
choosing whether antibiotic treatment is absolutely necessary (Weese et al., 2000) and 
when choosing an antibiotic to use (Wilson, 2001). More selective use of antibiotics 
could potentially reduce the incidence of AAD in horses, as this phenomenon has been 
observed in human hospitals (Spencer, 1998). It is also important to be familiar with what 
antibiotics are commonly associated with AAD and the effect of region on AAD 
occurrence (Hollis and Wilkins, 2009).   
Dietary modifications to support the stability and function of the normal flora 
could also be beneficial in preventing AAD in horses.  As mentioned previously in a 
study by Willing and colleagues (2009), it was demonstrated that diets high in fiber 
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promoted stability of the microbial population while diets high in non-structural 
carbohydrates were associated with disruption of the microflora. Rapidly fermentable 
carbohydrates are commonly associated with digestive disturbances in horses (Garner et 
al., 1978; Horner et al., 2000; Bailey et al., 2003).  Therefore, increasing dietary fiber 
and decreasing the amount of rapidly fermentable carbohydrate prior to antibiotic 
treatment, could prove a beneficial option for promoting stability of the hindgut 
microflora. In addition, a lot of research in swine has been performed looking at the 
effects of restricting dietary protein levels and providing high forage diets as opposed to 
high concentrate diets and the consequent effects on the incidence of diarrhea. These 
studies have demonstrated that the aforementioned dietary interventions could decrease 
incidence of pathogen colonization/proliferation including Clostridia in some instances 
as well as reduce the incidence of diarrhea in these animals (Partanen et al., 2002; 
Hopwood et al., 2004; Heo et al., 2008; Bhandari et al., 2009; Heo et al., 2009) 
Many studies performed in humans support the use of probiotics in the prevention 
of AAD (Floch et al., 2011).  Although equine specific probiotics have been available 
commercially for many yrs, very few controlled studies have been performed to evaluate 
the use of these probiotics in prevention of AAD.  Studies on the use of probiotics and 
consequent Salmonella-shedding in an equine hospital setting have demonstrated mixed 
results.  In a study by Ward and colleagues (2005), they found that the administration of a 
probiotic reduced Salmonella-shedding when it was administered to horses hospitalized 
for reasons not related to their GIT.  However, in two other studies when horses were 
hospitalized undergoing colic surgery there were no beneficial effects of probiotic 
administration (Parraga et al., 1997; Kim et al., 2001). Weese and colleagues (2004) 
suggested that the lack of result with probiotic administration could be due to inadequate 
dosing of viable organisms.  Several factors should be taken into consideration when 
selecting a probiotic including, the type and number of organisms as well as the timing of 
administration.  More research is necessary to elucidate the potential role of probiotics for 
the treatment of AAD in horses.  
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Current study: Changes to the equine hindgut microflora in response to antibiotic 
challenge 
 
Little is known about the severity and duration of microbial disturbances that 
occur with antibiotic treatment and its effects on digestion of feedstuffs in horses. The 
objectives of the current study were to determine the effects of sodium ceftiofur and 
trimethoprim-sulfadiazine on 1) the normal flora (lactobacilli and cellulolytic bacteria), 
AAD-associated pathogens (Clostridium difficile, Clostridium perfringens, Salmonella 
spp.) and overall microbial species richness in healthy horses and 2) microbial 
fermentative digestion and the production of energetic end-products (VFAs). The 
hypotheses included 1) that 1 or both of the normal flora enumerated would decrease 
after antibiotic challenge, and there would be a concomitant increase in at least 1 AAD-
associated pathogen, 2) microbial species richness would be altered with antibiotic 
challenge and 3) microbial fermentative digestion would be compromised by antibiotic 
challenge causing a decrease in digestibility and consequent VFA production.  The 
results of the current study could potentially help in devising intervention strategies to 
mitigate these disturbances.  Some prospective prevention or intervention options could 
include: supplemental antimicrobials, vaccinations, dietary interventions, prebiotics or 
probiotics.   
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Chapter 3: Materials and Methods 
All procedures were approved by the Institutional Animal Care and Use Committee at the 
University of Kentucky (IACUC Protocol #: 2010-0708). 
Animal Management 
Experimental Horses 
The experimental population for this study included 17 horses consisting of 
Thoroughbreds (n = 15), a Quarter Horse (n = 1) and a Paint × Thoroughbred cross (n = 
1) that were selected from the resident herd maintained by the Department of Animal and 
Food Sciences at Maine Chance Farm, Lexington KY. Horses were selected based on the 
following criteria: between 2 to14 y of age, no history of gastrointestinal disease, 
antibiotic or anti-inflammatory administration for at least 4 mo prior to the beginning of 
the study, and sufficiently sound for exercise. Each horse was dewormed with a broad 
spectrum anthelmintic 1 mo prior to antibiotic challenge.  
Treatment Assignments 
The experimental design was a randomized complete block using 3 treatments 
and 6 horses per treatment. The 3 treatments included the control treatment which 
received no antibiotic, the T. S. treatment in which the horse received 30.0 mg kg
-1
 of 
trimethoprim-sulfadiazine orally (Apple Uniprim, Macleod Pharmaceuticals, Inc., Fort 
Collins, CO), and the ceftiofur treatment in which horses received 2.2 mg kg
-1
 of sodium 
ceftiofur by intramuscular injection (Naxcel®, Pfizer Animal Health, Madison, NJ).   
Horses were divided into 6 blocks based on age and gender and 1 horse in each 
block was assigned to each treatment (Table 3.1). One block of 3 horses was used at a 
time because many of the experimental measurements were labor intensive. In addition, 
only 17 horses in the resident herd met the study criteria therefore, horse SC was placed 
in 2 blocks, block 1 as a control horse receiving no antibiotics and block 6 in the ceftiofur 
treatment (Appendix A). One wk prior to the adaptation period, horses were shod and 
then housed together in a paddock.  
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Table 3.1.: Experimental horse information, blocking and treatment assignments 
 
 
1 
Dates listed in 2011 
2 
M = Mare; G = Gelding 
3 
TB = Thoroughbred; QH = Quarter Horse; TB x PH = Thoroughbred × Pain Horse 
Cross 
 
   Control 
Sodium 
Ceftiofur 
Trimethoprim- 
sulfadiazine 
 
Date Range
1 
 
Gender
2 
Breed
3 
Age Breed Age Breed 
 
Age 
Block (mo/d – mo/d) (M/G) - (y) - (y) - (y) 
#1 04/18 - 05/23 M TB 11 TB 7 TB 11 
#2 05/30 – 07/05 G TB 5 TB 3 TB× PH 4 
#3 06/27 – 08/01 G TB 2 TB 5 TB 4 
#4 08/01 – 09/06 M QH 14 TB 13 TB 13 
#5 08/29 – 10/03 M TB 8 TB 6 TB 8 
#6 09/26 – 10/31 M TB 11 TB 11 TB 14 
Avg. 
Age 
- -  8.5  7.5  9 
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Each experimental block was 5 wks long (Table 3.2). Prior to receiving 
treatments, the horses were adapted to their individual diet, housing and exercise program 
for 3 wks (d -21  d -1). Two baseline fecal samples were obtained in the last wk of the 
adaptation period. The antibiotic treatments were then imposed for 1 wk (antibiotic 
challenge period; d 0  d 6) followed by a 1 wk (d 7  d 13) withdrawal period. All 
treatments were administered by trained third parties that did not have regular contact 
with the horses.  Three fecal samples were collected during both the antibiotic challenge 
and withdrawal periods.  The first antibiotic dose was given on d 0 of the antibiotic 
challenge period and the last dose was given on d 6 of the antibiotic challenge period. 
Consequently, the d 1 fecal sample collected during the antibiotic challenge period was 
collected 24 h after the first dose of antibiotic in the T.S. and ceftiofur groups, and the d 8 
fecal sample from the withdrawal period was taken 48 h after the last dose of antibiotic in 
the T.S. and ceftiofur groups.  The control horses were included to demonstrate that any 
changes in T.S. and ceftiofur horses were due to antibiotic treatment and not 
environmental changes or time. 
Housing 
Horses were housed in the Nutrition Shed at Maine Chance Horse Farm, 
University of Kentucky in individual 3 ×15 m partially covered runs with crushed 
limestone footing.  Horses were spaced with 1 run separating each horse as to avoid 
shared water source and minimize horse interaction. Each run contained an automatic 
water source (Mirafount 3390, MiraCo, Grinnell, IA) that was not accessible by other 
horses for the duration of each block. In addition, the feeding area of the run was 
equipped with rubber mats and a large rubber tub (1.35 m L × 0.635 m H; 378.54 L) 
bolted to the wall with screw eyes and clips to minimize feed loss and aid in collections 
of orts.  
Horses were allowed 6 h of turnout d
-1
 in a 43 × 17 m dry lot that was divided into 
3 equal segments by panels with 1 entrance/exit to keep cross fecal-contamination at a 
minimum (Block 1 - 3) or into 3 individual dry lots that were 10 × 10 m square pens 
(Block 4 - 6). Horses were randomly assigned to a specific pen and dry lot at the start of 
the adaptation period and the assignment did not change for the duration of the block  
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Table 3.2.: Schematic representation of the fecal sampling schedule
1
 used in the 
experiment 
1
Numbers in bold indicate days in which fecal samples were taken 
Treatment Period 
Range of 
Days 
Days 
Adaptation 
-21  -15 -21   -20   -19   -18    -17   -16     -15 
    -14  -8 -14   -13   -12   -11    -10   -9       -8 
-7  -1 -7     -6      -5    -4      -3     -2       -1 
Antibiotic Challenge 0  6  0      1        2      3      4        5       6 
Withdrawal   7  13  7      8        9     10    11     12      13 
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as to avoid cross contamination between treatments.  Each horse was also assigned a set 
of utensils (buckets, tubs, stall cleaning utensils) at the start of each block. Runs and pens 
were cleaned once daily after the morning feeding.  All assigned cleaning utensils and 
components of the runs and pens were thoroughly washed and disinfected between each 
block of horses.   
Diet 
Horses were fed alfalfa cubes (Hallway Feeds, Lexington, KY), pelleted 
concentrate (Hallway Feeds), and long stem grass hay (Maine Chance Farm).  Samples of 
the dietary components fed were sent to Dairy One (Dairy One, Ithaca, NY) for analysis 
after every block (Table 3.3, Appendix B). 
Concentrate and hay cubes were offered in a 20 : 80 ratio to all horses at either 2 
or 2.25% BW depending on body condition.  All horses within a block were fed at the 
same percentage of BW.  Horses were also offered 4.54 kg of grass hay in hay nets once 
daily.  
Full alfalfa cube and long stem grass hay daily allotments were given to each 
horse at 3:00 pm in their individual runs after turnout. Daily concentrate was divided in 
half with each horse receiving half of their concentrate at 7:00 am and the other half at 
3:00 pm. Morning concentrate was always fed at least 1.5 h prior to exercise as to avoid 
GI disturbance.  
Exercise 
Horses were exercised 4 d wk
-1
 for 35 min in a euro-style exerciser (Stratton 
Equine Enterprises Inc., Lexington) for the entire duration of each block. Horses were 
exercised at 8:30 am as to avoid the heat of the day. The exercise regimen consisted of 3 
different speeds: walk @1.61m s
-1
, a slow trot @ 2.71m s
-1
, and a moderate trot @          
3 m s
-1
.   
During the first 2 wks of adaptation, horses were gradually adapted to their pre-
determined exercise regimen starting with a lower intensity exercise program (primarily  
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Table 3.3.: Mean composition of the alfalfa cubes, concentrate and long stem hay fed to 
all horses (DM Basis) 
1, 2
  
1 
Dairy One Laboratories, Ithaca, NY 
2 
Mean ± SD; n=6 
3
 DM = Dry Matter; DE = Digestible Energy; CP = Crude Protein; ADF = Acid    
Detergent Fiber; NDF = Neutral Detergent Fiber; Ca = Calcium; P = Phosphorus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Feed 
Analyses
3          Alfalfa Cubes            Concentrate         Long Stem Hay 
% DM 89.50 ± 0.73 
 
90.1 ± 0.38 
 
91.9 ± 0.88 
 
DE 
(Mcal/kg) 
2.48 ± 0.12 
 
3.29 ± 0.13 
 
1.98 ± 0.07 
 
% CP 21.92 ± 1.84 
 
15.2 ± 1.15 
 
12.28 ± 0.54 
 
% ADF 29.75 ± 2.87 
 
12.35 ± 2.32 
 
40.5 ± 2.27 
 
% NDF 36.72 ± 4.56 
 
24.33 ± 4.43 
 
66.2 ± 2.24 
 
% Ca 1.95 ± 0.25 
 
1.17 ± 0.15 
 
0.64 ± 0.04 
 
% P 0.31 ± 0.05 0.92 ± 0.26 0.68 ± 0.07 
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walk and slow trot intervals). The rate of conditioning to the final exercise regimen was 
variable between blocks based on the physicality of the horses assigned to each specific 
block. All horses were performing their final exercise regimen by wk 3 of the adaptation 
period and continued until the end of each block. This final regimen started with a warm-
up of 5 min of walk, followed by 4 min at a slow trot and 3 min at a moderate trot. 
Horses were reversed and walked for 3 min followed by the same trot cycle. Horses were 
then again reversed, walked for 3 min followed by 5 min of slow trot and a 5 min 
walking cool down. The total distance traveled was approximately 4.7 km for each 
exercise bout.  
After exercise was complete, any horse that had not sufficiently cooled down or 
was still excessively sweaty was cold hosed or given a cold sponge bath.  Horses were 
then put into their dry lots for approximately 6 h.  
Feed Refusals 
Individual horse feed refusals were collected during the last wk of adaptation to 
determine a baseline intake and then during the antibiotic challenge and withdrawal 
periods. Leftover feed was collected from each horse 1.5 h after morning feeding each 
day. Feed was collected using pre-assigned disinfected cleaning utensils and pre-weighed 
collection buckets. 
 Refused feed was divided into concentrate, alfalfa cubes, clean hay, and dirty 
hay. Dirty hay consisted of any long stem grass hay that was urinated or defecated on, 
wet due to weather conditions, or not easily separated from another compound, such as 
hay in a dirt clod. Dirty hay, prior to weighing back, was put in a mesh laundry bag 
specific to the horse and was rinsed with water until the water ran clear. The bag was then 
hung until the bag and contents were dry, and then was weighed back to determine 
refusal amount.  All other feed refusals were weighed immediately after collection, and 
weights were logged separately in the refused feed log. Percent refused concentrate, 
alfalfa cubes, and long stem grass hay was then determined for each day by calculation 
using the amount initially provided of each feedstuff.  
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Temperature/Weight 
Rectal temperatures were taken twice daily with a digital thermometer and 
electively if compromised health was suspected.  Horses were also weighed twice a wk 
on a large animal scale (Trancell Technology, TI-500BNL, Buffalo Grove, IL).  
Measurements and Sampling Procedures 
Each sample day was scheduled and carried out in a similar manner as to avoid 
variation between blocks and individual sample days. On sample days, blood was first 
collected from each horse by venipuncture for laboratory analyses followed immediately 
by the morning allotment of concentrate. The morning feeding was provided at a similar 
time as on exercise days, and all other sample day events were scheduled accordingly.  
After completion of the meal, fecal samples were collected and aliquots were separated 
and processed. Once all fecal samples were obtained and in transport to the lab for 
analyses, physical exams on each horse were performed by a practicing veterinarian blind 
to treatments. Upon completion of all sample day scheduled events, horses were given 
their daily turnout allotment.  Horses were never exercised on sampling days.  However, 
sampling days were always preceded by an exercise day.   
Blood Samples 
Blood was drawn via jugular venipuncture on selected sample days (d -1, 1, 6, 8 
and 13), as a measure of health, but were not used for comparative purposes.  Blood 
draws were done using a vacutainer needle (20G × 1 ½ in, Becton, Dickinson and 
Company (BD), Franklin Lake, NJ) with 2 tubes drawn per horse, prior to morning 
feeding. The first tube drawn was a tri-potassium ethylenediaminetetraacetic acid (K3 
EDTA) 7.0 mL tube (BD) and the second was a serum 10.0 mL tube (BD).  These tubes 
were immediately transported to Rood and Riddle Equine Hospital for complete blood 
count (CBC) and serum chemistry analyses. Serum chemistry analyses included: blood 
urea nitrogen, creatinine, aspartate aminotransferase, total bilirubin, direct bilirubin, 
alkaline phosphatase, lactate dehydrogenase, creatine kinase, sorbitol dehydrogenase, 
gamma-glutamyl transpeptidase, albumin, calcium, phosphorus and glucose.    
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Fecal Sampling Procedures 
Following the completion of morning feeding, fecal samples were taken from 
each horse during defecation as catch samples prior to contact with the floor as to avoid 
ground contamination. The fecal sample was then weighed to make sure the sample was 
greater than or equal to 600 g. If the fecal sample was large enough it was then divided 
into 5 aliquots:  
Aliquot #1: 
 Aliquot #1 consisted of a ~1 g fecal sample for bacterial cultivation. The fecal 
sample was placed in a sterile Hungate tube. The rubber stoppers and twist caps were 
then replaced, and the tubes were purged of air with CO2 via a sterile 3 mL syringe and 
tuberculin needle (21G x 1 ½ in.; BD).  The sample was then placed in an insulated 
container that was maintained at 37 ºC with hot water bags.   
Aliquot #2:  
Aliquot #2 consisted of a ~250 g fecal sample to be used for in vitro dry matter 
digestibility (IVDMD) analysis, and to determine fecal DM and fecal pH. The sample 
was placed in a sterile plastic bag which was then purged of air with CO2 using a 3 mL 
sterile syringe (BD). Gasing continued until positive pressure was observed in the bag. 
The bag was twisted and tied off and placed in another identical bag that was twisted and 
tied off. This sample was then placed in an insulated container that was maintained at 37 
ºC with hot water bags.  
Aliquot #3:  
Aliquot #3 consisted of a ~ 150 g fecal sample to be used for measurement of in 
vitro gas production. The sample was placed in a sterile plastic bag which was purged of 
air with CO2 using a sterile 3 mL syringe (BD). Gasing continued until positive pressure 
was observed in the bag.  The bag was then twisted and tied off and placed in another 
identical plastic bag that was then twisted and tied off. This sample was then placed in an 
insulated container that was maintained at 37 ºC with hot water bags. 
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Aliquot #4:   
Aliquot #4 consisted of a ~50 g fecal sample that was placed in a sterile 50 mL 
conical tube (BD), shipped to the lab on ice, then frozen (-20 ºC) for HPLC analysis 
(Dionex, Sunnyvale, CA) to measure volatile fatty acid (VFA) composition of the fecal 
material.  
Aliquot #5:  
Aliquot #5 consisted of a ~50 g fecal sample that was placed in a sterile 50 mL 
conical tube (BD) and put immediately on ice. This sample was subdivided, frozen (-20 
ºC) and then later analyzed using polymerase chain reaction-denaturing gradient gel 
electrophoresis (PCR-DGGE) and for determining the presence of Clostridium difficile 
toxins A and B.  
All fecal samples were transported into the laboratory within 1 h of collection.  
Physical Exams 
Physical exams were performed by a practicing veterinarian on all sample days 
after fecal collections were completed.  Mucous membrane color, capillary refill time, 
heart rate, respiration rate, rectal temperature, attitude, and hindgut motility of all 4 
digestive quadrants were evaluated.  Notes on any other variable the veterinarian felt was 
pertinent to the health status of the horse were also recorded. A sample of the physical 
exam worksheet is available in appendix C. The practicing veterinarian performing the 
routine health checks was kept blind to treatment. If there was a need for experimental 
treatment assignments to be taken into consideration for diagnosis, a separate third party 
veterinarian was employed. 
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Laboratory Analyses 
Bacterial Media and Enumeration 
Upon arrival at the laboratory, the fecal samples were first weighed and then 
suspended in anaerobic phosphate buffered saline (PBS, 1:10 w/w, Appendix D) using 
aseptic technique.  The sample and PBS were mixed with a vortex until the suspension 
was homogenous (1 min).  The fecal suspension was then transported into an anaerobic 
chamber (Coy, Grass Lake, MI; 95% CO2, 5% H2) and subjected to serial dilution (10-
fold w/w, PBS) using a sterile 1ml tuberculin syringe and needle (1cc; 21G x 1 ½ in.; 
BD).  The dilution series were used to anaerobically inoculate enumeration media for 
Clostridium difficile, Clostridium perfringens, and cellulolytic bacteria.  Dilutions were 
then transported out of the anaerobic chamber to inoculate aerobic enumeration media for 
Salmonella spp. and Lactobacillus spp.  Solid media were inoculated (0.2 mL) with a 
sterile spreader. Plates with > 300 colonies were considered uncountable and were 
considered confluent growth. Countable plates were enumerated after incubation (37 ºC, 
3 d).   Liquid media were inoculated (1 mL) with a tuberculin syringe and needle (1cc; 
21G x 1 ½ in.; BD).  All bacterial enumeration components are summarized in Table 3.4. 
Cellulolytic Bacteria: 
Cellulolytic bacteria were enumerated in previously described anaerobic liquid 
media (Julliand et al., 1999; Appendix F) from dilutions 10
-1 
to 10
-10
 with amorphous 
cellulose as the substrate (Whatman #1 filter paper, Whatman, Tonglu, China).  
Incubations were carried out at 37ºC for 10 d.  Growth of cellulolytics were evaluated by 
dissolution of cellulose and microscopy every 24 h for 10 d.  The final dilution exhibiting 
dissolution of amorphous cellulose by d 10 was recorded as the viable number of 
cellulolytic bacteria.  The lag period prior to amorphous cellulose dissolution was also 
recorded for each sample.  Lag period is defined as the time between inoculation of the 
media and dissolution of the first cellulose strip. 
 
 70 
 
 
 
Table 3.4.: Summary of media, incubation conditions and identifying characteristics used 
to enumerate selected bacteria 
Bacteria Media Type Colony ID 
Anaerobic/ 
Aerobic 
Incubation 
Length, 
Temperature 
Cellulolytic 
Bacteria 
Cellulolytic Bacteria 
Medium 
dissolution of 
cellulose 
Anaerobic 10    37 ˚  
Lactobacillus 
spp. 
Rogosa SL Agar 
(BD) 
All colonies Aerobic 3    37 ˚  
Salmonella 
spp. 
BBL
TM 
CHROMagar
TM
 
Salmonella (BD) 
Dark mauve to 
light mauve 
colonies 
Aerobic 3    37 ˚  
Clostridium 
difficile 
Clostridium Difficile 
Selective Media 
(CDSA, BD) 
filamentous edges 
and yellow UV 
luminescent 
colonies 
Anaerobic 3    37 ˚  
Clostridium 
perfringens 
Sulfite Polymyxin 
Sulfadiazine Agar 
(SPS, BD) 
Black colonies Anaerobic 3    37 ˚  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 71 
 
Lactobacillus spp.: 
Lactobacillus spp. were enumerated on Rogosa SL Agar (BD) for dilutions 10
-1 
to 
10
-10  R   s  S       w s pr p r    s p r   u   tur r‘s su   st   s (App    x G)   
The plates were incubated aerobically (37 ºC, 3 d). All colonies were counted as 
lactobacilli. The highest dilution plate that was considered countable (< 300 colonies) on 
d 3 was recorded as the viable number of Lactobacillus spp.  
Salmonella spp.: 
Salmonella species were enumerated on pre-prepared BBL
TM 
CHROMagar
TM
 
Salmonella (BD) for dilutions 10
-1 
to 10
-10
.  BBL
TM 
CHROMagar
TM
 Salmonella was 
purchased as a pre-prepared media type. The plates were incubated aerobically (37 ºC, 3 
d). Dark mauve to light mauve colonies were counted as Salmonella spp. The highest 
dilution plate that was considered countable (< 300 colonies) on d 3 was recorded as the 
viable number of Salmonella spp. 
Clostridium difficile:  
C. difficile was enumerated on pre-prepared Clostridium Difficile Selective Agar 
(CDSA; BD) for dilutions 10
-1
 to 10
-3
. The plates were incubated in the anaerobic 
chamber (37 ºC, 3 d). Colonies with filamentous edges and yellow UV luminescence 
were counted as C. difficile.  The highest dilution plate that was considered countable (< 
300 colonies) on d 3 was recorded as the viable number of C. difficile. 
Clostridium perfringens: 
C. perfringens was enumerated on Sulfite Polymyxin Sufladiazine Agar (SPS; 
BD, Franklin Lake, NJ) for dilutions 10
-1
 to 10
-3
.  SPS media was prepared as per 
   u   tur r‘s su   st   s (App    x E)  T   p  t s w r     u  t      t       r     
chamber (37 ºC, 3 d). Black colonies were counted as C. perfringens. The highest 
dilution plate that was considered countable (< 300 colonies) on d 3 was recorded as the 
viable number of C. perfringens.  
 
 72 
 
Fecal Dry Matter, Fecal pH, Daisy II Incubation 
Upon arrival to the laboratory, aliquot #2 was opened and 1 g of feces was 
weighed out using an analytical balance (AE260 Deltarange Balance, Mettler-Toledo 
Inc., Columbus, OH) into a pre-weighed aluminum drying pan.  Each sample was then 
placed in a forced air drying oven at 55 ºC (VWR, Bridgeport, NJ). The sample was 
allowed to dry for 24 h or until a consistent weight was obtained. When taken out of the 
oven, samples were placed in a desiccator until they were weighed back using the same 
analytical balance. All fecal dry matters were performed in duplicate.   
Dry matter was calculated by using the equation: 
(Dry sample weight (g) ÷ Wet sample weight (g)) × 100 = % Dry Matter 
After the material for fecal dry matter was removed, a portable pH meter (IQ 
Scientific Instruments Inc., San Diego, CA) calibrated using a 4.0 pH solution and 7.0 pH 
solution was used to assess fecal pH.  The pH was taken for each sample without dilution.  
All fecal pH measurements were taken in duplicate.  
In vitro dry matter digestibility analysis was performed using a Daisy II Incubator 
(ANKOM Technology) following the method described by Earing and colleagues (2010). 
This type of incubator simulates digestion of the horse using digestion vessels in a heated 
cabinet. Vessels are equipped with   1 w y v  t    v  v  t  t     ws t   v ss  ‘s    t  ts 
to remain anaerobic. Each vessel is filled with a mixture of pre-prepared buffers and fecal 
material to simulate large intestinal digestion in the horse.  Samples of selected feedstuffs 
in filter bags are added to the jars prior to 48 h of incubation and dry matter 
disappearance from the bags is used to estimate dry matter digestibility. Three feedstuffs 
were tested: alfalfa hay, orchard grass hay, and tall fescue hay. These feedstuffs were 
chosen based on their differences in content of NDF and ADF.  
  Prior to sampling days, 0.25 g of each feedstuff were weighed into acetone rinsed, 
pre-labeled filter bags (ANKOM Technology) using an analytical balance (AE260 
Deltarange Balance, Mettler-Toledo Inc.).  Each feedstuff was prepared in triplicate with 
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2 control filter bags (empty), with a total of 11 filter bags for each fecal sample collected. 
The bags were then heat sealed and stored for further use.  
The night before each collection day the serological water bath (Boekel Scientific, 
F  st rv      PA) w s tur           s t t     t t  37 5 ˚   O  t    r              t    
buffers A and B (Appendix H) were placed in the water bath to pre-heat, and the Daisy II 
incubators were turned on.  After preheating, buffers A and B were mixed and placed in 
the incubation jars with assigned filter bags. These incubation jars were then placed in the 
pre-warmed incubator.  
When the fecal samples arrived they were placed in the water bath.  One at a time 
each sample was taken out of the water bath and 200 g of feces was weighed, placed in a 
blending jar, combined with pre-warmed mixed buffer solution and anaerobically 
blended for 30 sec.  This fecal/mixed buffer solution was placed in the pre-warmed 
incubation jar. The pH of the jar solution was adjusted to 7.0 and then purged of air with 
CO2     p         t      u  t r  J rs w r     u  t     r 48    t 37 5 ˚  w t     t  u us 
agitation.  After incubation filter bags were removed from the jar and washed with a 
gentle stream of cold water until the rinse water ran clear. Rinsed bags were then placed 
       r      r  v    t 55 ˚    r 24    r u t       w    ts w r     s st  t   In vitro dry 
matter digestibility (IVDMD) was calculated using these results. 
IVDMD was calculated for each sample and substrate using the equations:   
((Empty pre-bag weight × Bag correction factor) + Pre-sample weight) – Total post 
weight) = DM disappearance 
(DM disappearance ÷ Pre sample weight) × 100 = % IVDMD 
Gas Production System 
Fecal samples were used as inoculum for gas production measurements with 
alfalfa cubes as the substrate.  The ANKOM Gas Production System (ANKOM 
Technology) uses high sensitivity pressure monitoring with wireless communication from 
the gas production vessels to the computer software.    
 74 
 
The night before a sample day the shaking water bath (Thermo Scientific, 
W  t     S) w s tur           s t t  37 5 ˚        u   rs A       w r  p         t   
water bath to equilibrate to temperature overnight (Appendix I). On the morning of 
collection buffer A and B were mixed and were purged of air with CO2 for 2 h.  The 
  x    u   r‘s pH w s t      just   t  6 8 us      p rt     pH  t r (IQ S    t     
Instruments, Inc.). Ground substrate (1 g, alfalfa hay cubes) was added to each gas 
production vessel as well as a small volume of mixed buffer to moisten the substrate.  
When the fecal samples arrived they were placed in a water bath (Thermo 
S    t    ) t   qu    r t  t  37 ˚  u t   pr   ss     A      t      v  u       x    u   r 
was added to each vessel and the vessels were gassed with CO2, capped, and placed in the 
water bath.  One at a time each fecal sample was taken out of the water bath and 150 g of 
fecal inoculum was weighed out using a bench top scale (Mettler Toledo).  The inoculum 
was then placed in a pre-warmed blending jar with mixed buffer and homogenized 
anaerobically. 
  Blended fecal/mixed buffer solution was filtered through cheese cloth to remove 
any large particles and was distributed into the assigned anaerobic gas production vessels. 
The vessels were then mixed and fitted with modules. After purging the vessels to ensure 
a necessary anaerobic environment for fermentation, these modules were connected to the 
gas production system (ANKOM Technology) and sample analysis was started. For each 
fecal sample the substrate analysis was performed in triplicate with 2 control vessels per 
sample containing no substrate.  Gas production was measured for 24 h. Cumulative gas 
production for the 3 vessels containing substrate was calculated by subtracting the mean 
value of the 2 control vessels from the value of each sample vessel. After the recording 
period, gas production modules were removed and the pH of the vessel was measured 
using a portable pH meter (IQ Scientific Instruments Inc.). These values were used to 
check for similarity within the triplicate vessels and not for data collection purposes. 
VFA Analysis 
Fecal samples were tested for their VFA composition using HPLC (Dionex, 
Sunnyvale, CA) with a refractive index detector (Shodex/Showa Denko, Kanagawa, 
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Japan). A guard column was employed to protect the ion exclusion column from 
impurities (Micro-Guard Cation-H cartridge, Bio-Rad, Hercules, CA). The ion exchange 
column (Aminex, HP-87H, Bio-R    H r u  s   A) w s  p r t    t 50 ˚   t      w r t  
of .4 mL min
-1 
for 45 - 70 min per run, with a 5 mM H2SO4 mobile phase (Fisher, 
Pittsburgh, PA).  With this method most VFAs can be quantified including lactate 
concentrations as well as sugars and alcohols. VFAs specifically of interest in this study 
include: acetate, propionate, butyrate, lactate, phenylacetic acid isovalerate and/or 
methylbutyrate (IVMB).  All measures were performed in duplicate. The protocol for 
fecal sample preparation prior to HPLC analyses can be found in Appendix  J.    
Microbial Species Richness 
Microbial species richness in the equine hindgut was assessed by PCR-DGGE.  
The method consisted of first extracting metagenomic DNA from the fecal samples. This 
was done using the commercially available QiaAMP DNA Mini Stool Kit (QIAGEN, 
Valencia, CA; Appendix K).  DNA was extracted from each fecal sample in duplicate 
and combined prior to PCR. 
  The small ribosomal subunit was then amplified by PCR using universal 16S 
primers, 341-GC and 901R (Casamayor et al., 2000; Appendix L).  Each sample was 
amplified in duplicate, and PCR products were combined to attain a necessary volume for 
DGGE.  Each PCR product was also electrophoresed and imaged on an agarose gel to 
verify the presence of DNA and amplicons of an expected length (Appendix M). PCR 
product was stored at -20 ºC until DGGE.   
 A 6% polyacrylamide gel was prepared using a 40 to 60% denaturing gradient 
and a 20 well comb (Appendix N).  After polymerization, the gel was placed in 1 x TAE 
buffer in the DCode System (BioRad) where it was loaded with PCR-amplified DNA.  
To aid in loading accuracy, PCR products were first mixed with a loading dye for ease of 
visualization.  Additionally, preliminary work performed by Earing et al. (2012), 
      t   t  t ‗s      ‘   t      urs    t    uts        s    s qu  t y s  w    t   
banding pattern. Therefore, the 2 outermost lanes were left empty (Figure 3.1).  
Amplified DNA was run in duplicate in adjacent lanes.   
   
7
6
 
 
 
 
 
 
 
Figure 3.1.: Illustration of 20- well polyacrylamide gel sample and control placements. Each rectangle represents one lane on the gel.  
Lanes 1, 2, 19 and 20 were left empty. Lanes 3, 8, 13 and 18 were control samples used for standardization purposes.  Duplicate 
samples were run in adjacent lanes.   
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Control samples, used to normalize each gel, were run in multiple lanes across the gel. 
After loading was completed, samples were electrophoresed for 17 h at 56 ºC.  Following 
electrophoresis, the gel was stained using Gel Red and imaged using the Kodak Gel 
Logic 200 Imaging System (1D Image Analysis Software V3.6.5, Rochester, NY).   The 
banding pattern observed in each lane represented the microbial species richness of each 
individual sample (Figure 3.2).      
Gel images were imported into BioNumerics Software (Applied Maths, Austin, 
TX).  Although each sample was run in duplicate, the lane with the most bands was 
selected for subsequent analysis.  The 4 bands in the control lanes were treated as 
reference points and were selected and used to normalize the gel.   The minimum 
profiling value was set at 5% of the maximum value of the lane.  Bands were identified 
by the software and additional apparent bands were manually identified.  The banding 
p tt r s w r     p r    s   p r   t s     r ty   tw    s  p  s us        ‘s     r t      
Clostridium difficile Toxins A and B 
The presence of Clostridium difficile toxins A and B in fecal samples were 
detected by use of a specific enzyme-linked immunosorbant assay (ELISA; C. Difficile 
Tox A/B II, Techlab, Blacksburg, VA).  Fecal samples were sent to the University of 
Kentucky Veterinary Diagnostic Laboratory for analyses.   
Statistical Analyses 
All data were analyzed as individual sample days. Enumeration data were 
normalized by log10 transformations prior to statistical analyses while all other data 
collected were analyzed as raw values.  
The following statistical procedure was performed for the analysis of fecal pH, 
fecal DM, bacterial enumerations, in vitro dry matter digestibility and in vitro gas 
production. Adaptation d -4 and d -1 w r    rst    p r    y   Stu   t‘s t-test.   If there 
was no difference between the sample days (P > 0.05), d -4 was excluded from the data 
analysis. The first analyses were performed to discern the effect of antibiotic challenge.  
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Figure 3.2.: Example image of a DGGE gel following staining with Gel Red 
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Days -1, 1, 3 and 6 were analyzed using a repeated measures design with the PROC 
MIXED procedure of SAS (version 9.2, SAS Institute, Inc. Cary, NY). The class 
statement in all PROC MIXED models employed specified horse, treatment, time and the 
variable of interest as the categorical effects. A model statement was included to define 
the mean regression model for the data, including the response variable of interest (pH, 
dry matter, etc.) as the dependent variable and  block, treatment, time and the interaction 
between these variables (treatment × time) as fixed effects. Horse was also included in 
the statistical model as a random effect.   The Kenward-Roger method was used to 
compute the denominator degrees of freedom for the fixed effects.  Furthermore, in the 
lsmeans statement, the pdiff option was selected to request that the differences of the 
least square means of all possible comparisons made, be displayed in the output.  Lastly, 
5 different repeated statements were tested with each analysis. All statements included a 
different covariance structure; autoregressive 1 (ar1), unstructured (unr), ante-dependence 
(ante 1), banded toeplitz (toep) and heterogenous autoregressive 1 (arh) and included a 
prompt (rrcorr) for the output to display the correlation relationship.  The statistical 
      w t  t     w st S w ‘s   y s    I   r  t     r t r   ( I ) v  u  w s t    us   
to interpret results for each variable of interest.   
When there was an overall effect of treatment, time or a treatment × time 
  t r  t    (P < 0 05)     st squ r     s w r  s p r t   us      Stu   t‘s t-test 
comparing control to T. S. and control to ceftiofur within time point. In addition, pairwise 
comparisons were made within each treatment group to compare individual treatment 
groups over time. This statistical procedure was repeated for each variable of interest to 
determine the effect of antibiotic withdrawal using d 6, 8, 10 and 13 as described above. 
One horse (My Boy George, Block #2, T. S.) was removed from these analyses due to 
missing data during the withdrawal period.   
Feed refusal results and VFA concentrations were also analyzed using the 
statistical model described above.  However, because analyses were performed at 
different time points for these measurements (VFA: d -4, -1, 1, 6, 13; Feed Refusals: d -7 
to 13), comparisons were made between all days within the same statistical model as 
opposed to 2 separate analyses for the effect of antibiotic challenge and withdrawal.  
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For the microbial species richness analyses (PCR-DGGE) fecal samples from d -
4, -1, 1, 6 and 13 were analyzed. Comparisons within treatment group over time and 
  tw    tr  t   t  r ups w t      t    p   t  w r      us        ‘s     r t   
reported as percent similarity. An UPGMA analysis was conducted and a dendogram was 
constructed to visually identify relationships. Percent similarity differences were 
identified using PROC GLM of SAS.  If there was no difference between similarities of 
sample days d -4 and d -1(P > 0.05), similarity values including d -4 were excluded from 
the data analysis. Statistical significance in the current study was set at P < 0.05. 
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Chapter 4: Results 
Feed Refusals 
 Feed refusals were measured during the last week of adaptation, during the 
antibiotic challenge period and during the withdrawal period. Because horses were fed 
different amounts (based on BW) feed refusals are represented as % of feed offered.  
When comparing alfalfa cube percent refusals (Table 4.1.a) there were no treatment (P = 
0.4839), time (P = 0.6557) or treatment by time interaction (P = 0.4733).  The mean 
refusal of alfalfa cubes for all horses on the study was 7.82% during adaptation, 7.26% 
during the antibiotic challenge and 6.41 % during the withdrawal period.  
   Similar results were found for pelleted concentrate (Table 4.1.b) and long stem 
hay percent refusals (Table 4.1.c). When comparing pelleted concentrate percent refusals, 
there were no treatment (P = 0.9878), time (P = 0.9643) or treatment by time interactions 
(P = 0.9985).  The mean refusal of pelleted concentrate was 0.09% during adaptation, 
0.01% during the antibiotic challenge and 0% during the withdrawal period.   
When comparing percent refusals of long stem hay there were no treatment (P = 
0.1281), time (P = 0.2689) or treatment by time interactions (P = 0.7563).  The mean 
refusal of long stem hay was 74.00% during adaptation, 71.85% during the antibiotic 
challenge and 70.59% during the withdrawal period. Raw data for feed refusals can be 
found in appendix 0.  
Cellulolytic Bacteria 
During the adaptation period (d -4, -1) 10
5 
to 10
8 
cellulose-degrading bacteria per 
gram of feces were observed in the samples.  There was a treatment by time interaction 
for cellulolytics when comparing samples taken at the end of the adaptation period (d -1) 
and during the antibiotic challenge (d 1, 3, 6; P = 0.0004; Figure 4.1.). The number of 
cellulolytic bacteria in the feces of control horses (no antibiotic) did not change (P > 
0.05). However, 24 h after the first antibiotic dose (d 1), both the T. S. (P < 0.05) and the 
ceftiofur (P < 0.05) horses had a decrease in cellulolytics. Cellulolytic bacteria in T. S. (P 
< 0.05) and ceftiofur (P < 0.05) horses continued to decrease through the last day of 
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Table 4.1. a: Effects of antibiotics on alfalfa cube refusals (Least square means) 
Refused Alfalfa Cubes (Avg. % offered)
1,2
 
Treatment 
Group
3 
Adaptation 
Period 
Antibiotic Challenge 
Period 
Withdrawal 
Period 
Avg. 
(%)  
Control 
 
6.26 
 
4.90 3.12 4.77 
T. S.
 
 
10.90 
 
8.58 9.43 9.63  
Ceftiofur 
 
6.28 
 
8.28 6.68 4.77 
Avg. (%) 
 
7.82  
 
7.26  
 
 
6.41  
 
1
Treatment: P = 0.4839; Time: P = 0.6557; Treatment × Time: P = 0.4733 
2
Pooled SEM: Treatment = 2.75, Time = 1.75, Treatment × Time = 3.03 
3
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
Table 4.1. b: Effects of antibiotics on pelleted concentrate refusals (Least square means) 
1
Treatment: P = 0.9878; Time: P = 0.9643; Treatment × Time: P = 0.9985 
2
Pooled SEM: Treatment = 0, Time = 0, Treatment × Time = 0 
3
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
Refused Pelleted Concentrate (Avg. % offered)
1,2
 
Treatment 
Group
3 
Adaptation 
Period 
Antibiotic Challenge 
Period 
Withdrawal 
Period 
Avg. 
(%) 
Control 
 
0.13 
 
0 0 0.04 
T. S. 
 
0.01 
 
0 0 0  
Ceftiofur 
 
0.13 
 
0.04 0 0.06  
Avg. (%)
 
 
0.09  
 
0.01 0   
 83 
 
 
Table 4.1. c: Effects of antibiotics on long stem hay refusals (Least square means) 
1
Treatment: P = 0.1281; Time: P = 0.2689; Treatment × Time: P = 0.7563 
2
Pooled SEM: Treatment = 4.24, Time = 2.72, Treatment × Time = 4.71 
3
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Refused Long Stem Hay (Avg. % offered)
1,2
 
Treatment 
Group
3 
Adaptation 
Period 
Antibiotic Challenge 
Period 
Withdrawal 
Period 
Avg. 
(%) 
Control 
 
67.53 
 
62.25 63.52 64.44  
T. S. 
 
79.44 
 
76.94 75.40 77.26  
Ceftiofur 
 
75.05 
 
76.35 72.86 64.44  
Avg. (%) 
 
 
74.00  
 
71.85  70.59   
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Figure 4.1.: Viable number of cellulolytic bacteria in feces of horses at the end of the 
adaptation period (d -1) and during the antibiotic challenge period (d 1, 3, 6). 
Horses were administered: no antibiotic (control; hatched bars), trimethoprim-
sulfadiazine (T. S.; oral, 30 mg kg
-1
; black bars), or sodium ceftiofur (ceftiofur; 
intramuscular, 2.2 mg kg
-1
; grey bars). The enumerations were performed in 
anaerobic liquid media with amorphous cellulose as the growth substrate.  The 
tubes were incubated (37 °C) for 10 d. Samples taken at the end of adaptation 
period (d -1) and during the antibiotic challenge period (d 1, 3, 6) are separated by 
a vertical dashed line. Means lacking a common English letter are different within 
time point (P < 0.05). Means lacking a common Greek letter are different over 
time within a treatment group (P < 0.05); Treatment: P = 0.0002, time: P < 
0.0001 and treatment × time:  P = 0.0004; Pooled SEM: treatment = 0.18, time = 
0.16 and  treatment × time = 0.28 (log10 transformed). 
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the antibiotic challenge (d 6). On d 6 the T. S. and ceftiofur horses had 10-fold to 1,000-
fold fewer cellulolytics than on d -1 of the adaptation period.   Furthermore, 8 of the 12 
horses that received an antibiotic had 10,000 or less cellulolytic bacteria per gram of 
feces after 7 d of antibiotic challenge.   
 When comparing the end of the antibiotic challenge (d 6) and the withdrawal 
period, there was no treatment by time interaction (d 8, 10, 13; P = 0.7023) or overall 
effect of time (P = 0.2241) for cellulolytic bacteria (Figure 4.2.). However, there was a 
treatment effect (P < 0.0001) for T. S (P < 0.05) and ceftiofur (P < 0.05) horses to have 
less cellulolytic bacteria detected than control horses. Even after 7 d of withdrawal from 
antibiotics, all but one horse treated with antibiotics had 10,000 or fewer cellulolytic 
bacteria per gram of feces.  Raw data from cellulolytic bacteria enumerations can be 
found in Appendix R.  
Cellulolytic Bacteria Lag Time 
            The mean lag time (the time in d from inoculation to dissolution of the first 
cellulose strip) of cellulolytic bacteria growth during the adaptation period was 
approximately 2 d for all treatment groups. There was a treatment by time interaction for 
cellulolytic bacteria lag time when comparing the end of the adaptation period (d -1) and 
the samples taken during antibiotic challenge (d 1, 3, 6; P = 0.0082; Figure 4.3.).  There 
were no changes observed in lag time of cellulolytic growth in control horses (P = 
0.6271). However, only 24 h after the first antibiotic dose was administered, ceftiofur 
horses had an increase in lag time to over 3 d (P < 0.05).  After 72 h of antibiotic 
challenge the T. S. horses also demonstrated this increase in lag time of cellulolytic 
growth (P < 0.05). Both T. S. (P < 0.05) and ceftiofur (P < 0.05) lag times then remained 
elevated throughout the antibiotic challenge period (d 6).  On d 6 cellulolytic bacteria 
from T. S. horses had a mean lag time of 3.3 d while cellulolytic bacteria in ceftiofur 
horses had a mean lag time of 3.7 d.    
When comparing lag time at the end of the 1 wk antibiotic challenge (d 6) and the 
withdrawal period (d 8, 10, 13), there was no treatment by time interaction (P = 0.8843) 
or overall effect of time (P = 0.5681; Figure 4.4).   
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Figure 4.2.: Viable numbers of cellulolytic bacteria in feces of horses at the end of the 
antibiotic challenge period (d 6) and during the withdrawal period (d 8, 10, 13).  
Horses were administered: no antibiotic (control; hatched bars), trimethoprim-
sulfadiazine (T. S.; oral, 30 mg kg
-1
; black bars), or sodium ceftiofur (ceftiofur; 
intramuscular, 2.2 mg kg
-1
; grey bars). The enumerations were performed in 
anaerobic liquid media with amorphous cellulose as the growth substrate.  The 
tubes were incubated (37 °C) for 10 d. Samples taken at the end of the antibiotic 
challenge period (d 6) and during the withdrawal period (d 8, 10, 13) are 
separated by a vertical dashed line. Means lacking a common English letter are 
different within time point (P < 0.05); Treatment: P < 0.0001, time: P = 0.2241 
and treatment × time:  P = 0.7023; Pooled SEM: treatment = 0.17, time = 0.15, 
treatment × time = 0.24 (log10 transformed). 
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Figure 4.3.: Fecal cellulolytic bacteria lag time in feces of horses at the end of the  
adaptation period (d -1) and during the antibiotic challenge period (d 1, 3, 6). 
Horses were administered: no antibiotic (control; hatched bars), trimethoprim-
sulfadiazine (T. S.; oral, 30 mg kg
-1
; black bars), or sodium ceftiofur (ceftiofur; 
intramuscular, 2.2 mg kg
-1
; grey bars). The enumerations were performed in 
anaerobic liquid media with amorphous cellulose as the growth substrate.  The 
tubes were incubated (37 °C) for 10 d.  Samples taken at the end of the adaptation 
period (d -1) and during the antibiotic challenge period (d 1, 3, 6) are separated by 
a vertical dashed line. Means lacking a common English letter are different within 
time point (P < 0.05). Means lacking a common Greek letter are different over 
time within a treatment group (P < 0.05); Treatment: P = 0.0001, time: P < 
0.0001 and treatment × time:  P = 0.0082; Pooled SEM: treatment = 0.15, time = 
0.14 and  treatment × time = 0.24 (log10 transformed). 
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Figure 4.4.: Lag time of cellulolytic bacteria in feces of horses at the end of the  
antibiotic challenge period (d 6) and during the withdrawal period (d 8, 10, 13). 
Horses were administered: no antibiotic (control; hatched bars), trimethoprim-
sulfadiazine (T. S.; oral, 30 mg kg
-1
; black bars), or sodium ceftiofur (ceftiofur; 
intramuscular, 2.2 mg kg
-1
; grey bars). The enumerations were performed in 
anaerobic liquid media with amorphous cellulose as the growth substrate.  
The tubes were incubated (37 °C) for 10 d.  Samples taken at the end of the 
antibiotic challenge period (d 6) and during the withdrawal period (d 8, 10, 13) 
are separated by a vertical dashed line. Means lacking a common English letter are 
different within time point (P < 0.05); Treatment: P < 0.0001, time: P = 0.5681 
and treatment × time:  P = 0.8843; Pooled SEM: treatment = 0.16, time = 0.14, 
treatment × time = 0.24 (log10 transformed). 
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However, there was a treatment effect, for T. S. and ceftiofur horses to have longer lag 
times of cellulolytic growth than control horses (P < 0.0001). In fact, 6 of the 33 
antibiotic treated samples taken during the withdrawal period had a lag time of 5 d.  Even 
after 7 d of withdrawal from antibiotics T.S. and ceftiofur horses had a mean lag time of 
3.8 d and 3.5 d, respectively while control horses remained at a lag time of 2 d. Raw data 
for cellulolytic bacteria lag time can be found in Appendix S. 
Lactobacillus spp.  
 When horses were adapted to their diet, housing and exercise schedule, 
approximately 60,000 to 815,000 colony forming units (c.f.u.) lactobacilli per gram of 
feces were observed in the samples. There was a treatment by time interaction for 
Lactobacillus spp. when comparing samples taken  at the end of  the adaptation period (d 
-1) and the antibiotic challenge (d 1, 3, 6; P = 0.0453; Figure 4.5.).   The mean number of 
lactobacilli in all treatment groups on d -1 was approximately 2.5 × 10
5 
c.f.u. per gram of 
feces.  The number of detectable lactobacilli did not change in the control horses over the 
course of the study (P > 0.05).  However, after only 24 h of the antibiotic challenge, fecal 
samples from ceftiofur horses had 45% fewer detectable lactobacilli in comparison to d -
1 enumerations (P < 0.05).  The number of detectable Lactobacillus spp. continued to 
decrease over the course of the 7 d antibiotic challenge (P < 0.05). After 7 d of antibiotic 
challenge (d 6), ceftiofur horses had 78% fewer lactobacilli than detected during 
adaptation (d -1).   There was a trend for T. S. horses to have decreased numbers of 
detectable lactobacilli after 7 d of antibiotic challenge in comparison to adaptation values 
(P = 0.0544).  On d 6, T. S. horses had 61% fewer lactobacilli than numbers detected on 
d -1.  
   When comparing the 1 wk withdrawal period (d 8, 10, 13) with the end of the 
antibiotic challenge (d 6), there was no treatment by time interaction (P = 0.1011).  
However, there was a treatment effect (P = 0.0253) for ceftiofur horses to have lower 
numbers of lactobacilli detected than control horses (P < 0.05), and a trend for T. S. 
horses to also have lower detectable numbers of lactobacilli (P = 0.0671; Figure 4.6.).  In 
addition, there was an effect of time (P = 0.0048) in which the detectable number of  
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Figure 4.5.: Viable number of Lactobacillus spp. in feces of horses at the end of the  
adaptation period (d -1) and during the antibiotic challenge period (d 1, 3, 6). 
Horses were administered: no antibiotic (control; hatched bars), trimethoprim-
sulfadiazine (T. S.; oral, 30 mg kg
-1
; black bars), or sodium ceftiofur (ceftiofur; 
intramuscular, 2.2 mg kg
-1
; grey bars). The enumerations performed Rogosa agar.  
The plates were incubated aerobically (37 °C) for 3 d. Samples taken at the end of 
the adaptation period (d -1) and during the antibiotic challenge period (d 1, 3, 6) 
are separated by a vertical dashed line. Means lacking a common English letter 
are different within time point (P < 0.05). Means lacking a common Greek letter 
are different over time within a treatment group (P < 0.05); Treatment: P = 
0.0192, time: P = 0.0048 and treatment × time:  P = 0.0453; Pooled SEM: 
treatment = 0.11, time = 0.08 and  treatment × time = 0.14 (log10 transformed). 
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Figure 4.6.: Viable number of Lactobacillus spp. in feces of horses at the end of  
the antibiotic challenge period (d 6) and during the withdrawal period (d 8, 10, 
13). Horses were administered: no antibiotic (control; hatched bars), 
trimethoprim-sulfadiazine (T. S.; oral, 30 mg kg
-1
; black bars), or sodium 
ceftiofur (ceftiofur; intramuscular, 2.2 mg kg
-1
; grey bars). The enumerations 
were performed on Rogosa agar.  The plates were incubated aerobically (37 °C) 
for 3 d. Samples taken at the end of the antibiotic challenge period (d 6) and 
during the withdrawal period (d 8, 10, 13) are separated by a vertical dashed line. 
Means lacking a common English letter are different within time point (P < 0.05). 
Means lacking a common Greek letter are different over time (P < 0.05); 
Treatment: P = 0.0253, time: P = 0.0048 and treatment × time:  P = 0.1011; 
Pooled SEM: treatment = 0.13, time = 0.09, treatment × time = 0.14 (log10 
transformed). 
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lactobacilli was lower on the last day of antibiotic challenge (d 6) in comparison to all 
fecal samples taken during the withdrawal period (d 8, 10, 13; P < 0.05). However, after 
7 d of withdrawal from antibiotics, T. S. and ceftiofur horses had 57% and 66.5% higher 
numbers of detectable lactobacilli than on the last day of the antibiotic challenge (d 6), 
respectively. Raw data for lactobacilli enumerations can be found in Appendix T. 
 Salmonella spp.  
During the adaptation period, the presence of salmonella in collected fecal 
samples was extremely variable.  The viable number of salmonella detected over all fecal 
samples taken during the adaptation period ranged from 0 to 5,000 c.f.u. of Salmonella 
spp. per gram of feces. Furthermore, 29 of the 36 samples taken during adaptation were 
salmonella positive.  However, despite this large variation among samples, there was a 
treatment by time interaction for the viable number of Salmonella spp. when comparing 
the end of the adaptation period enumerations (d -1) to samples during the 1 wk antibiotic 
challenge (d 1, 3, 6; P = 0.0114; Figure 4.7.).  Fecal samples from horses treated with T. 
S. demonstrated a > 25 fold increase on average in detectable numbers of salmonella 
from adaptation (d -1) to the last day of the antibiotic challenge (d 6; P< 0.05). 
Furthermore, there were no salmonella-negative samples in the T. S. group during 
antibiotic challenge.  In contrast, the number of viable salmonella in feces of control 
horses decreased 96.95% from d -1 to d 3 (P < 0.05) and remained low through the 
remainder of the 1 wk antibiotic challenge period (P < 0.05). Ceftiofur horses remained 
the same from adaptation (d -1) to the end of the antibiotic challenge period (d 6; P > 
0.05).  Ten of the 18 control samples and 2 of the 18 ceftiofur samples had no detectable 
salmonella during the 1 wk antibiotic challenge. 
 When comparing the last day of antibiotic challenge (d 6) to the 1 wk withdrawal 
period samples (d 8, 10, 13), there was no treatment by time interaction (P = 0.6528) or 
overall effect of time (P = 0.0890; Figure 4.8.).  There was a treatment effect (P = 
0.0098) in which T. S. (P > 0.05) and ceftiofur (P > 0.05) fecal samples had higher 
detectable levels of salmonella than control horses. After 7 d of withdrawal from 
antibiotics, fecal samples from horses that had been treated with T. S. and ceftiofur had  
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Figure 4.7.: Viable number of Salmonella spp. in feces of horses at the end of the  
adaptation period (d -1) and during the antibiotic challenge period (d 1, 3, 6). 
Horses were administered: no antibiotic (control; hatched bars), trimethoprim-
sulfadiazine (T. S.; oral, 30 mg kg
-1
; black bars), or sodium ceftiofur (ceftiofur; 
intramuscular, 2.2 mg kg
-1
; grey bars). The enumerations were performed on 
   ™  HRO    r™ S          (    Fr             NJ)   S  p  s t      t 
the end of the adaptation period (d -1) and during the antibiotic challenge period 
(d 1, 3, 6) are separated by a vertical dashed line. Means lacking a common 
English letter are different within time point (P < 0.05). Means lacking a common 
Greek letter are different over time within a treatment group (P < 0.05); 
Treatment: P = 0.0195, time: P = 0.8437 and treatment × time:  P = 0.0114; 
Pooled SEM: treatment = 0.15, time = 0.13, treatment × time = 0.23 (log10 
transformed). 
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Figure 4.8.: Viable number of Salmonella spp. in feces of horses at the end of the 
antibiotic challenge period (d 6) and during the withdrawal period (d 8, 10, 13). 
Horses were administered: no antibiotic (control; hatched bars), trimethoprim-
sulfadiazine (T. S.; oral, 30 mg kg
-1
; black bars), or sodium ceftiofur (ceftiofur; 
intramuscular, 2.2 mg kg
-1
; grey bars). The enumerations were performed on 
   ™  HRO    r™ S          (    Fr             NJ)   T   p  t s w r  
incubated aerobically (37 °C) for 3 d.  Samples taken at the end of the antibiotic 
challenge period (d 6) and during the withdrawal period (d 8, 10, 13) are 
separated by a vertical dashed line. Means lacking a common English letter are 
different within time point (P < 0.05); Treatment: P = 0.0098, time: P = 0.0890 
and treatment × time:  P = 0.6528; Pooled SEM: treatment = 0.21, time = 0.16, 
treatment × time = 0.25 (log10 transformed). 
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300 times and 75 times the number of salmonella in comparison to control horses, 
respectively.  Raw data for salmonella enumerations can be found in Appendix U.  
Clostridium difficile 
There was no detectable C. difficile in fecal samples on d -1, and there was no C. 
difficile in samples from any control horse over the course of the study. There was a 
treatment by time interaction for C. difficile when comparing samples taken  at the end of 
the adaptation period (d -1) and during the 1 wk antibiotic challenge (d 1, 3, 6; P < 
0.0001; Figure 4.9.).  Only 24 h after the first antibiotic dose, fecal samples from both the 
T. S. horses (P < 0.05) and the ceftiofur horses (P < 0.05) had detectable level of C. 
difficile. C. difficile numbers in the fecal samples from T. S. horses continued to increase 
until d 3 of the antibiotic challenge (P < 0.05) and remained elevated throughout the 
remainder of the challenge (d 6; P > 0.05).  C. difficile in fecal samples from ceftiofur 
horses did not increase any further after d 1, however they did remain elevated through 
the remainder of the 1 wk antibiotic challenge (d 6; P > 0.05).  All horses that received 
antibiotics were C. difficile-positive during the treatment period.  The mean number of C. 
difficile in fecal samples of horses treated with T. S. and ceftiofur was approximately 
20,000 and 10,000 c.f.u. per gram of feces, respectively, at the end of the antibiotic 
challenge (d 6).   
When comparing the last day of antibiotic challenge (d 6) to the 1 wk withdrawal 
period samples (d 8, 10, 13) there was a treatment by time interaction (P = 0.0209; Figure 
4.10.).  There continued to be no detectable levels of C. difficile in samples from control 
horses during the withdrawal period.  Ceftiofur horses had decreased numbers of fecal C. 
difficile on d 10 of the withdrawal period in comparison to the end of the antibiotic 
challenge (d 6; P < 0.05) but remained at the same level for the remainder of the 
withdrawal period. Horses in the T. S. group had decreased fecal enumerations of C. 
difficile at the end of the withdrawal period (d 13) in comparison to the end of the 1 wk 
antibiotic challenge (d 6; P < 0.05).  At the end of the 1 wk withdrawal period (d 13) T. 
S. and ceftiofur horses had 92% and 95% less C. difficile than at the end of the antibiotic 
challenge (d 6), respectively.  Raw data for C. difficile enumerations can be found in 
Appendix V.  
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Figure 4.9.: Viable number of Clostridium difficile in feces of horses at the end of  
the adaptation period (d -1) and during the antibiotic challenge period (d 1, 3, 6). 
Horses were administered: no antibiotic (control; hatched bars), trimethoprim-
sulfadiazine (T. S.; oral, 30 mg kg
-1
; black bars), or sodium ceftiofur (ceftiofur; 
intramuscular, 2.2 mg kg
-1
; grey bars). The enumerations performed on 
Clostridium Difficile Selective Agar (BD, Franklin Lake, NJ). The plates were 
incubated anaerobically (37 °C) for 3 d. Samples taken at the end of the 
adaptation period (d -1) and during the antibiotic challenge period (d 1, 3, 6) are 
separated by a vertical dashed line. ND-not detected.  Means lacking a common 
English letter are different within time point (P < 0.05). Means lacking a common 
Greek letter are different over time within a group (P < 0.05); Treatment: P < 
0.0001, time: P < 0.0001and treatment × time:  P < 0.0001; Pooled SEM: 
treatment = 0.22, time = 0.19, treatment × time = 0.33 (log10 transformed). 
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Figure 4.10.: Viable number of Clostridium difficile in feces of horses at the end of the 
 antibiotic challenge period (d 6) and during the withdrawal period (d 8, 10, 13).  
Horses were administered: no antibiotic (control; hatched bars), trimethoprim-
sulfadiazine (T. S.; oral, 30 mg kg
-1
; black bars), or sodium ceftiofur (ceftiofur; 
intramuscular, 2.2 mg kg
-1
; grey bars). The enumerations performed on 
Clostridium Difficile Selective Agar (BD, Franklin Lake, NJ). The plates were 
incubated anaerobically (37 °C) for 3 d. Samples taken at the end of the antibiotic 
challenge period (d 6) and during the withdrawal period (d 8, 10, 13) are 
separated be a vertical dashed line.  ND- not detected. Means lacking a common 
English letter are different within time point (P < 0.05). Means lacking a common 
Greek letter are different over time within a treatment group (P < 0.05). 
Treatment: P = 0.0006, time: P = 0.0007 and treatment × time:  P = 0.0209; 
Pooled SEM: treatment = 0.36, time = 0.30, treatment × time = 0.55 (log10 
transformed). 
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C. difficile toxins A and B were not detected in any sample taken over the course 
of the study.  
Clostridium perfringens 
Six of 36 samples taken during the adaptation period were positive for C. 
perfringens. C. perfringens occurred in all treatment groups, but there was no treatment 
by time interaction when comparing the adaptation period (d -1) and the 1 wk antibiotic 
challenge (d 1, 3, 6; P = 0.3858; Table 4.2.a).  The greatest number of C. perfringens in 
any sample was 2,500 c.f.u. per gram of feces. When comparing the end of the antibiotic 
challenge (d 6) with the 1 wk withdrawal period (d 8, 10, 13), there was no treatment (P 
= 0.0837), time (P = 0.2514) or treatment by time interaction (P = 0.8298) in detectable 
C. perfringens (Table 4.2.b).  Raw data for C. perfringens enumerations can be found in 
Appendix W.   
Fecal pH 
When comparing fecal pH measurements from the end of the adaptation period (d 
-1) to antibiotic challenge period samples (d 1, 3, 6) there were no treatment (P = 
0.3488), time (P = 0.0699) or treatment by time interaction (P = 0.4858; Table 4.3 a).  
Furthermore, there were no treatment (P = 0.2811), time (P = 0.0848), or treatment by 
time interaction (P = 0.7010) when comparing the end of the antibiotic challenge period 
(d 6) to samples during the withdrawal period (d 8, 10, 13; Table 4.3 b). Fecal pH values 
were very consistent over the course of the study. On d -1 the mean fecal pH over all 
treatment groups ranged from 6.46 to 6.63. During the antibiotic challenge period fecal 
pH ranged from 6.24 to 6.65 and ranged from 6.15 to 6.54 during the withdrawal period.  
The mean fecal pH of all samples collected was 6.39.  Raw data for fecal pH 
measurements can be found in Appendix X.  
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Table 4.2. a: Viable number of Clostridium perfringens in feces of horses at the end of 
the adaptation period (d -1) and during the antibiotic challenge period (d 1, 3, 6) 
 
1
Treatment: P = 0.0626; Time: P = 0.1866; Treatment × Time: P = 0.3858 
2
Pooled SEM: Treatment = 0.16, Time = 0.19, Treatment × Time = 0.33 (log10 
transformed) 
3
 The enumerations performed on Sulfite Polymyxin Sulfadiazine Agar (BD, Franklin 
Lake, NJ). The plates were incubated anaerobically (37 °C) for 3 d.  
4
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
Table 4.2. b: Viable number of Clostridium perfringens in feces of horses at the end of 
the antibiotic challenge period (d 6) and during the withdrawal period (d 8, 10, 13) 
1
Treatment: P = 0.0837; Time: P = 0.2514; Treatment × Time: P = 0.8298 
2
Pooled SEM: Treatment = 0.31, Time = 0.37, Treatment × Time = 0.41 (log10 
transformed) 
3
 The enumerations performed on Sulfite Polymyxin Sulfadiazine Agar (BD, Franklin 
Lake, NJ). The plates were incubated anaerobically (37 °C) for 3 d.  
4
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
Clostridium perfringens (c.f.u.  gram
-1
 of feces)
1,2,3
 
Treatment 
Group
4 
Adaptation 
Period (d) 
Antibiotic Challenge 
 Period (d) 
Avg. (c.f.u.  
gram
-1
 of feces) 
-1 1 3 6 
Control 33.33 41.67 25 0 25 
T. S.
 
16.67 300 66.67 416.67 200.00 
Ceftiofur 0 91.67 58.33 91.67 60.42 
Avg. (c.f.u.  
gram
-1
 of feces)
 
16.67 
 
144.45 
 
50 
 
169.45 
 
Clostridium perfringens (c.f.u.  gram
-1
 of feces)
1,2,3
 
Treatment 
Group
4 
Antibiotic 
Challenge Period 
(d) 
Withdrawal  
Period (d) 
Avg. (c.f.u.  
gram
-1
 of feces) 
6 8 10 13 
Control 0 0 0 0 0 
T. S.
 
416.67 70 50 20 139.17 
Ceftiofur 91.67 175 41.67 25 83.34 
Avg. (c.f.u.  
gram
-1
 of feces)
 
169.45 
 
81.67 
 
30.56 
 
15 
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Table 4.3. a: Fecal pH measurements in horses at the end of the adaptation period (d -1) 
and during the antibiotic challenge period (d 1, 3, 6; least square means) 
 
 
 
 
 
 
 
 
 
1
Treatment: P = 0.3488; Time: P = 0.0699; Treatment × Time: P = 0.4858 
2
Pooled SEM: Treatment = 0.28, Time = 0.66, Treatment × Time = 1.14  
3
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
Table 4.3. b: Fecal pH measurements in horses at the end of the antibiotic challenge 
period (d 6) and during the withdrawal period (d 8, 10, 13; least square means) 
 
 
 
 
 
 
 
 
 
 
1
Treatment: P = 0.2811; Time: P = 0.0848; Treatment × Time: P = 0.7010 
2
Pooled SEM: Treatment = 0.09, Time = 0.54, Treatment × Time = 1.03 
3
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
 
 
 
 
 
 
Fecal pH (pH)
1,2
 
Treatment 
Group
3 
Adaptation 
 Period (d) 
Antibiotic Challenge 
Period (d) Avg. pH (pH) 
-1 1 3 6 
Control 6.46 6.31 6.47 6.65 6.47 
T. S.
 
6.63 6.24 6.40 6.47 6.44 
Ceftiofur 6.57 6.30 6.30 6.31 6.37 
Avg. pH (pH)
 
6.55 6.28 6.39 6.47 
Fecal pH (pH)
1,2
 
Treatment 
Group
3 
Antibiotic Challenge 
 Period (d) 
Withdrawal  
Period (d) Avg. pH (pH) 
6 8 10 13 
Control 6.65 6.40 6.36 6.54 6.49 
T. S.
 
6.47 6.27 6.43 6.52 6.42 
Ceftiofur 6.31 6.23 6.15 6.27 6.24 
Avg. pH (pH)
 
6.47  6.30  6.31  6.44  
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Fecal Dry Matter 
When comparing fecal dry matter measurements from the end of the adaptation 
period (d -1) to samples taken during the antibiotic challenge (d 1, 3, 6) there was no 
effect of treatment (P = 0.6156), time (P = 0.5426) or any treatment by time interaction 
(P = 0.8837; Table 4.4.a).  Furthermore, there were no treatment (P = 0.3448), time (P = 
0.7863), or treatment by time interactions (P = 0.5170) when comparing the end of the 
antibiotic challenge (d 6) to samples during the withdrawal period (d 8, 10, 13; Table 
4.4b). On d -1 fecal dry matter on average ranged from 19.69% to 20.84%.  During the 
antibiotic challenge period fecal dry matter ranged on average from 22.49% to 24.27% 
and ranged on average from 19.96% to 24.63% during the withdrawal period.  Raw data 
for fecal dry matter measurements can be found in Appendix Y.   
In vitro Dry Matter Digestibility (IVDMD) Analysis 
 When comparing fecal alfalfa IVDMD values at the end of the adaptation period 
(d -1) to the antibiotic challenge period (d 1, 3, 6) there was no effect of time (P = 
0.2883), treatment (P = 0.0736) or any treatment by time interaction (P = 0.9824; Table 
4.5. a).  There were also no effects of treatment (P = 0.7073), time (P = 0.1902) or a 
treatment by time interaction (P = 0.6739) when comparing IVDMD of alfalfa at the end 
of the antibiotic challenge period (d 6) to the withdrawal period (d 8, 10, 13; Table 4.5. 
b).  Alfalfa IVDMD ranged on average from 56.41% to 68.32% during the adaptation 
period, 48.68% to 64.88% during the antibiotic challenge period and 49.14% to 64.79% 
during the withdrawal period.   
 Similar results were observed when using orchard grass and fescue as substrates. 
When comparing fecal orchard grass IVDMD at the end of the adaptation period (d -1) to 
the antibiotic challenge period (d 1, 3, 6) there was no effect of treatment (P = 0.2088) or 
any treatment by time interaction (P = 0.7434; Table 4.6. a). However, there was an 
effect of time (P = 0.04) in which orchard grass IVDMD was higher on d -1 than on d 1 
(P < 0.05). There were also no effects of treatment (P = 0.9945), time (P = 0.2133) or a 
treatment by time interaction (P = 0.6718; Table 4.6. b) when comparing IVDMD of 
orchard grass at the end of the antibiotic challenge period (d 6) to the withdrawal 
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Table 4.4. a: Fecal dry matter (%) measurements in horses at the end of the adaptation 
period (d -1) and during the antibiotic challenge period (d 1, 3, 6; least square means) 
 
 
 
 
 
 
 
 
 
 
1
Treatment: P = 0.6156; Time: P = 0.5426; Treatment × Time: P = 0.8837 
2
Pooled SEM: Treatment = 0.60, Time = 1.70, Treatment × Time = 2.70  
3
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
Table 4.4. b: Fecal dry matter (%) measurements in horses at the end of the antibiotic 
challenge period (d 6) and during the withdrawal period (d 8, 10, 13; least square means) 
 
 
 
 
 
 
 
 
 
 
1
Treatment: P = 0.3448; Time: P = 0.7863; Treatment × Time: P = 0.5170 
2
Pooled SEM: Treatment = 1.62, Time = 0.41, Treatment × Time = 0.72 
3
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
 
 
 
 
 
 
 
Fecal Dry Matter (%)
1,2
 
Treatment 
Group
3 
Adaptation  
Period (d) 
Antibiotic Challenge 
Period (d) Avg. DM (%) 
-1 1 3 6 
Control 20.84 23.36 24.27 24.05 23.13 
T. S.
 
20.45 24.09 23.10 23.30 22.74 
Ceftiofur 19.69 24.08 23.07 22.49 22.33 
Avg. DM (%)
 
20.32 23.84 23.48 23.38 
Fecal Dry Matter (%)
1,2
 
Treatment 
Group
3 
Antibiotic Challenge 
 Period (d) 
Withdrawal 
Period (d) Avg. DM (%) 
6 8 10 13 
Control 24.05 23.69 24.63 24.59 24.24 
T. S.
 
23.30 19.96 18.79 20.13 24.59 
Ceftiofur 22.49 23.07 22.66 22.26 22.62 
Avg. DM (%)
 
23.28 22.24 22.03 22.33 
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Table 4.5. a: Alfalfa in vitro dry matter digestibility (IVDMD) measurements at the end 
of the adaptation period (d -1) and during the antibiotic challenge period (d 1, 3, 6; least 
square means) 
 
1
Treatment: P = 0.0736; Time: P = 0.2883; Treatment × Time: P = 0.9824 
2
Pooled SEM: Treatment = 2.96, Time = 2.76, Treatment × Time = 4.78  
3 
Method: Appendix H 
4
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
Table 4.5. b: Alfalfa in vitro dry matter digestibility (IVDMD) measurements at the end 
of the antibiotic challenge period (d 6) and during the withdrawal period (d 8, 10, 13; 
least square means) 
1
Treatment: P = 0.7073; Time: P = 0.1902; Treatment × Time: P = 0.6739 
2
Pooled SEM: Treatment = 3.55, Time = 6.94, Treatment × Time = 12.05 
3
Method: Appendix H 
4
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
Alfalfa IVDMD (%)
1,2,3
 
Treatment 
Group
4 
Adaptation 
Period (d) 
Antibiotic Challenge 
Period (d) Avg. IVDMD (%) 
-1 1 3 6 
Control 56.41 56.11 48.68 54.75 53.99 
T. S.
 
64.19 64.35 60.95 62.26 62.94 
Ceftiofur 68.32 64.88 59.01 60.44 63.16 
Avg. IVDMD 
(%)
 62.97 61.78 56.21 59.15 
Alfalfa IVDMD (%)
1,2,3
 
Treatment 
Group
4 
Antibiotic Challenge 
Period (d) 
Withdrawal 
Period (d) Avg. IVDMD (%) 
6 8 10 13 
Control 54.75 56.43 51.37 59.49 55.51 
T. S.
 
62.26 64.79 55.76 63.08 61.47 
Ceftiofur 60.44 55.25 49.14 49.84 53.67 
Avg. IVDMD 
(%)
 59.15 58.83 52.09 57.47 
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Table 4.6. a: Orchard grass in vitro dry matter digestibility (IVDMD) measurements at 
the end of the adaptation period (d -1) and during the antibiotic challenge period (d 1, 3, 
6; least square means) 
α β
Within a row, means without a common superscript differ (P < 0.05).
 
1
Treatment: P = 0.21; Time: P = 0.04; Treatment × Time: P = 0.74 
2
Pooled SEM: Treatment = 2.19, Time = 2.12, Treatment × Time = 3.68  
3
Method: Appendix H 
4
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
Table 4.6. b: Orchard grass in vitro dry matter digestibility (IVDMD) measurements at 
the end of the antibiotic challenge period (d 6) and during the withdrawal period (d 8, 10, 
13; least square means) 
1
Treatment: P = 0.9945; Time: P = 0.2133; Treatment × Time: P = 0.6718 
2
Pooled SEM: Treatment = 2.45, Time = 4.89, Treatment × Time = 8.48 
3
Method: Appendix H 
4
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
 
 
 
Orchard Grass IVDMD (%)
1,2,3
 
Treatment 
Group
4 
Adaptation 
Period (d) 
Antibiotic Challenge 
Period (d) 
Avg. IVDMD 
(%) 
-1 1 3 6 
Control 47.84 38.40 45.00 45.41 44.16 
T. S.
 
48.69 44.90 49.08 46.49 47.29 
Ceftiofur 57.00 46.57 46.06 49.99 49.91 
Avg. IVDMD 
(%)
 51.18
α 
43.29
β 
46.71
α 
47.30
α 
Orchard Grass IVDMD (%)
1,2,3
 
Treatment 
Group
4 
Antibiotic Challenge 
Period (d) 
Withdrawal 
Period (d) Avg. IVDMD (%) 
6 8 10 13 
Control 45.41 41.88 43.19 44.47 44.10 
T. S.
 
46.56 47.87 37.30 43.87 44.47 
Ceftiofur 49.91 43.72 36.92 45.85 43.89 
Avg. IVDMD 
(%)
 47.29 44.49 39.13 44.73 
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period (d 8, 10, 13).  Orchard grass IVDMD ranged from 47.84% to 57% during the 
adaptation period, 38.4% to 49.99% during the challenge period and 36.13% to 47.87% 
during the withdrawal period.  When comparing tall fescue IVDMD at the end of the 
adaptation period (d -1) to the challenge period (d 1, 3, 6) there was no effect of treatment 
(P = 0.6998; Table 4.7. a). There was an effect of time (P = 0.0012) in which fescue 
IVDMD was lower on d 3 than on d -1, 1, or 6 (P < 0.05) and a trend for a treatment by 
time interaction for ceftiofur horses to have lower tall fescue IVDMD during the 
antibiotic challenge period (d 1, 3, 6) than during the adaptation period (d -1; P = 
0.0989). There were no effects of treatment (P = 0.0914) or time (P = 0.4021) when 
comparing IVDMD of fescue at the end of the antibiotic challenge period (d 6) to the 
withdrawal period (d 8, 10, 13; Table 4.7. b). However, there was a treatment by time 
interaction (P = 0.0364), in which T. S. horses had lower IVDMD values for fescue on d 
10 than on d 8 and had higher IVDMD on d 8 than both ceftiofur and control horses. 
Control horses also had higher fecal IVDMD values for fescue on d 13 than on d 8.  
Fescue IVDMD ranged on average from 33.23% to 44.04% during the adaptation period, 
28.53% to 35.87% during the antibiotic challenge and 23.04% to 39.76% during the 
withdrawal period.  Raw data for in vitro dry matter digestibility analyses can be found in 
Appendix Z.   
In vitro Gas Production 
When comparing in vitro gas production measurements at the end of the 
adaptation period (d -1) to fecal samples during the antibiotic challenge period (d 1, 3, 6) 
there was no effect of time (P = 0.0577), treatment (P = 0.8039) or any treatment by time 
interaction (P = 0.5967; Table 4.8. a).  There were also no effects of treatment (P = 
0.5367), time (P = 0.1066) or a treatment by time interaction (P = 0.3867) when 
comparing in vitro gas production measurements at the end of the antibiotic challenge 
period (d 6) to the withdrawal period (d 8, 10, 13; Table 4.8. b).  It is important to note 
that block #1 horses were excluded from the data set due to technical difficulties (some 
modules were faulty). In addition, other values were also excluded based on abnormal 
measurements (negative gas production values).  In vitro gas production ranged on  
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Table 4.7. a: Tall fescue in vitro dry matter digestibility (IVDMD) measurements at the 
end of the adaptation period (d -1) and during the antibiotic challenge period (d 1, 3, 6; 
least square means) 
 
α β
Within a row, means without a common superscript differ (P < 0.05).
 
1
Treatment: P = 0.6998; Time: P = 0.0012; Treatment × Time: P = 0.0989 
2
Pooled SEM: Treatment = 2.18, Time = 1.71, Treatment × Time = 2.97  
3
Method: Appendix H 
4
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 Table 4.7. b: Tall fescue in vitro dry matter digestibility (IVDMD) measurements at the 
end of the antibiotic challenge period (d 6) and during the withdrawal period (d 8, 10, 13; 
least square means) 
α β
Within a row, means without a common superscript differ (P < 0.05).
 
a,b 
Within a column, means without a common superscript differ (P < 0.05) 
1
Treatment: P = 0.0914; Time: P = 0.4021; Treatment × Time: P = 0.0364 
2
Pooled SEM: Treatment = 2.23, Time = 3.04, Treatment × Time = 5.27 
3
Method: Appendix H 
4
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
Tall Fescue IVDMD (%)
1,2,3
 
Treatment 
Group
4 
Adaptation 
Period (d) 
Antibiotic Challenge 
Period (d) 
Avg. IVDMD 
(%) 
-1 1 3 6 
Control 33.23 34.60 28.53 33.43 32.44 
T. S.
 
34.78 34.34 30.14 35.87 33.78 
Ceftiofur 44.04 32.23 29.18 34.93 35.10 
Avg. IVDMD 
(%)
 37.35
α 
33.72
α 
29.28
β 
34.74
α 
Tall Fescue IVDMD (%)
1,2,3
 
Treatment 
Group
4 
Antibiotic Challenge 
Period (d) 
Withdrawal 
Period (d) 
Avg. IVDMD 
(%) 
6 8 10 13 
Control 33.43
a 
28.93
a 
29.90
a 
34.02
a 
31.57 
T. S.
 
36.50
  α β 
39.76
  α 
32.96
  α β 
33.24
  β 
35.61 
Ceftiofur 34.29
a 
28.08
a 
23.04
a 
27.25
a 
28.16 
Avg. IVDMD 
(%)
 34.74 32.26 28.64 31.50 
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Table 4.8. a: In vitro gas production (GP) measurements at the end of the adaptation 
period (d -1) and during the antibiotic challenge period (d 1, 3, 6; least square means) 
1
Treatment: P = 8039; Time: P = 0.0577; Treatment × Time: P = 0.5967 
2
Pooled SEM: Treatment = 3.20, Time = 0.96, Treatment × Time = 1.66  
3
Method: Appendix I 
4
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
Table 4.8. b: In vitro gas production (GP) measurements at the end of the antibiotic 
challenge period (d 6) and during the withdrawal period (d 8, 10, 13; least square means) 
1
Treatment: P = 0.5376; Time: P = 0.1066; Treatment × Time: P = 0.3867 
2
Pooled SEM: Treatment = 1.85, Time = 1.22, Treatment × Time = 2.01 
3
Method: Appendix I 
4
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
 
 
 
 
 
 
In vitro GP (mL gas g of substrate
-1
)
1,2,3
 
Treatment Group
4 
Adaptation 
Period (d) 
Antibiotic Challenge 
Period (d) Avg. GP (mL g
-1
) 
-1 1 3 6 
Control 32.18 27.75 35.27 34.07 32.32 
T. S.
 
37.38 16.69 36.02 38.71 32.20 
Ceftiofur 38.18 24.16 36.98 40.17 34.87 
Avg. GP (mL g
-1
)
 
35.91 22.86 36.09 37.65 
In vitro GP (mL gas g of substrate
-1
)
1,2,3
 
Treatment Group
4 
Antibiotic Challenge 
Period (d) 
Withdrawal 
Period (d) Avg. GP ( mL g
-1
) 
6 8 10 13 
Control 36.27 36.72 38.09 34.13 36.30 
T. S.
 
39.36 40.51 37.66 37.94 38.87 
Ceftiofur 40.93 38.89 38.41 37.60 38.96 
Avg. GP ( mL g
-1
)
 
38.85 38.71 38.05 36.56 
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average from 32.18 to 38.18 mL g of substrate
 -1
 during the adaptation period, 16.69 to 
40.17 mL g of substrate
 -1 
during the antibiotic challenge and 34.13 to 40.51 mL g of 
substrate
 -1 
during the withdrawal period.  Raw data for in vitro gas production can be 
found in Appendix AA.  
Fecal Volatile Fatty Acid Composition 
Due to extremely low or undetectable levels of lactate and isovalerate and/or 
methylbutyrate (IVMB) these data will not be reported. When comparing fecal acetic 
acid concentrations on a DM basis, there was no effect of treatment (P = 0.7463), time (P 
= 0.3154) or any treatment by time interaction (P = 0.7061; Table 4.8. a).  Fecal acetic 
acid concentrations ranged on average from 94.19 mM to 145.99  mM during the 
adaptation period, 133.02 mM to 155.15 mM during the antibiotic challenge period and 
140.00 mM to 187.60 mM during the withdrawal period.   
When comparing fecal propionic acid concentrations on a DM basis, there was no 
effect of treatment (P = 0.2294), time (P = 0.1107) or any treatment by time interaction 
(P = 0.4680; Table 4.8. b).  Mean fecal propionic acid concentrations ranged from 21.89 
mM to 31.84 mM during the adaptation period, 21.02 mM to 24.83 mM during the 
antibiotic challenge period and from 23.91 mM to 33.67 mM during the withdrawal 
period.   
When comparing fecal butyric acid concentrations on a DM basis, there was no 
effect of treatment (P = 0.5658), time (P = 0.3459) or any treatment by time interaction 
(P = 0.3021; Table 4.8. c).  Mean fecal butyric acid concentrations ranged from 10.09 
mM to 15.02 mM during the adaptation period, 9.56 mM to 13.58 mM during the 
antibiotic challenge period and from 12.90 mM to 16.77 mM during the withdrawal 
period.   
When comparing fecal phenylacetic acid concentrations on a DM basis, there was 
no effect of treatment (P = 0.2847), time (P = 0.3710) or any treatment by time 
interaction (P = 0.4538; Table 4.8. d).  Mean fecal phenylacetic acid concentrations 
ranged from 10.12 mM to 15.07 mM during the adaptation period, 9.44 mM to 16.74 mM 
during the antibiotic challenge period and from 11.77 mM to 14.72 mM during the  
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Table 4.9. a: Effect of antibiotic challenge on fecal acetic acid concentrations (least 
square means) 
Acetic Acid (mM; DM Basis)
1,2,3 
Treatment 
Group
4                                                                                                                                                                                                                                         
Adaptation  
Period (d) 
Antibiotic Challenge 
Period (d) 
Withdrawal 
Period (d) 
Avg. mM 
(DM Basis) 
-4 -1 1 6 13 
Control 94.19 143.10 154.26 151.93 166.56 142.01 
T. S. 145.92 145.99 113.02 155.15 187.60 149.54 
Ceftiofur 122.06 140.45 147.62 135.05 140.00 137.03 
Avg. mM 
(DM Basis) 
120.72 143.18 138.30 147.38 164.72  
1
Treatment: P = 0.7463; Time: P = 0.3154; Treatment × Time: P = 0.7061 
2
Pooled SEM: Treatment = 11.69, Time = 14.20, Treatment × Time = 24.67 
3
Method: Appendix J 
4
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
 
 
Table 4.9. b: Effect of antibiotic challenge on fecal propionic acid concentrations (least 
square means) 
1
Treatment: P = 0.2294; Time: P = 0.1107; Treatment × Time: P = 0.4680 
2
Pooled SEM: Treatment = 2.33, Time = 2.28, Treatment × Time = 3.95 
3
Method: Appendix J 
4
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
Propionic Acid (mM; DM Basis)
1,2,3 
Treatment 
Group
4 
Adaptation  
Period (d) 
Antibiotic Challenge 
Period (d) 
Withdrawal 
Period (d) 
Avg. mM 
(DM Basis) 
-4 -1 1 6 13 
Control 21.89 28.72 23.84 24.83 23.91 24.82 
T. S. 30.80 23.61 21.02 32.53 29.40 26.99 
Ceftiofur 31.44 31.84 24.59 22.13 33.67 27.50 
Avg. mM 
(DM Basis) 
28.04 28.06 23.15 26.50 28.99  
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Table 4.9. c: Effect of antibiotic challenge on fecal butyric acid concentrations (least 
square means) 
1
Treatment: P = 0.5658; Time: P = 0.3459; Treatment × Time: P = 0.3021 
2
Pooled SEM: Treatment = 1.76, Time = 1.23, Treatment × Time = 1.35 
3
Appendix: J 
4
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
 
Table 4.9. d: Effect of antibiotic challenge on fecal phenylacetic acid concentrations 
(least square means) 
1
Treatment: P = 0.2847; Time: P = 0.3710; Treatment × Time: P = 0.4538 
2
Pooled SEM: Treatment = 1.28, Time = 1.44, Treatment × Time = 2.41 
3
Method: Appendix J 
4
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
 
Butyric Acid (mM; DM Basis)
1,2,3 
Treatment 
Group
4 
Adaptation  
Period (d) 
Antibiotic Challenge 
Period (d) 
Withdrawal 
Period (d) 
Avg. mM 
(DM Basis) 
-4 -1 1 6 13 
Control 10.09 13.46 13.37 11.48 16.31 12.94 
T. S. 15.02 14.79 9.56 16.67 16.77 14.56 
Ceftiofur 10.43 13.58 13.58 9.59 12.90 12.02 
Avg. mM 
(DM Basis) 
11.85 13.94 12.17 12.58 15.33  
Phenylacetic Acid (mM; DM Basis)
1,2,3 
Treatment 
Group
4 
Adaptation  
Period (d) 
Antibiotic Challenge 
Period (d) 
Withdrawal 
Period (d) 
Avg. mM 
(DM Basis) 
-4 -1 1 6 13 
Control 10.12 13.56 13.40 11.52 16.49 13.02 
T. S. 15.07 14.87 9.63 16.74 17.27 14.72 
Ceftiofur 10.34 13.02 13.47 9.44 12.57 11.77 
Avg. mM 
(DM Basis) 
11.84 13.82 12.17 12.57 15.45  
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withdrawal period. There were no detectable levels of phenylacetic acid in 34.48 % of T. 
S. and ceftiofur horses and 31.01 % of control horses. 
When comparing fecal acetic to propionic acid ratios there was no effect of 
treatment (P = 0.5554), time (P = 0.1666) or any treatment by time interaction (P = 
0.9821; Table 4.8. e).  The mean fecal acetic to propionic acid ratio ranged from 4.70:1  
to 5.26:1 during the adaptation period, 5.16:1 to 7.12:1 during the antibiotic challenge 
period and from  6.02:1 to 6.30:1 during the withdrawal period.   
When comparing total VFA concentrations on a DM basis, there was no effect of 
treatment (P = 0.5652), time (P = 0.2658) or any treatment by time interaction (P = 
0.7409; Table 4.8. f).  Mean total VFA concentrations ranged from 131.29 mM to 202.69 
mM during the adaptation period, 148.27 mM to 212.99 mM during the antibiotic 
challenge period and from 183.85 mM to 245.16 mM during the withdrawal period.  Raw 
data for volatile fatty acid concentrations can be found in Appendix BB. 
PCR-DGGE 
 The effect of antibiotic administration on the percent similarities of microbial 
species richness between fecal samples were compared using PCR- GGE‘s     ‘s 
analysis of percent similarities.   Similarity of microbial richness was determined within a 
  rs   v r t          tw      rs s  v r t         ‘s     ys s    put   s     r t  s 
between samples based on banding pattern, and constructed a corresponding UPGMA 
dendogram.  Samples of similar treatment, block, or time point did not group together. 
Therefore, there was no detectable effect of antibiotic challenge on microbial species 
richness. Analysis using the proc GLM procedure of SAS (version 9.2, SAS Institute, Inc. 
Cary, NY) confirmed this observation in that there were no treatment (P = 0.2649), time 
(P = 0.4358 or any treatment by time interaction (P = 0.7902) based on percent 
similarities (Figure 4.9. and Figure 4.10.). The mean percent similarity in microbial 
species richness was 60.81% for control samples, 64.46% for the T. S. samples and 
60.81% for the ceftiofur samples over the course of the study.  Raw data for PCR-DGGE 
percent similarity analysis can be found in Appendix CC. 
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Table 4.9. e: Effect of antibiotic challenge on fecal acetic acid : propionic acid ratio (least 
square means) 
1
Treatment: P = 0.5554; Time: P = 0.1666; Treatment × Time: P = 0.9821 
2
Pooled SEM: Treatment = 0.39, Time = 0.50, Treatment × Time = 0.86 
3
Method: Appendix J 
4
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
 
 
Table 4.9. f: Effect of antibiotic challenge on fecal total VFA concentrations (least square 
means) 
1
Treatment: P = 0.5652; Time: P = 0.2658; Treatment × Time: P = 0.7409 
2
Pooled SEM: Treatment = 14.82, Time = 19.12, Treatment × Time = 33.12 
3
Method: Appendix J 
4
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
 
 
 
 
 
 
 
Acetic Acid : Propionic Acid Ratio (mM; DM Basis)
1,2,3 
Treatment 
Group
4 
Adaptation  
Period (d) 
Antibiotic Challenge 
Period (d) 
Withdrawal 
Period (d) 
Avg. mM 
(DM Basis) 
-4 -1 1 6 13 
Control 4.70 5.08 6.04 6.63 6.30 5.75 
T. S. 4.83 5.04 5.67 5.16 6.02 5.34 
Ceftiofur 5.01 5.26 6.09 7.12 6.13 5.92 
Avg. mM (DM 
Basis) 
4.85 5.13 5.93 6.30 6.15  
Total Volatile Fatty Acids (mM; DM Basis)
1,2,3 
Treatment 
Group
4 
Adaptation  
Period (d) 
Antibiotic Challenge 
Period (d) 
Withdrawal 
Period (d) 
Avg. mM 
(DM Basis) 
-4 -1 1 6 13 
Control 131.29 155.19 197.76 196.05 213.13 178.68 
T. S. 202.69 163.48 148.27 212.99 245.16 194.52 
Ceftiofur 162.82 154.17 192.53 170.50 183.85 172.77 
Avg. mM 
(DM Basis) 
165.60 157.61 179.52 193.18 214.05  
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Table 4.10.: Effect of antibiotic challenge on microbial species richness of fecal samples 
(raw data)  
PCR- GGE     ‘s A   ys s P r   t S     r t  s1,2  
(% Similarity) 
Treatment
3 
Block 
Sample Day vs. Sample Day
4
  
-1 vs. 1 -1 vs. 6 -1 vs. 13 1 vs. 6 1 vs. 13 6 vs. 13 
Control 
1 56.5 79.4 75.8 53.1 53.8 84.1 
2 63.6 71.7 42.1 70.4 35.7 46.2 
3 59.5 62.5 57.7 51.6 62.7 43.5 
4 71.7 62.7 57.7 62.7 61.2 55.3 
5 59.7 65.7 47.8 66.7 53.3 50.9 
6 69.1 61.2 76.9 75 61.5 60 
Avg. % Similarity 63.35 67.2 59.67 63.25 54.7 56.67 
T. S. 
1 62.1 61.3 62.3 71.9 66.7 71.6 
2 59.5 68.6 - 50 - - 
3 45.3 59.4 59.7 55.8 50 51.1 
4 64.3 62.5 67.8 70.6 66.7 84.5 
5 60.4 68.1 64.4 69.6 72.4 57.7 
6 75 69.1 73.3 64.2 75.9 70.2 
Avg. % Similarity 55.08 64.83 65.5 63.68 66.34 67.02 
Ceftiofur 
1 62.5 66.7 52.2 78.4 56.5 56.5 
2 60 70.4 73.3 54.2 55.6 55.6 
3 71.6 64.5 62.3 78.9 65.7 65.7 
4 35.6 57.1 70.6 63.6 60 60 
5 71.1 62.5 62.2 46.5 55 55 
6 67.8 74.6 61 70 70 70 
Avg. % Similarity 61.43 65.97 63.6 65.27 60.47 59.27 
1
Treatment: P = 0.2649; Time: P = 0.4358; Treatment × Time: P = 0.7902 
2
Method: Appendices K, L, M, N 
3
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
4 
Adaptation period (d -1); Antibiotic challenge period (d 1, 6); Withdrawal period (d 13) 
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Table 4.11.: Summary of the effect of antibiotic challenge on microbial species richness 
of fecal samples (least square means)  
PCR- GGE     ‘s A   ys s P r   t S     r t  s1,2 
(% similarity) 
 Sample Day vs. Sample Day
4 
 
Treatment 
Group
3 -1 vs. 1 -1 vs. 6 -1 vs. 13 1 vs. 6 1 vs. 13 6 vs. 13 
Avg. % 
Similarity 
Control 63.35 67.20 59.67 63.25 54.70 56.67 60.81 
T. S. 61.10 64.83 64.92 63.68 65.76 66.44 64.46 
Ceftiofur 61.43 65.97 63.60 65.27 60.47 59.27 60.81 
Avg. % 
Similarity 
61.96 66.00 62.73 64.07 60.31 60.79  
1
Treatment: P = 0.2649; Time: P = 0.4358; Treatment × Time: P = 0.7902 
2
Method: Appendices K, L, M, N 
3
Control = No antibiotics; T. S. = Trimethoprim-sulfadiazine (oral; 30 mg kg
-1
); Ceftiofur 
= Sodium ceftiofur (intramuscular; 2.2 mg kg
-1
)  
4 
Adaptation period (d -1); Antibiotic challenge period (d 1, 6); Withdrawal period (d 13) 
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Chapter 5: Discussion  
Mutualism is defined as species living together for common benefit (Ferriere et 
al., 2002).  It has been demonstrated that many mutualist microbial species live in the GI 
tract, and these microbial ecosystems have been well studied and characterized in humans 
and food-animals (Ley et al., 2006).  Less research has been performed looking at the 
microbiology of the horse. H w v r  s v r   ― u  t       r ups‖  r  u   s   v       
identified in the equine hindgut (De Fombelle et al., 2003), including the lactate-utilizers, 
saccharolytic bacteria, proteolytic bacteria, cellulolytic bacteria, etc. These guilds are 
composed of many ecological niches that are responsible for fermentation of specific 
su str t s    t     rs ‘s    t   When these microbial guilds are disrupted, e.g. antibiotic 
administration, there could be detrimental side effects on the horse both energetically and 
physiologically. 
Horses are strict herbivores and primarily subsist on plant material that is fibrous. 
Therefore, horses rely on microbial enzymes (i.e. cellulases) produced by cellulolytic 
bacteria to digest these fibers (cellulose and hemicellulose). Unlike ruminants who are 
foregut fermenters, the hindgut is the primary site of fiber digestion in the horse (Kern et 
al., 1973).  Because of their anatomical GI structure, horses are able to absorb nutrients 
made available by gastric and pancreatic/biliary digestion prior to reaching the hindgut.  
Therefore, little soluble carbohydrate is available for microbial fermentation when horses 
are consuming high-fiber diets, which can prove beneficial in maintaining a healthy 
stable microflora (Willing et al., 2009). 
Fermentation of plant structural carbohydrates in the hindgut results in the 
production of volatile fatty acids (VFA).  Researchers and reviewers have speculated that 
the total VFAs produced by microbial fermentation could contribute as much as 70 to 
80% of total dietary energy to the horse (Al Jassim and Andrews, 2009).  Therefore, fiber 
digestion by mutualistic microbes most notably cellulolytic bacteria and consequent VFA 
production is a major part of their metabolic energy.  
  When the horses in this study were given either antibiotic, there was a decrease 
in cellulolytic bacteria after only 24 hrs of antibiotic challenge.  The cellulolytic bacteria 
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enumerations in the horses continued to decrease through the end of antibiotic challenge, 
with 10-fold to 1,000-fold fewer bacteria on d 6.  Even 7 d after withdrawal from 
  t    t  s  t     rs s‘     u   yt      t r     u  r t   s r          pr ss    w t     
sign of recovery.  
 Additionally, cellulolytic lag time of growth was evaluated in these fecal 
samples. Lag time increased with antibiotic challenge and remained longer than control 
horses at the end of the 7 d withdrawal period. Although, this increase in lag time could 
be partially due to a decrease in cellulolytic numbers, it would also indicate that the 
metabolism of cellulolytic bacteria could have been affected. The current study is the first 
to look at the effect of antibiotic treatment on cellulolytic bacteria.  The decrease in 
cellulolytic enumerations and increase in lag time observed with antibiotic challenge 
indicate that both T. S. and ceftiofur antibiotics could potentially decrease total dietary 
energy available to the horse by suppressing cellulolytic populations and metabolic 
functionality.   
Despite the enormous changes observed in cellulolytic bacteria, there were no 
detectable effects of either antibiotic challenge on in vitro dry matter digestibility 
(IVDMD) of alfalfa hay and orchard grass substrates, in vitro gas production, or fecal 
VFA concentrations.  However, there was a trend for tall fescue IVDMD values to be 
lower in ceftiofur horses during the antibiotic challenge period (d 1, 3, 6) in comparison 
to values in the same horses during adaptation (d -1). This trend could indicate that 
ceftiofur challenge has negative implications on digestibility. Furthermore, it is possible, 
that the reason why IVDMD suppression was only observed with the tall fescue substrate 
is because tall fescue has the highest NDF content of the substrates employed. Therefore, 
it is presumably more affected by a decrease in cellulolytic bacteria numbers and 
functionality. Also, since alfalfa hay and orchard grass hay have lower NDF contents, 
differences in IVDMD with antibiotic challenge may have been apparent if samples were 
taken earlier in the incubation.  
 IVDMD values recorded in the current study ranged on average for individual 
treatment groups over time from 48.68% to 68.32% for alfalfa, 36.92% to 57.00% for 
orchard grass and 23.04% to 44.04% for tall fescue.  There was some variation detected 
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within horse over time in IVDMD measurements, however, overall the average values 
measured were similar to both the IVDMD and DMD values reported in other studies for 
these feedstuffs (Vander Noot and Gilbreath, 1970; Koller et al., 1978; Crozier et al., 
1997; Bush et al., 2001; Lattimer et al., 2007; Earing et al., 2010).  In addition, IVDMD 
values on average were always ranked alfalfa, orchard grass and tall fescue from the 
highest IVDMD to the lowest.  These digestibility rankings would be expected based on 
the NDF content of the feedstuffs used in the current study with alfalfa having the lowest 
NDF at 28%, orchard grass at 63% NDF and tall fescue having the highest at 70.8% 
NDF. This ranking of NDF values is also consistent with previous studies (Warren et al., 
1974; Hemken et al., 1979; Mabjeesh et al., 2000; Cherney et al., 2004).  
The Daisy II procedure for IVDMD using a fecal inoculum is still being refined. 
Studies in the past have reported that this method does not necessarily produce IVDMD 
values for feedstuffs that are exactly the same as values obtained in vivo. Although, there 
is a strong relationship between values obtained in vivo and values obtained with in vitro 
methods (Daisy II; Earing et al., 2010).  In addition, there is a lot of variability between 
previous studies on IVDMDs measured for similar feedstuffs (alfalfa) using a fecal 
inoculum (Crozier et al., 1997; Bush et al., 2001; Lattimer et al., 2007; Earing et al., 
2010). This variation can be explained by the differences in quality and nutrient content 
between alfalfa substrates employed in these studies (Lattimer et al., 2007; Earing et al., 
2010). In addition, it is possible that some variation could be explained by procedural 
variability.  Some potential considerations, based on the methods employed in the current 
study that may improve consistency and accuracy of results include: time lapse between 
collection and inoculation, anaerobic technique, chosen microbial inoculum and variation 
in manual bag washing.  
In addition to observing no effect of either antibiotic challenge on IVDMD, there 
were also no detectable effects on in vitro gas production.  A few research studies have 
reported that use of a fecal inoculum yields similar gas production results as a rumen 
fluid inoculum (Macheboeuf, 1997; Lowman et al., 1999).  However, very little research 
has been done to date using in vitro gas production measurements with a fecal inoculum 
in horses. Therefore, this technique is still being adjusted procedurally and explored for 
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potential use in equine research. Many data points were missing from the gas production 
data set due to several problems encountered with the apparatus (frequently faulty 
modules), unexpected power outages and technician error.  Based on the inconsistencies 
observed in the current study, more research is necessary to further modify and perfect 
this technique to allow for more consistent and repeatable results in the future.  
There was no effect of either antibiotic challenge on fecal pH, fecal dry matter, or 
fecal VFA concentrations. These results are consistent with both the IVDMD and gas 
production results in the current study. Microflora present in the equine hindgut are 
primarily responsible for VFA production. As mentioned previously, it has been stated 
t  t VFA‘s pr  u     y   r        r   t t      u      tr  ut   s u    s 70 t  80%    
total dietary energy available to the horse (Al Jassim and Andrews, 2009).  Therefore, a 
decrease in VFA production in consequence of antibiotic administration could be 
extremely detrimental to the horse.  Since the normal flora cellulolytics were suppressed 
by antibiotic challenge, which is evidenced by the culture results of the current study, we 
would have expected to see a concomitant decrease in VFA production with a consequent 
increase in fecal pH.  However, this result was not observed in the current study. VFA 
production (propionate, acetate, butyrate and phenylacetic acid) was not affected by 
either T. S. or ceftiofur challenge. Unfortunately, no previous studies were identified that 
reported individual fecal VFA concentrations from horses on comparable diets. However, 
in a study by Hussein and colleagues (2004), a 3:1 fecal acetate to propionate ratio was 
reported for horses fed a similar ratio of concentration to alfalfa cubes (17:83) as 
employed in the current study (20:80).  In contrast, the acetate to propionate ratios were 
much higher in the current study (5.75:1 in control fecal samples, 5.34:1 in T. S. fecal 
samples and 5.92:1 in ceftiofur fecal samples). This could indicate increased fermentative 
activity of microflora producing acetate as opposed to propionate-producing bacteria. In 
addition, horses in the study by Hussein and colleagues (2004) were fed at 1.2% of BW 
in comparison to the 2 – 2.25% of BW provided in the current study. This difference in 
intake could account for the shift in the bacterial population and an increase in acetate 
production. Fecal pH values collected in the current study fell within typical ranges as 
recorded in healthy horses fed similar diets in previous studies (Hussein et al., 2004; Al 
Jassim et al., 2006).  
 119 
 
Fecal lactobacilli were also negatively affected by antibiotic administration.  
Horses challenged with ceftiofur had 45% less fecal lactobacilli detected after only 24 hrs 
of antibiotic challenge (1 dose).  These lactobacilli enumerations continued to decrease 
through the end of the antibiotic challenge, with 78% fewer lactobacilli than detected in 
the same horses during adaptation. Furthermore, horses treated with T. S. had a trend for 
decreased numbers of lactobacilli after 7 d of antibiotic challenge, with a 61% decrease 
on average. By the end of the 1 wk antibiotic withdrawal, both treatment groups had 
increased numbers of lactobacilli in comparison to the end of the antibiotic challenge. 
However, it was unclear whether the bacteria fully recovered.  
The decrease in lactobacilli observed in the current study is consistent with a 
previous study by White and Prior (1982), in which antibiotic administration led to a 
decrease in the normal flora Veillonella spp. Lactobacillus spp. produce lactic acid which 
is required for propionate production by lactate-utilizing bacteria, such as Veillonella spp.  
Therefore, the decrease observed in Veillonella spp. could be explained by antimicrobial 
action against lactobacilli. White and Prior (1982), also documented a concomitant 
increase in Clostridium perfringens with oxytetracycline administration. Clostridium 
perfringens is one of the pathogens associated with equine AAD (Weese et al., 2001). 
However, there was no observed effect of either antibiotic challenge on enumerations of 
C. perfringens in the current study.  
As mentioned previously, Salmonella spp. and Clostridium difficile are also 
pathogens commonly implicated in equine AAD (Weese et al., 2001).  Salmonella is 
asymptomatically carried in many livestock species (Callaway et al., 2008). In horses 
specifically, it has been demonstrated that 71.4% of horses carry Salmonella spp. at 
slaughter (McCain and Powell, 1990).  Therefore, it was not surprising that the majority 
of the samples collected in the current study were salmonella-positive.  Salmonella spp. 
numbers in fecal samples from control horses and horses challenged with ceftiofur were 
extremely variable during the adaptation and antibiotic challenge period. However, when 
horses were treated with T. S. they demonstrated a > 25-fold increase on average in 
detectable numbers of Salmonella spp. from those measured in adaptation samples. In 
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addition, during the withdrawal period both ceftiofur and T. S. horses had higher 
enumerations of Salmonella spp. than control horses.  
A study by Owen (1975) found that when horses were administered antibiotics, 
50% of horses had AAD and were also shedding Salmonella spp. Many other studies in 
horses have also demonstrated an association between antimicrobial therapy and 
Salmonella spp. shedding (Baker and Leyland, 1973; Owen et al., 1983; Staempfli et al., 
1992).  These results are consistent with the increase in fecal Salmonella spp. observed in 
the current study. However, despite these observations, due to a high percentage of 
asymptomatic carriage of Salmonella spp. in horses, diagnosis of salmonellosis can be 
difficult. Therefore, in order to definitively implicate salmonella in AAD, a positive fecal 
sample must be acquired and other possible causative agents must be ruled out (Bartlett, 
2002).   
In contrast, C. difficile is not typically carried by healthy horses with a 
documented carrier rate of 0% to 7.59% depending on the study (Weese et al., 2001; 
Båverud et al., 2003; Medina-Torres et al., 2011).  In the current study, C. difficile was 
not detected in any horse during the adaptation period or in any control horse. However, 
with either antibiotic challenge there were detectable levels of C. difficile after only 24 
hrs (1 dose).  This substantial increase persisted after 7 d of withdrawal with no sign of 
recovery.  
Many studies have demonstrated a relationship between cultivable C. difficile and 
AAD in horses (Madwell et al., 1995; Gustafsson et al., 1997; Båverud et al., 1997; 
Gustafsson et al., 2004; Taha et al., 2007)    r  sp         y  AA  pr        y β-
lactam antibiotic administration, like one of the antibiotics used in the current study 
sodium ceftiofur, has been associated with C. difficile shedding in previous studies.   In 
one such study it was reported that of 10 horses diagnosed with C. difficile AAD, all had 
     pr v  us y tr  t   w t     y β-lactam antibiotics (Båverud et al., 1997).  
Furt  r  r   Gust  ss              u s (2004) r p rt   t  t p          tr  t   t (  β-
lactam antibiotic) increased fecal shedding of C. difficile in horses. Trimethoprim – 
sulfonamide antibiotics have not previously been associated with C. difficile proliferation 
or C. difficile AAD specifically.  However, results in the current study did not 
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demonstrate any differences between either antibiotic challenge in levels and duration of 
C. difficile detected in fecal samples.  
No C. difficile toxins were detected in any sample collected in the current study, 
which is not surprising because diarrhea did not occur.  There are many different 
explanations for the absence of toxins.  C. difficile produces toxins when required 
substrates are limiting (specific amino acids, sugars).  It is possible that these required 
substrates were not limiting and therefore toxins were not produced (Karlsson et al., 
2008). Furthermore, in swine it has been demonstrated that pathogenic bacteria, including 
Clostridia, use amino acids to produce compounds that are detrimental to gut health 
(Pluske et al., 2002).  Consequently, a restricted amount of protein reaching the hindgut 
could reduce the incidence of diarrhea. Although, the diet provided in the current study 
was fed in excess of protein requirements, it may not have provided C. difficile with 
sufficient specific required amino acids to produce toxins.  Furthermore, in a study by 
Dupuy and Sonenshein (1998), it was demonstrated that toxin production by C. difficile 
was suppressed during growth phase of the bacterium and increased substantially once 
the C. difficile population was stable. In the current study, C. difficile enumerations did 
not increase significantly after d 3 of antibiotic challenge. However they numerically 
continued to increase until the end of the antibiotic challenge period. Therefore, it is 
possible that C. difficile toxin production was suppressed in the current study because the 
bacteria had not reached a steady state.  
 Other possibilities include that the toxins were sequestered by the normal flora 
i.e. lactobacilli (Carasi et al., 2012), the virulent strains were not present or the amount of 
toxin that was being produced was below the limit of detection of the ELISA employed. 
In a study by Naaber and colleagues (2004), relationships were identified between C. 
difficile toxicity, resistance to antibiotics and susceptibility to antimicrobial agents 
produced by lactobacilli.  Based on their observations it was speculated that highly-
toxigenic C. difficile were typically antibiotic resistant, but susceptible to lactobacilli 
antimicrobial activity. Consequently, in order for highly toxigenic C. difficile to 
proliferate, lactobacilli must be deeply suppressed. Therefore, it is possible that the 
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decrease in fecal lactobacilli observed in the current study with antibiotic challenge was 
not sufficient to induce proliferation of highly-toxigenic C. difficile.   
The normal flora, including lactobacilli, are believed to contribute to colonization 
resistance against pathogenic bacteria (Vollaard and Clasener, 1994). To investigate 
colonization resistance in the current study, data were pooled across treatment groups and 
t    r  r up     t        s  p  s t  t      r     ‘t   v    t  t     C. difficile.  In result, 
the C. difficile-positive samples had fewer detectable cellulolytic bacteria (P < 0.0001) 
and lactobacilli (P < 0.0001) in comparison to C. difficile-negative samples.  In addition, 
when the same procedure was performed to investigate the relationship between the 
presence of salmonella and levels of normal flora (lactobacilli and cellulolytics), a similar 
result was found.  Salmonella-positive samples had fewer detectable cellulolytic bacteria 
(P < 0.0001) and lactobacilli (P = 0.0395) in comparison to salmonella-negative samples. 
These data confirm an inverse relationship between normal flora proliferation and 
pathogenic bacteria proliferation, indicating that normal flora colonization resistance was 
disrupted by antibiotic challenge in the current study.   
Normal flora, including lactobacilli contribute to colonization resistance against 
pathogenic bacteria by many different mechanisms.  One such mechanism is by 
competition for nutrients (Rolfe, 2000).  The biological competition theory presumes that 
competitors cannot coexist in a climax community (community that has reached a steady 
state by means of ecological succession; Krebs, 1989).  For example, if two bacterial 
species require the same limiting nutrient, the more fit species will drive the less fit 
competitor into extinction within the habitat.  Unfortunately, no study has been 
performed to elucidate a competitive relationship in vivo between a Lactobacillus spp. or 
cellulolytic bacteria and an AAD-associated pathogen. However, lactobacilli consume 
many of the same nutrients that are also required for growth of Clostridia including: 
amino acids, simple sugars and essential vitamins, so it is plausible that competition for 
nutrients could occur between the two genera (Dunn et al., 1947; Muhammed et al., 
1975; Morishita et al., 1981; Wilson and Perini, 1988).   
Other viable proposed mechanisms for colonization resistance include: 
competition for adhesion sites and antimicrobial action. Lactobacilli have been 
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demonstrated to compete for adhesion sites on intestinal epithelium with the pathogen 
Salmonella enterica in vitro (Jankowska et al., 2008). Normal flora can also produce 
antimicrobial compounds such as metabolic end-pr  u ts       VFAs (Hӧ    u r et al., 
1998), bacteriocins (Klaenhammer, 1998) and small antimicrobial molecules like reuterin 
(Bernard et al., 2011) that contribute to colonization resistance.  It has been demonstrated 
that lactobacilli that were more antagonistic to C. difficile produced higher levels of H2O2 
and lactic acid in comparison to other Lactobacillus spp. (Naaber et al., 2004). These 
results indicate that production of metabolic end-products may be an important 
mechanism of colonization resistance for Lactobacillus spp.  It has been demonstrated 
that some Lactobacillus spp. also produce a variety of different bacteriocins (Savadogo et 
al., 2004). For example, Lactobacillus acidophilus, a known mutualist in the GI 
microflora of horses (Fujisawa et al., 1993) can produce two different bacteriocins that 
inhibit C. difficile and other pat           t r   (    v č-  t j ń ć et al., 1998). 
Cellulolytic bacteria have also been demonstrated to produce bacteriocins. However, 
these bacteriocins have been studied in the context of their inhibition of other cellulolytic 
species in competition for substrate (Chen et al., 2004). Little research has been done to 
elucidate antagonistic effects of cellulolytic bacteriocins on pathogenic bacteria.  
Furthermore, studies in humans and other animal models have demonstrated the 
production of antimicrobial compounds from multiple lactobacilli strains (Silva et al., 
1987; Asahara et al., 2001).  In a study by Bernard and colleagues (2011), six different 
species of lactobacilli indigenous to the equine hindgut were identified that had positive 
antimicrobial activity against the pathogen salmonella.  
The results of the current study indicate that the decrease in normal flora observed 
was compensated for by the remaining flora and was not sufficient to induce a difference 
in microbial efficiency.  However, it is not clear how a 99.9% decrease in cellulolytic 
bacteria enumerations after 7 d of withdrawal from antibiotics, did not have an effect on 
the digestibility of fibrous feedstuffs or VFA production. It is likely that the cellulolytic 
culture protocol employed in the current study was not capable of sustaining all of the 
cellulolytic bacteria present in the equine hindgut. Therefore, the cellulolytic bacteria that 
were not cultured could have compensated for the decrease observed in the current study.  
Furthermore, the diet provided in the current study was not extremely high in cellulose 
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and the majority of the DE provided was from the non-structural carbohydrate component 
of the pelleted concentrate and the alfalfa cubes. Therefore, these components were 
primarily digested and absorbed in the foregut and did not require microbial fermentation 
in the hindgut. This could explain why there were no detectable differences in fecal 
VFAs in the horses challenged with antibiotics despite the enormous effects on 
cellulolytic bacteria. If this study was repeated with a higher NDF content forage-only 
diet it is possible that differences in VFA production would be detectable.    
As discussed previously, the culture results in this study demonstrated that 
antibiotic administration can disrupt the normal flora of the equine hindgut, and allow 
pr     r t     y p t           t r    v   w    AA     s   t    ur   H w v r   t‘s 
unclear whether the disruption by antibiotic challenge was in overall microbial species 
richness of the hindgut or if it is primarily due to decreased proliferation of specific 
microbial species. To answer this question PCR-DGGE a microbial fingerprinting 
technique, was employed to look at percent similarities between each fecal sample. In 
result, there were no effects of antibiotic challenge on microbial species richness. 
However, there was variability within individual horses over time, and variation between 
duplicates suggesting that the method may not be technically robust enough to fully 
represent the complexity of the adult equine microflora. Therefore, future application of 
this method in adult horses could be more useful, if specific primer sets for bacteria of 
interest were employed.   
Antibiotic treatment has also been associated with a decrease in appetite which 
could contribute to disruption of the microflora (Wilson, 2001).   Abrupt dietary changes 
whether they are in dietary composition or the amount being consumed by the animal, are 
the leading cause of microbial disruption and consequent disorders like colic and 
laminitis in horses (Goodson et al., 1988; De Fombelle et al., 2001).   However, in our 
study, horses were given an adaptation period to their diet (3 wks) and there were no 
documented differences in feed refusals when horses were treated with antibiotics. 
Therefore, it can be assumed that changes in the composition and enumeration of 
microflora in this study were indeed due to antibiotic treatment and not to dietary changes 
or feed refusals.   
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The results in this study were similar for T. S. and ceftiofur, even though they 
have different mechanisms of action and modes of delivery. Trimethoprim and 
sulfadiazine are both folate synthesis inhibitors (Haggett and Wilson, 2008). T. S. is 
administered orally as a cocktail of the two drugs; therefore it would not have been 
surprising if T. S. had a greater effect on the hindgut microflora.  In contrast, ceftiofur is 
a cephalosporin (peptidoglycan synthesis inhibitor) and is typically administered by 
intramuscular (I.M.) or intravenous (I.V.) injection. However, it has been demonstrated 
that gut bacteria are still exposed to cephalosporins even when not administered orally. In 
a study by Tanayama and colleagues (1980), when rats were administered a 
cephalosporin I.M. approximately 30% of the antibiotic was excreted in the feces. These 
results are consistent with the finding that ceftiofur antibiotics can cause diarrhea in 
horses (Haggett and Wilson, 2008). 
There have been numerous reports on the clinical effects of antibiotics on horses 
(diarrhea, presence of pathogenic bacteria, inappetance etc.), but little attention has been 
paid to the events that precede the establishment of these organisms in the gastrointestinal 
tract. Our results demonstrate that antibiotic treatment can disrupt the normal flora of the 
equine hindgut, and allow proliferation by pathogenic bacteria even without detectable 
changes in digestibility or development of outward clinical symptoms like diarrhea. 
Horses treated with either antibiotic had an immediate enormous decrease in cellulolytic 
bacteria and lactobacilli with a concomitant increase in the AAD-associated pathogens C. 
difficile and salmonella. In addition, multiple bacterial populations did not recover after a 
7 d withdrawal from antibiotics. This result indicates that antibiotics have long lasting 
effects on equine hindgut microbial populations even without the onset of AAD. In 
addition, a withdrawal period longer than 7 d from antibiotics is necessary to see full 
recovery of the hindgut microflora.   
 Our results support the theory that normal flora are able to competitively exclude 
or directly inhibit pathogens from colonizing when healthy.  However, when the normal 
flora are disturbed (antibiotic administration) pathogens are able to colonize, even when 
AAD does not occur.  In the future this experimental model could be useful to: 1) study 
disruptions of the hindgut microflora, 2) determine factors that inhibit the growth of 
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pathogenic bacteria, and 3) test intervention strategies that improve the resistance and 
resilience of the microbial community.  These interventions could include vaccines, 
supplemental antimicrobials, probiotics, prebiotics or dietary interventions. 
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Appendix A: Complete horse information, blocking and treatment assignments
1,2 
 
 
 
 
 
 
 
 
 
 
 
 
1
M = Mare; G = Gelding 
2
TB = Thoroughbred; QH = Quarter Horse; TB x PH = Thoroughbred × Pain Horse Cross 
 
 
 
 
 
 
 
 
 
 
  
Date Range 
 
Sex Control Breed Age 
Sodium 
Ceftiofur Breed Age 
Trimethoprim 
Sulfadiazine Breed 
 
Age 
Block (mm/dd/year – mm/dd/year) (M/G) - - (years) (IM) - (years) (oral) - (years) 
 #1 04/18/2011 - 05/23/2011 M 
Sister 
Cashmere 
TB 11 
Show Me the 
Lillies 
TB 7 Bingo Betty TB 11 
 #2 05/30/2011 – 07/05/2011 G 
Townsend 
Lad 
TB 5 
Downtown 
Leroy 
TB 3 My Boy George TB×PH 4 
 #3 06/27/2011 – 08/01/2011 G 
Matty G 
Unit 
TB 2 R s  ‘s Ex TB 5 Friendly Fella TB 4 
 #4 08/01/2011 – 09/06/2011 M 
T ‘s  u  y 
Deelite 
QH 14 Menka TB 13 Tonosi TB 13 
#5 08/29/2011 – 10/03/2011 M 
Matty G 
Whiz 
TB 8 Quick Flite TB 6 Rancho Valencia TB 8 
#6 09/26/2011 – 10/31/2011 M 
Smart 
Balance 
TB 11 
Sister 
Cashmere 
TB 11 Windspeil TB 14 
Avg. 
Age 
- - - 
 
8.5 - 
 
7.5 - 
 
9 
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Appendix B: Total Feedstuff Analyses
1 
 
1 Dairy One, Ithaca, NY 
 
1 Dairy One, Ithaca, NY 
 
1 Dairy One, Ithaca, NY
Alfalfa Cubes1 
Block 
% 
DM 
DE Mcal/kg 
% 
CP 
% 
ADF 
% NDF 
% 
Ca 
% 
P 
#1 89.6 2.62 24.2 26.4 31.2 2.14 .29 
#2 90.1 2.46 21.5 30.2 37.7 2.09 .29 
#3 90.4 2.44 20.4 30.2 38.6 1.96 .31 
#4 88.8 2.42 20.1 31.8 39.2 1.87 .28 
#5 88.5 2.33 21.1 33.5 42.4 1.5 .4 
#6 89.6 2.62 24.2 26.4 31.2 2.14 .29 
Pelleted Concentrate1 
Block 
% 
DM 
DE Mcal/kg 
% 
CP 
% 
ADF 
% NDF 
% 
Ca 
% 
P 
#1 90.1 3.48 14.2 8.7 17.5 1.04 .58 
#2 90.1 3.39 13.5 11 21.2 1.15 .66 
#3 89.8 3.28 15.8 11.6 24.8 .95 .86 
#4 90.3 3.21 15.3 14.3 26.6 1.31 1.16 
#5 89.6 3.23 16.6 13.9 25.7 1.34 1.15 
#6 90.7 3.12 15.8 14.6 30.2 1.23 1.11 
Long Stem Grass Hay1 
Block 
% 
DM 
DE Mcal/kg 
% 
CP 
% 
ADF 
% NDF 
% 
Ca 
% 
P 
#1 90.4 2.04 12.6 39.3 64.0 .62 .59 
#2 92.5 1.91 13 42.5 68.4 .63 .64 
#3 92.4 1.89 12.1 43.4 68.8 .61 .67 
#4 92.4 2.00 12.1 38.7 65.3 .64 .75 
#5 91.8 2.05 11.6 38.6 64.5 .72 .75 
#6 92.0 2.05 11.4 39.4 64.3 .63 .64 
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Appendix C: Example Health/Wellness Exam Worksheet 
 
Date/Time: 
Block: 
Stage: 
Horse Name: 
 
Health/Wellness Exam 
 
Mucous Membrane: 
 
Capillary Refill Time: 
 
Heart Rate: 
 
Respiration Rate: 
 
Temperature: 
 
Disposition: 
 
Gut Sounds:  
 
 
  
 
 
 
Notes: 
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Appendix D: Phosphate Buffered Saline (PBS) Protocol 
 
Phosphate Buffered Saline (PBS)    
(1 Liter of 1x PBS) 
 
1. Start with 800 mL of distilled H2O 
2. Add 8 g of NaCl 
3. Add .2 g of KCl 
4. Add 1.44 g of Na2HPO4 
5. Add .24 g of KH2PO4 
6. Adjust pH to 7.4 with HCl 
7. Add distilled H2O until a total volume of 1 Liter 
8. Autoclave 20 minutes at 121˚C Liquid Cycle 
9. Remove from autoclave at 90˚C and immediately place under N2 gas 
10. Allow to cool until room temperature  
11. Dispense into tubes 9 mL per Hungate tube while gasing with N2 
12. Autoclave tubes 20 minutes at 121˚C 
**Ready for Use 
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Appendix E: Sulfite Polymyxin Sufladiazine (SPS) Agar for the enumeration of 
Clostridium perfringens (BD) 
 
SPS Agar (BD)       
(1 Liter) 
1. Suspend 41 grams of SPS powder in 1 Liter of double deionized water. 
2. Heat with frequent agitation and boil for 1 minute to completely dissolve the 
powder 
3. Take pH ~7.0 ± 0.2 
4. Transfer to volumetric flask and cover in tin foil 
5. Autoclave at 121˚C for 15 minutes 
6. Wait until cools to touch and pour plates.  
**Ready for Use 
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Appendix F: Cellulolytic Bacteria Medium and Undefined Component Protocols 
 
Equine Specific Cellulolytic Bacteria Medium   
(1L of Media) 
Media  
1. Add 40 mL of Mineral Solution #1  
2. Add 40 mL of Mineral Solution #2    
3. Add 450 mL of Distilled Water    
4. Add 1 mL Resazurin @ .1%    
5. Boil for 10 minutes 
6. Add 200 mL of Sterile Rumen Fluid     
7. Add 200 mL of Sterile Fecal Fluid     
8. Add 0.5 g of Cysteine HCl     
9. Boil for 20 minutes 
10. Cool until room temperature while saturating with CO2 until decoloration is 
complete 
11. Add 5.0g of NaHCO3  
12. Adjust pH to 7.3 
Tubes 
 
13. Place band of Whatman filter paper (~8cm x 1cm) in each Hungate tube 
14. Divide the media into 9mL per tube under a current of CO2 or in an anaerobic 
chamber 
15. Autoclave tubes for 20 min at 120˚C 
 
 
 
Mineral Solution #1 (per liter) 
7.3 g K2HPO4 * 3H2O 
OR 
6.0 g K2HPO4 
 
 
 
 
 133 
 
Mineral Solution #2 (per liter) 
**Add one at a time or will not go into solution 
6.0 g KH2PO4 
12.0 g (NH4)2SO4 
12.0 g NaCl 
2.5 g MgSO4 * 7H2O 
1.6 g CaCl2 * 2H2O 
 
Sterile Fecal Fluid Procedure       
50 feces: 50 distilled water 
 
1. Mix in 500 mL beaker with glass stirring rod 
2. Allocate fecal/water solution into centrifuge bottles and balance 
Note: Do not fill bottles more than ½ full 
3. Place bottles in Sorvall Centrifuge @ 4,000 x g for 10 minutes 
4. After spin is complete make sure not to disturb contents of bottle and move into 
lab 
Set Up: 
 
 
 
 
    
5. Take supernatant from centrifuge bottles and put in round bottom flask (500mL) 
6. Turn on CO2 and put needle in round bottom to act as a boiling chip and to gas 
out fecal solution 
7. Place vacuum apparatus and turn on to reduce emissions 
8. Light Bunsen burner and allow the fecal solution to come to a boil for about 1 
minute 
9. Turn off Bunsen burner and allow the solution to cool to room temperature 
10. Use 50 mL pipette aid to allocate into gasing CO2 serum bottles and use 
anaerobic method to close 
11. Autoclave for 15 minutes at 121˚C 
**Ready for use 
 Gas 
CO2 
Vacuum 
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Appendix G: Rogosa SL Agar for the enumeration of Lactobacillus species (BD) 
Rogosa SL Agar (BD)       
(1 Liter) 
1. Suspend 75 grams of SPS powder in 1 Liter of double deionized water. 
2. Heat with frequent agitation and boil for 1 minute to completely dissolve the 
powder 
3. Add 1.32 mL of glacial acetic acid. Mix well, and boil for 2-3 minutes 
4. Take pH ~5.4 ± 0.2 
5. DO NOT Autoclave 
6. Wait until cools to touch and pour plates.  
**Ready for Use 
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Appendix H: Daisy II Procedure: Using Equine Feces Inoculum   
 
Daisy II Procedure        
 
Buffer Preparation 
 
Buffer Solution A    1L    20L  
KH2PO4     10g    200g 
MgSO4 * 7H2O    0.5g    10g 
NaCl      0.5g    10g 
CaCl2      0.1g    2.0g 
Urea      0.5g    10g 
Dilute to:     1L    20L 
 
Buffer Solution B    1L    6L  
Na2S * 9H2O     1g    6g 
Na2CO3     13.3g    80g 
Dilute to:     1L    6L 
 
Procedure 
 
Bag Preparation: 
 
-Rinse ANKOM bags in acetone and label 
-Weigh the bags and record tare weight 
-Add ~.25g of sample to each bag, record sample weight, and heat seal 
Each Jar: 3 bags of each sample (3 total samples) and 2 control bags 
 
Night Before: 
 
1. Set up water bath to a constant temperature of 37.5 degrees Celsius. 
2. Lay out pre-weighed filter bags with sample for each jar 
 
Morning Of: 
 
3. Pre-heat Buffer A & B (may take a few hours so start early) and mixing jar 
4. Turn on Incubators 
5. After Preheated Mix Buffers A & B together in a 4 L Erlenmeyer flask using a stir 
plate and a stir bar. (1500mL of Buffer A + 300mL of Buffer B; 5:1 ratio) 
6. Place mixed buffer solution in the incubation jar with assigned ANKOM filter bags 
7. Place the jar in the pre-warmed incubator. 
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Fecal Samples Arrive: 
 
8. Upon feces arrival place fecal sample containers in warm water bath. Allow time for 
the feces to equilibrate to temperature  
9. Remove one container of feces from the water bath and weigh out 200 grams of feces 
in a weigh dish and transfer to the pre-heated mixing jar.  
10. Purge the container with the remaining feces for 15 seconds with CO2 and place back 
in the water bath for later use 
 
Note: After placing back into the water bath allow the sample to re- equilibrate before 
using again. 
 
11. Remove desired incubation jar from the Daisy II and remove 400 mL of mixed 
buffer solution using a graduated cylinder. 
12. Add 400 mL of mixed buffer solution to the mixing jar  
13. Purge the mixing jar with CO2 for 15 seconds 
14. After purge cap the mixing jar and blend for 30 seconds 
15. Transfer the fecal/mixed buffer solution into the incubation jar. 
16.  Adjust the pH to 7.0 using either buffer A or B 
 
Note: Make sure to stir well between each pH reading to make sure added solution is 
evenly distributed 
 
17. Purge incubation jar with CO2 for 30 seconds and return to incubators 
18. Set the timer for the jar and begin incubation 
**Repeat steps 8-17 on the remaining 5 jars 
Note: Make sure to note the length of incubation for each jar (48 hours), the timer 
position of the jar, the sample the jar contains, and the location of the jar. 
 
Bag Washing 
 
-Remove Jars from incubator  
-Dump jars individually into a strainer and collect filter bags (11bags/jar). 
 
 Note: All other contents of jars can be disposed of at this time. 
 
-After all of the bags are collected separate the bags into 4 separate strainers based on 
content. i.e. blanks, alfalfa, orchardgrass, and fescue 
-Place bags in strainer evenly spaced with no overlapping bags 
-Rinse bags in strainer by using a gentle stream of cold water  
 
 Note: Water should not disturb the contents of the bag 
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-Flip the bags over and rinse the other side 
-Continue rinsing both sides of the bag until rinse water is clear 
-Place bags on drying oven tray. Make sure bags are evenly spaced with no overlapping 
bags. 
-Place tray containing bags in a forced air oven at 55˚C for 24 hours or until bag weights 
are consistent 
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Appendix I: ANKOM Gas Production Procedure: Using Equine Feces Inoculum 
 
 
ANKOM Gas Production Procedure     
 
Buffer Preparation 
 
Buffer Solution A:    g/20L    g/4L 
KH2PO4     200g    40g 
MgSO4 * 7H2O    10g    2g 
NaCl      10g    2g 
CaCl2 *2H20     2g    0.4g 
Urea      10g    2g 
 
Buffer Solution B:    g/20L    g/4L 
Na2CO3     300g    60g 
Na2S * 9H2O     20g    4g 
 
**Mix to Volume with Nanopure Water** 
Note: Mix Chemicals in Smaller Beaker or Flask. Bring To Final Volume Using 
Graduated Cylinder or Volumetric Flask  
1 Run: 
15 total jars ((1 sample x 3 replicates x 3 horses) + 2 controls per horse) 
135 mL/jar x 15 jars = 2600 mL of Mixed A & B Buffer (Includes 500 mL extra for 
errors) 
4:1 Ratio: 2080 mL of Buffer A + 520 mL of Buffer B 
Note: Make sure to mix extra for each run (Calculation allots a 50mL correction factor 
for each gas production bottle) ***** 
Procedure 
Night Before: 
1. Charge Batteries for Modules 
2. Heat Water Bath to 37.5 degrees Celsius 
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3. Place 2080 mL buffer A and 520 mL buffer B in the water bath 
Morning of: 
4. Mix the buffers in an approximate 4:1 ratio, A:B ratio in a 4L flask. 
Note: 2080 mL of Buffer A + 520 mL of Buffer B 
5. Place buffer mixture in the water bath and allow equilibrating to 37.5 degrees 
Celsius. 
6. Place the blending jar in the water bath to equilibrate 
7. Purge the buffer mixture with CO2 for 2 hours prior to use.  
8. Adjust the pH to 6.8 using buffer B 
9. Add 1.000 g of forage sample to each bottle 
10. Add a stir bar to each bottle 
11. Add 5 mL of pH adjusted buffer to each bottle 
Inoculum Arrives: 
12. Place inoculum (feces)  into the water bath to equilibrate to 37.5 degrees Celsius 
13. Adjust the pH of the buffer mixture to 6.8 using buffer B 
14. Add 95 mL of the pH adjusted buffer mixture to each gas production bottle. 
15. Purge the headspace with CO2 for 15 seconds and cap with orange cap. Allow 
t    u   r     s  p   t   qu    r t  t  37 5˚     t   w t r   t  
16. Remove inoculum from water bath and weigh out ~150 g of feces 
Note: Remove one inoculum sample at a time and put back in the water bath when 
finished 
17. Place the weighed out inoculum into the pre-warmed blending jar and add 200mL 
of mixed buffer mixture 
18. Purge the buffer mixture/inoculum with CO2 for 15 seconds 
19. Blend at high speed for 60 seconds 
20. Squeeze blended inoculum through cheese cloth to remove large particles 
21. Add 35 mL of the blended inoculum to each gas production bottle (for specific 
horse & associated blanks) 
22. Purge with CO2 for 15 seconds 
23. Cap with orange caps 
REPEAT: Steps 16-22 for 2 other inoculums samples 
24. Mix all gas production bottles well using stir bars 
25. Take samples to room with gas production software setup 
26. Purge each gas production bottle with CO2 for 30 seconds 
27. Screw modules onto each gas production bottle 
28. Make sure batteries are fully charged 
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29. Allow the bottles to equilibrate to 37.5˚C  
30. Start the sample analysis 
31. Allow the run to go for 24 hours and then stop and collect data 
32. Remove modules from jars and cap with orange caps 
33. pH each sample and record 
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Appendix J: VFA Fecal Extraction-Bead Beating Protocol 
 
VFA Sample Preparation 
Note: 
1. All centrifugation is at 4ºC 
2. Keep all samples on ice 
3.  Duplicate samples and combine for step #8 to have enough sample for HPLC 
(need at least 500 uL or more if possible) 
 
Procedure 
1. Weigh or pipet out 250 mg of fecal sample place in 2 mL bead beating tube  
2. Add 1.5 mL of 5mM H2SO4 (sulfuric acid) plus 300 mg of 0.1mm zirconia beads 
(3 scoops of small spatula) and 100 mg of 0.5mm beads (4 scoop of small 
spatula) 
3. Vortex samples making sure contents are mixed well. 
4. Freeze samples long enough that they are frozen throughout. This may take up to 
2 hours or can do overnight. 
5. Vortex samples horizontally full speed for 3 minutes with bead beater. 
6. Centrifuge at 9000 x g for 20 minutes.  
7. Remove supernatant. 
8. Place in Amicon micro concentrator (max volume of 4 mL). 
9. Centrifuge 1 hour at 4000 rpm. 
10. Remove supernatant immediately after centrifugation and place in vials for HPLC 
analysis or can be stored overnight in frig or frozen for later analysis.   
 
Note: If freezing sample for later analysis place in micro centrifuge tubes. 
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Appendix K: QIAamp DNA Extraction Procedure (Feces)      
 
DNA Extraction from Equine Feces 
Notes: 
1. Wear gloves. 
2. Centrifugation steps: room temperature, 20,000 x g. 
3. Mix all buffers before start of procedure. 
4. Check ASL and AL buffers to make sure they are fully dissolved. If not, heat 
in a warm water bath for a few minutes to fully dissolve precipitate. 
 
  
Procedure 
1. Turn on heating block to 70ºC. 
2. Label 2 mL centrifuge tubes. Will run 2 pseudo-replicates per sample, and will 
transfer original sample 4 times (4 tubes/pseudo-replicate, 8 tubes total). 
3. Place 2 mL centrifuge tubes (2 per sample) on ice before removing fecal sample 
from freezer. 
4. Remove fecal sample from freezer. 
5. Place 180-220 mg of fecal material in cold 2 mL tube using metal spatula.  Repeat 
for pseudo-replicates and other samples for run.  
6. Cap sample tubes containing feces and place back on ice to prevent sample from 
thawing. 
7. Return unused stock fecal samples to freezer. 
8. Add 1.4 mL of buffer ASL and cap. Make sure the pipette tip does not touch the 
fecal sample when dispensing buffer into the tube.  
Note: From this point out all procedures can be done at room temperature. 
9. Vortex samples on high for 1 minute or until sample are thoroughly homogenized. 
10. Heat samples at 70ºC for 5 minutes in heating block. 
11. Vortex 15 seconds. 
12. Centrifuge 2 minutes. 
13. Remove 1.2 mL of supernatant into a new 2 mL labeled tube (remove as much 
supernatant as possible without disturbing the pellet). 
14. Add 1 InhibitEX tablet to tube.   
15. Vortex immediately for 1 minute, or until tablet is totally dissolved 
16. Incubate for 1 minute at room temperature. 
17. Centrifuge for 3 minutes. 
18. Remove all supernatant using a pipette (~200 uL) and dispense into a new 2 mL 
labeled tube. 
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19. Centrifuge for 3 minutes. 
20. Pipette 15 uL of proteinase K into a new 2 mL tube. 
21. Pipette 200 uL of supernatant from sample tube into tube with proteinase K. 
22. Add 200 uL of buffer AL. 
23. Vortex 15 seconds. 
24. Incubate at 70ºC for 10 minutes. 
25. Add 200 uL of EtOH (96% +).  
26. Vortex to mix. 
27. Transfer supernatant into QIAamp spin column in 2 mL collection tube from 
Qiagen.   
28. Centrifuge 1 minute. 
29. Remove spin filter (which now holds DNA) and place in a fresh 2 mL collection 
tube. Discard fluid and used collection tube. 
30. Add 500 uL of buffer AW1 and close cap. 
31. Centrifuge 1 minute. 
32. Remove spin filter and place in another new 2 mL collection tube (discard old 
tube).   
33. Add 500 uL of buffer AW2 and close cap. 
34. Centrifuge 1 minute. 
35. Remove spin filter and place in another new 2 mL collection tube (discard old 
tube). 
36. Centrifuge 1 minute. 
Note: Make sure all AW2 is removed before proceeding. 
37. Remove spin filter and place in a new 1.5 mL tube with cap cut off. 
38. Add 50 uL of sterile double distilled water. Close cap. 
39. Let incubate at room temperature for 2 minutes. 
40. Centrifuge 1 minute (DNA is now in supernatant). 
41. Discard spin filter and place cap on tube (make sure it is labeled properly). 
42. Check DNA concentration on Nanodrop 
a. S    t ―N    r p 100‖  r     s t p   
b.       ―Nu      A   ‖ t    
c. Wipe sample pedestal with Kim Wipe. 
d. Calibrate with sterile water (use same water as what sample was diluted 
with) by placing 1 uL of water on pedestal. 
e. Gently lower arm. Click OK to calibrate. 
f. Once done wipe pedestal clean with Kim Wipe. 
g. Bland with water by placing 1 uL of water on pedestal.  
h. Gently low r  r         t   ―     ‖ t      upp r    t  
i. Once done wipe pedestal clean with Kim Wipe. 
j. Load 1 uL of sample onto the pedestal.  
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k. G  t y   w r  r   I put s  p             x     t          ―   sur  ‖ 
l. Will show DNA concentration (ng/uL) at bottom of the screen (>40 ng/uL 
acceptable). Ideally 260/280 and 260/230 ratios should be 1.8 to 2.1. This 
suggests that the sample is relatively clean of carbohydrate and protein 
contamination.  
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Appendix L: PCR Bead Protocol      
 
 
PCR Bead Protocol 
 
Note: Wear gloves. 
 
Primer Solutions 
1. Make working primer solutions from original primer stock solution. 
a. Thaw original primer stock solutions (907 R and 341 F-GC).  
b. Mix each stock solution. 
907 R: Mix 45 uL sterile double distilled water and 5 uL of the original 907 R primer 
stock solution. 
341 F-GC: Mix 45 uL sterile double distilled water and 5 uL of the original 341 F-GC 
primer stock solution.  
2. Make 1:5 dilution of the working solutions for use in the PCR procedure 
a. Thaw working primer solutions (907 R and 341 F-GC).  
b. Mix each stock solution. 
907 R: Mix 40 uL sterile double distilled water with 10 uL of the 907 R working primer 
solution.  
341 F-GC: Mix 40 uL sterile double distilled water with 10 uL of the 341 F-GC working 
primer solution. 
 
PCR Protocol 
Notes:  
a. Before starting make sure the Thermocycler is available. 
b. Add solutions directly on side of tube to avoid touching the bead with any 
liquids before adding water. 
c. In between additions, place caps back on tubes to avoid environmental 
contamination.  
 
1. Add 1 uL of DNA and 1 uL of each primer (907 R and 341 F-GC) to each tube 
prior to adding 22 uL of sterile double distilled water.  
2. Cap the tubes and gently mix by flicking tubes with finger. 
3. Centrifuge tubes to make sure all liquid is off sides of tubes and pellet is fully 
dissolved. 
4. Place tubes in thermocycler, close lid and select “DGGE” program. 
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Thermocycler Protocol 
Pr  r          ― GGE‖ 
94ºC – 5 minutes 
94ºC – 30 seconds 
65ºC – 30 seconds 
72ºC – 45 seconds 
10x 
94ºC – 30 seconds 
60ºC – 30 seconds 
72ºC – 45 seconds 
25x 
72ºC – 5 minutes 
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Appendix M: Running PCR Products on an Agarose Gel Protocol   
 
PCR Gel Electrophoresis Protocol 
 
Note: Wear gloves. 
 
1. Prepare gel box:  
a. Place grey tray in white gel box, insert appropriate comb. 
i. S        s (~2‖ squ r ) 25 mL of agarose 
ii.   r      s (~4‖) 50 mL of agarose 
iii. X-Large gels (96 well) 100 mL of agarose 
2. Prepare agarose: 
a. For 50 mL of agarose: 
i. Weigh out ~0.5 g of agarose into a 250 mL Erlenmeyer flask 
ii. Add 50 mL 1x TAE. Swirl vigorously.  
iii. Place in microwave for 30 seconds. Swirl. Cook another 30 
seconds. Swirl. Cook for additional time until agarose is dissolved. 
 
Note: Erlenmeyer will be extremely hot! Use hot pads for handling. 
 
iv. Add 0.75 uL of EtBr. Swirl to mix.  
v. Let flask cool to touch (1-2 minutes).  
3. Pour agarose into gel box and allow to solidify for 45 minutes.  
4. Once solid gently remove the comb, lift gel out using the grey tray and place in 1x 
TAE buffer solution in gel runner. Make sure there is enough 1x TAE to cover the 
gel wells.  
5. Load Samples: 
a. Mix 2 uL of loading dye with 3 uL of PCR product on a piece of parafilm.   
b. Load sample/dye into well. 
6. Load Ladder (6 uL) into first or last well on gel. 
7. Place lid on gel runner. 
8. Turn voltage on to 100V. 
a. Run small gels (single row of lanes) for 40 minutes. 
b. Run 96 well gels (multiple rows of lanes) for 10-15 minutes. 
9. After the gel has run the appropriate time, shut off voltage and remove lid. 
10. Remove gel from 1x TAE buffer by lifting the grey tray. 
11. Imaging Gel: 
 148 
 
a. Wipe down the surface of the photobox with double distilled water and 
paper towels. 
b. Transfer gel from grey tray to clean surface of photobox.  Press gently to 
remove bubbles. 
c. Open the Kodak program from the Start Up menu. 
d. Click the “Capture” button at the top left of the window; a small window 
will open. 
e. Set the exposure length. 
f. Make sure the UV light is on. 
g. Select “Capture” to begin capturing image.  
 
Note: Will need to take multiple photos the get the gel centered and in focus. Zoom and 
focus can be adjusted by means of the camera lens.   
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Appendix N: Denaturing Gradient Gel Electrophoresis (DGGE) Protocol 
 
 
DGGE Protocol 
 
Denaturing Solution 
Component 
0% Denaturing 
Solution 
40% Denaturing 
Solution 
60% Denaturing 
Solution 
30% Acrylamide/Bis 
(37.5:1) (mL) 
 
10 10 10 
50x TAE (mL) 
 
1.0 1.0 1.0 
Formamide (mL) 
 
- 8.0 12.0 
Urea (g) 
 
- 8.4 12.6 
Glycerol (mL) 
 
- 1.0 1.0 
dd H2O 
 
 
Dilute to Volume 
Total Volume (mL) 50.0 50.0 50.0 
 
1. Use a 50 mL beaker wrapped in foil. 
2. Mix acrylamide, formamide, TAE and glycerol using small stir bar. Slowly add 
urea, a little at a time to aid in dissolution.  
3. Transfer to 50 mL conical tube and bring to 50 mL volume with ddH2O.  Wrap 
tubes in foil. 
4. Store in 4ºC fridge. Must chill ~2 hours before use. Maximum storage =1 
month. 
  
Ammonium Persulfate (APS) 
1. Dissolve 0.1 g APS in 1.0 mL of dd H2O. 
2. APS can be made ahead of time and aliquoted into 2 mL tubes and frozen for later 
use.  
 
50x TAE Buffer 
1. 242 g of Tris Base 
2. 57.1 mL Glacial Acetic Acid 
3. 100 mL 500mM EDTA, pH 8.0 
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4. 600 mL dd H2O 
5. Mix and bring to volume ~1L 
 
 
 Pouring the gradient Gel 
1. Assemble gel plates: 
a. Plates should be clean and dry before using. 
b. Put together both set of plates (2 plate setups necessary for 1 gel). 
c. Make sure corners and edges of the plates are not chipped. 
d. T   sp   rs‘   tched corner should go toward the top outer edge of the gel 
plates. 
e. Double check that the plates are evenly aligned.  
f. Tighten black screws until slightly snug. 
g. Remove plate apparatus from plate stand and turn stand 180º. 
h. Place grey rubber seal on front of the pate stand, insert plate apparatus. 
i. Place plate spacing paper in between plates and tighten black screws until 
snug. 
j. Remove spacing paper from in between plates. 
k. Secure plate apparatus. 
2. Set up pump and mixing block: 
a. Place mixing block on stir plate and place stir bar in right well of mixing 
block. 
 
Note: Make sure wells are closed. 
 
b. Run tubing around pumping apparatus. 
c. Place a pipette tip on the end of the pump line and tape to the inside of the 
plates in the center. 
d. Set speed dial at 10. 
3. Transfer 11.5 mL of 40% denaturing solution into the left well and 11.5 mL of 
60% denaturing solution into the right well of the mixing block. 
4. Add 81 uL APS and 4.5 uL TEMED to each mixing well.  
 
Note: These steps must be performed quickly so all necessary components should be 
prepared in advance so ready and available. 
  
5. Swirl mixing block. 
6. Tap to remove any air bubbles from the center line between the two wells.  
7. Open left valve (4 full turns) and clear bubbles by tapping gently. 
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Note: Should be able to see fluid movement from the left to the right well. Tap gently as 
to avoid flow in the opposite direction.  Alterations in flow will change gradient of final 
gel. 
 
8. Turn on stir bar. 
9. Turn on pump switch in the “Forward” position. 
10. Open right valve (3 full turns) and gel will begin pouring. 
 
Note:  Should be able to see the 40% denaturing solution being pulled into the 60% 
denaturing solution and then into the pump lines. As gel pours, watch for leaks in the 
corners of the plate apparatus. Avoid disturbing the pipette tip and tubing to ensure an 
evenly poured gel.  
 
11. When levels in the left and right well are even with the connecting tube, tip 
mixing block to get the last solution out.  
12. Leaving the pump on, add double distilled water to both wells.  
13. Remove the tubing/pipette tip from plate and place tip in corner of the plate to 
pour the water layer (1/2” thick). 
Note: Do not pour water in the center! It will disturb the gel gradient. 
14. Move pipette tip to beaker and leave the pump on to rinse the tubing. When 
rinsed, shut off the pump and dispose of the pipette tip; undo the line from the 
pump and allow to air dry. 
15. Allow gel to polymerize for at least 1 hour. 
Pouring the Stacking Gel 
1. Once the gradient gel has polymerized, remove the plate apparatus from the 
plate stand. 
2. Remove the water layer by tipping the apparatus to pour off the water. Blot 
any residual water with absorbent paper.  
Note: Do not touch gel with blotting paper. If you do touch the gel it can create air 
bubbles. If this occurs try pressing the two plates together just below the air bubble. This 
may remove the bubble.  
3. Secure the plate apparatus to the plate stand. 
4. Mix stacking gel in 15 mL conical tube: 
a. Add 70 uL APS and 4.5 uL TEMED to 8-8.5 mL of 0% denaturing 
solution.  
b. Cap tube and mix. 
5. Pour stacking gel by tipping the gel plate stand and apparatus back at a 60º 
angle and pouring the solution between the plates. The stacking gel should 
pour directly on top of the polymerized gradient gel.  
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6. Place 20 well comb in the stacking gel.  
a. Start the comb at a 30º angle at one side. 
b. Slowly insert the comb to avoid incorporation of any air bubbles. 
Note: If an air bubble does occur, remove comb and re-insert. Make sure the comb sits 
squarely. 
7. Allow the stacking gel to polymerize for 2 hours.  
Preparing the gel rig 
1. Immediately after pouring the stacking gel, pour 7 L of 1x TAE buffer into the 
gel rig. 
a. Buffer can be used up to 4 times, 3 times is suggested. 
i. 1L 1x TAE= Dilute 20 mL of 50x TAE to 1000 mL with double 
distilled water.  
2. Place amber colored gel clamp in buffer. Gently place lid on rig. 
Note: Be careful of heating element and spinner. 
3. Tur     p w r sw t    s w     s t   ―Pu p‖     ―H  t‖ sw t    (W    t    >1 
hour to bring to 56ºC). 
Loading gel and samples 
1. Remove lid from rig and carefully place on black stand. 
2. Remove the amber gel clamp from pre-heated buffer. 
3. Remove the polymerized gel from the plate stand. Snap the gel apparatus into the 
amber clamp.  
a. The shorter plate will be facing the inside of the gel box. 
b. The gel clamp and apparatus requires some pressure to snap into place. 
Make sure the plates are lined up and square before applying excessive 
pressure.  
c. Snap the empty set of plates into the back location of the amber gel clamp. 
4. Lower the amber gel clamp/plates into the buffer.  
5. Gently and slowly remove the comb. 
 
Note: When removing the comb pull straight up. If a well side wall collapses, this can be 
fixed using a pipette tip or a straightened paper clip gently.  
 
6. Using a 200 uL pipette blow out the wells using the buffer from the gel rig.  
7. Prep PCR product for loading: 
a. The comb has 20 wells. The two wells on the far outsides are not used to 
 v        ‗s       ‘  4 w   s w              w t  st    r  (7 u     u   7 
uL 824 and 5 uL loading dye). The remaining 12 wells (6 samples in 
duplicate) will be used for loading samples (20 uL PCR product and 5 uL 
loading dye).  
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Note: Mix loading dye and standard/sample well before loading. 
8. Load samples into wells using a 20 uL pipette, dispensing the sample slowly.   
 
Note: Make sure to record which samples or standards were loaded into lanes. 
 
9. Place lid back on, ensuring that is sealed well. Turn on (all three switches listed 
earlier). 
10. Bring temperature back up to 56ºC 
11. Once at 56ºC, plug the black and red cable into the voltage source.  
12. Turn on the power of the voltage source, select program 1 (17h at 69V) and run 
program.  
Dying the gel 
1. Prepare the gel red dye: 
a. Mix 50 mL of 1x TAE buffer and 10 uL gel red in a 50 mL centrifuge 
tube.  
b. Pour into the 8x8 glass dish. 
2. Shut off the gel rig and gently remove lid. 
3. Place amber gel clamp/plates on to a clean covered lab bench. 
4. Remove plates from amber clamp by releasing the black lever. 
5. Remove side screw clamps from gel/plates. 
6. Gently remove 1 mm spacers (Do Not disturb plate or gel). 
7. Position plates/gel so that the shorter of the two plates is on top.  
8. Using the green tool between the plates (at the edge where spacers were 
removed), gently pry apart the two plates lifting the top plate slowly. 
9. Once the top plate is removed, using the green tool cut off the stacking gel and 
notch a corner of the gel for orientation and identification purposes. 
10. Stacking gel can be discarded in the garbage. 
11. Dip the green tool in buffer (from the gel rig) and gently run along the edges of 
the gel between the gel and the remaining plate. It also helps to add additional 
buffer to cover the entire gel. 
12. Turn plate over (so gel is on bottom now) over the 8x8 dish containing the gel red 
dye.  
13. Start at one corner and gently peel away edge of gel using the green tool, allowing 
the gel to fall into the dye.  
14. The gel oftentimes falls in a club and can be straightened by gently swishing the 
glass dish.  
15. Wrap the glass dish in aluminum foil so it is not exposed to any light. 
16. Set dish on agitator for 40 minutes. Set agitator to ~2. 
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Imaging the gel 
1. After the 40 minute incubation in gel red, take the glass dish and gel to the photo 
box.  
2. Rinse your gloves well, as there seems to be a powder of some kind on them and 
that can create a film on the gel. 
3. Clean the surface of the photo box with double distilled water.  
4. Cover the photo box plate with double distilled water so no dry spots are 
apparent. 
5. Place dish on the corner of the gel box. Stretch your fingers wide, spanning the 
width of the dish. Starting at the opposite side, pull the gel towards you gently. 
The gel will fold over on itself and as you get the gel against the side of the dish, 
roll your wrists forward (away from you) so the gel is pulled into your hands. 
Gently pick up your hands, fully supporting the gel, and place the gel on the photo 
box. 
6. Allow the gel to unfold itself. If necessary use a stream of double distilled water 
to unfold the gel. Avoid any hand contact with the gel! 
7. Using the water bottle rinse the top of the unfolded gel to get a clearer picture.  
8. Close the photo box door, turn on the UV lamp and capture the image.  
a. Take photos of the gel at multiple exposures (increments of 2 seconds 
from 4 to 16 seconds). 
9. To capture the image: 
a. Open the Kodak program from the Start Up menu. 
b. Click the “Capture” button at the top left of the window; a small window 
will open. 
c. Set the exposure length. 
d. Make sure the UV light is on. 
e. Select “Capture” to begin capturing image.  
Note: Will need to take multiple photos the get the gel centered and in focus. Zoom and 
focus can be adjusted by means of the camera lens.   
Clean up 
1. Clean up area/wipe down gel box when finished. 
2. DGGE gel can be discarded in regular trash when finished. 
3. Wash glass plates with soapy water and make sure to rinse them well. Avoid 
chipping any corners since this can lead to a leaky gel.  Allow glass plates to air 
dry. 
4. Rinse plates and all other components (except gel lid) with deionized tap water 
and allow to air dry. 
5. Wipe out the bottom of the gel lid with a damp cloth 
6. Put away the voltage and power source.   
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7. Gel mixing block often requires extra cleaning. This can be done by 
disassembling and employing a paper clip to remove all excess polymerized gel.  
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Appendix O: Feed Refusal Raw Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control Group – Refused Alfalfa Cubes (%) 
 
 Adaptation Period (d) Antibiotic Challenge Period (d) Withdrawal Period (d) 
Horse -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 
Sister 
Cashmere 
16.7 6.6 0 2.6 0 3.2 5.4 5.3 0 8.6 0 0 0 0 0 0 0 0 0 0 0 
Townsend 
Lad 
0 6.7 17.5 0 0 7.4 0 0 0 0 4.2 0 0 0 5.1 0 4 0 0 3.2 5.3 
Matty G 
Unit 
2.1 0 3 0.5 0 0 0 0 0 0 0 0 6.5 0 0 0 0 2.4 0 0 0 
T ‘s 
Lucky 
Deelite 
17.2 8.9 40.2 7.6 11.3 10.9 3.7 8.0 1.3 0.9 1.5 7.6 4.6 0 0 8.2 14.1 14.6 9.6 10.2 4.4 
Matty G 
Whiz 
2.4 0 0 1.5 7.0 0 0 12.9 0.1 2.1 0 0 0 0 0 0 0 0 0 0 0 
Smart 
Balance 
11.7 13.4 15.6 13.9 14.1 0 1.5 9.1 15.8 10.4 3.5 28.1 13.9 8.2 9.7 10.6 7.1 6.9 6.7 5.0 6.3 
Avg. d 
(%) 
8.35 5.9 12.7 4.4 5.4 3.6 1.8 5.9 2.9 3.7 1.5 6.0 4.2 1.4 2.5 3.1 4.2 4.0 2.7 3.1 2.7 
 Avg. (%) Adaptation Period = 6.0 Avg. (%) Antibiotic Challenge Period = 3.6 Avg, (%) Withdrawal Period = 3.2 
  
1
5
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Sodium Ceftiofur – Refused Alfalfa Cubes (%) 
 
 Adaptation Period (d) Antibiotic Challenge Period (d) Withdrawal Period (d) 
Horse -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 
Show Me 
the Lillies 
39.1 13.7 16.4 34.1 20.8 28.4 13.9 11.4 6.7 18.7 7.9 18.4 27.0 25.6 13.6 28.3 6.1 12.0 10.5 26.6 7.6 
Downtown 
Leroy 
0 0 0 0 3.7 0 0 7.1 20.3 4.8 21.8 5.8 6.5 0 7.6 2.2 0 0 5.8 1.3 1.3 
R s  ‘s Ex 4.6 7.3 0 9.4 4.4 0 6.9 3.1 8.2 6.5 18.3 8.4 13.0 8 15.1 10.9 12.6 17.2 4.8 30 6.3 
Menka 20.7 8.1 15.5 3.9 3.5 0 0 2.4 0 6.5 28.7 42.7 42.3 13.8 3.9 11.8 14.6 12.8 5.9 3.2 2.6 
Quick Flite 1.9 2.1 0 0 0.4 0 0 0 2.6 0 0 0 0 0 1.1 0 0 0 0 0 0 
Sister 
Cashmere 
0 0 0 3.6 0 0 0 0 0 0 0 0 3.4 0 0 2.8 3.0 0 0 0 0 
Avg. d (%) 11.1 5.2 5.3 8.5 5.5 4.7 3.5 4 6.3 6.1 12.8 12.6 15.4 7.9 6.9 9.3 6.1 7 4.5 10.2 3.0 
 Avg. (%) Adaptation Period = 6.2 Avg. (%) Antibiotic Challenge Period = 9.3 Avg, (%) Withdrawal Period = 6.7 
  
1
5
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Trimethoprim-sulfadiazine– Refused Alfalfa Cubes (%) 
 
 Adaptation Period (d) Antibiotic Challenge Period (d) Withdrawal Period (d) 
Horse -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 
Bingo Betty 31.8 26.3 8.4 21.9 7.7 12.2 12.4 18.4 22 36.6 14 8.2 7.8 13.3 4.7 16.9 12.8 5.4 7.6 11.5 8.5 
My Boy 
George 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 - - - - - - - 
Friendly 
Fella 
20.2 7.4 3.4 8.9 0 0 0 3.4 5.5 0 7.7 2.6 0 1.7 0 2.6 0 5 5.8 37.9 1.4 
Tonosi 6.3 7.1 6.1 8.4 6.3 6.5 3.1 4.2 0 0 6.1 2.3 3.4 1.3 8.2 8.4 0 0 8 0 2.9 
Rancho 
Valencia 
49.8 38.5 29.4 9.8 41.8 6.2 18.5 24.2 17.8 40.9 28.9 9.3 3.1 24.2 10 9.6 13.1 10.7 24.7 16.7 14.9 
Windspeil 20.9 9.4 7.6 6.2 6.4 0 0 6.7 4.8 9.2 0 8 7.1 7.1 12.2 13.5 21.8 23.5 7.5 21.9 22 
Avg. d (%) 21.5 14.8 9.2 9.2 10.4 4.2 5.7 9.5 8.4 14.5 9.5 5.1 3.6 7.9 7 10.2 9.5 8.9 10.7 17.6 9.9 
 Avg. (%) Adaptation Period = 10.7 Avg. (%) Antibiotic Challenge Period = 8.3 Avg, (%) Withdrawal Period = 10.6 
  
1
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Control – Refused Long Stem Hay (%) 
 
 Adaptation Period (d) Antibiotic Challenge Period (d) Withdrawal Period (d) 
Horse -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 
Sister 
Cashmere 
73.2 82.8 80.2 100 96.5 93 57.7 92.1 88.1 88.6 77.1 74.9 63 87.7 84.6 87.2 74.9 100 84.1 84.6 74.9 
Townsend 
Lad 
94.3 99.2 96.9 95.6 85 89.4 78.9 94.3 85 77.1 95.6 81.1 67.8 73.6 94.7 82.4 89.9 86.8 100 100 86.8 
Matty G 
Unit 
66.5 100 85 89 87.7 93 84.6 76.2 77.5 63 65.2 60.4 88.6 70.9 63.9 67 81.1 84.1 73.1 91.6 60.4 
T ‘s  u  y 
Deelite 
94.7 8.8 76.7 59.9 62.6 69.7 0 71.8 60.8 49.8 76.2 65.6 68.3 52.9 65.2 87.2 48.5 40.5 69.6 56 29.1 
Matty G 
Whiz 
6.2 20.3 18.5 3.5 0 57.3 4 18.1 44.5 8.4 15.3 12.8 - 11.9 26 55.1 41 5.7 18.9 3.1 23.8 
Smart 
Balance 
74 96.5 67 73.6 64.8 45.8 52.9 73.1 64.3 81.5 63.4 33.7 54.2 37.9 18.3 54.2 51.5 64.8 48.5 56.8 45.8 
Avg. d (%) 68.2 67.9 70.7 70.3 66.1 74.7 46.4 70.9 70 61.4 65.5 54.8 68.4 55.8 58.8 72.2 64.5 63.7 65.7 65.4 53.5 
 Avg. (%) Adaptation Period = 66.3 Avg. (%) Antibiotic Challenge Period = 63.8 Avg, (%) Withdrawal Period = 63.4 
  
1
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Sodium Ceftiofur – Refused Long Stem Hay (%) 
 
 Adaptation Period (d) Antibiotic Challenge Period (d) Withdrawal Period (d) 
Horse -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 
Show Me 
the Lillies 
79.3 85.5 57.3 75.8 68.3 71.4 76.2 75.3 74 99.1 62.1 96 74.5 89.4 74.9 67.4 58.2 72.3 93.8 75.8 82.8 
Downtown 
Leroy 
96.9 100 92.5 94.7 100 64.8 97.8 97.8 100 100 99.1 87.2 100 92.5 100 97.4 91.2 100 100 100 95.2 
R s  ‘s Ex 81.1 74.5 86.8 93.8 87.2 90.8 97.4 100 96 96.5 91.2 95.6 92.1 91.2 86.8 89.9 98.9 97.4 88.6 80.2 78.9 
Menka 93 100 86.3 87.7 95.6 97.8 56.4 83.3 83.3 97.4 84.6 100 91.6 100 74.9 100 90.3 74.5 81.9 36.6 53.3 
Quick Flite 42.7 100 68.3 70.9 58.2 39.2 22.9 32.2 37.9 33.7 25.1 56.4 44.1 43.6 65.2 42.7 78 28.6 41.9 22 7.9 
Sister 
Cashmere 
41.4 81.5 41.4 56 49.3 44.1 44.1 43.2 66.5 81.5 70 66.5 37.2 42.7 60.8 62.1 85.9 70.9 36.8 70 54.6 
Avg. d (%) 72.4 90.3 72.1 79.8 76.4 68 65.8 72 76.3 84.7 72 83.6 73.3 76.6 77.1 76.6 83.8 74 73.8 64.1 62.1 
 Avg. (%) Adaptation Period = 75 Avg. (%) Antibiotic Challenge Period = 76.9 Avg, (%) Withdrawal Period = 73.1 
  
1
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Trimethoprim-sulfadiazine – Refused Long Stem Hay (%) 
 
 Adaptation Period (d) Antibiotic Challenge Period (d) Withdrawal Period (d) 
Horse -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 
Bingo 
Betty 
34.8 97.8 83.3 82.4 80.6 86.8 77.5 73.6 93 90.3 82.8 75.3 100 93 82.8 81.5 78.9 81.5 75.3 97.4 100 
My Boy 
George 
70 83.7 82.4 74 78 74.9 48.5 100 67.8 64.8 81.9 53.7 69.6 73.9 - - - - - - - 
Friendly 
Fella 
92.5 100 97.4 95.2 88.1 95.6 95.6 96.9 95.6 92.3 84.1 95.2 96 94.7 87.2 90.8 86.3 90.8 93.8 92.5 94.3 
Tonosi 100 100 85.9 92.5 100 86.8 81.5 89 44.5 89.4 91.2 100 100 71.8 46.3 100 93 70.9 84.1 60.8 60.7 
Rancho 
Valencia 
48 73.6 83.3 73.6 51.1 63 47.1 53.7 83.3 74 29.1 17.6 40.5 68.7 61.7 73.1 37 24.7 67.8 74.5 66.1 
Windspeil 70 91.6 100 58.6 69.6 84.1 60.8 71.4 78 71.8 67.8 44.5 53.3 71.4 77.1 52.9 66.1 89.4 44.5 100 58.6 
Avg. d 
(%) 
69.2 91.1 88.7 79.4 77.9 81.9 68.5 80.8 77 80.4 72.8 64.4 76.6 78.9 71 79.7 72.3 71.5 73.1 85 75.9 
 Avg. (%) Adaptation Period = 79.5 Avg. (%) Antibiotic Challenge Period = 75.8 Avg, (%) Withdrawal Period = 75.5 
  
1
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Control – Refused Concentrate (%) 
 
 Adaptation Period (d) Antibiotic Challenge Period (d) Withdrawal Period (d) 
Horse -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 
Sister 
Cashmere 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Townsend 
Lad 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Matty G 
Unit 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
T ‘s  u  y 
Deelite 
5.2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Matty G 
Whiz 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Smart 
Balance 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg. d (%) 0.9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
 Avg. (%) Adaptation Period = 0.1 Avg. (%) Antibiotic Challenge Period = 0 Avg, (%) Withdrawal Period = 0 
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Sodium Ceftiofur – Refused Concentrate (%) 
 
 Adaptation Period (d) Antibiotic Challenge Period (d) Withdrawal Period (d) 
Horse -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 
Show Me 
the Lillies 
1.31 0 1.35 0 2.03 0 1.33 0 2 0 0 0 0 0 0 0 0 0 0 0 0 
Downtown 
Leroy 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
R s  ‘s Ex 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Menka 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Quick Flite 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Sister 
Cashmere 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg. d (%) 0.2 0 0.2 0 0.3 0 0.2 0 0.3 0 0 0 0 0 0 0 0 0 0 0 0 
 Avg. (%) Adaptation Period = 0.1 Avg. (%) Antibiotic Challenge Period = 0.05 Avg, (%) Withdrawal Period = 0 
  
1
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Trimethoprim-sulfadiazine – Refused Concentrate (%) 
 
 Adaptation Period (d) Antibiotic Challenge Period (d) Withdrawal Period (d) 
Horse -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 
Bingo Betty 0 0 0.78 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
My Boy 
George 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 - - - - - - - 
Friendly 
Fella 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Tonosi 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Rancho 
Valencia 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Windspeil 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg. d (%) 0 0 0.1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
 Avg. (%) Adaptation Period = 0.02 Avg. (%) Antibiotic Challenge Period = 0 Avg, (%) Withdrawal Period = 0 
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Appendix P: Body Weights Raw Data 
 
 
 
 
 
 
 
Block 1 – Body Weights (kg) 
 
  Adaptation (d) Challenge(d) Withdrawal (d) 
Horse Treatment - - 4.25 5.2 5.6 5.10 5.14 5.17 - 
Sister 
Cashmere 
Control - - 608.5 608.5 609 613 609 615.5 - 
Show Me 
The 
Lillies 
Sodium 
Ceftiofur 
- - 610 593.5 600 591.5 597.6 600.5 - 
Bingo 
Betty 
Trimethoprim-
sulfadiazine 
- - 522.5 517 515 515.5 515.5 525.5 - 
 
Block 2 – Body Weights (kg) 
 
  Adaptation (d) Challenge (d) Withdrawal (d) 
Horse Treatment - 6.7 6.11 6.14 6.18 6.21 6.25 6.28 7.2 
Townsend 
Lad 
Control - 542 543 540 549.5 544.5 555 561 553.5 
Downtown 
Leroy 
Sodium 
Ceftiofur 
- 529.5 529 533 533 525 538.5 532.5 535 
My Boy 
George 
Trimethoprim-
sulfadiazine 
- 511.5 522.5 527 528.5 526 535 - - 
 
Block 3 – Body Weights (kg) 
 
  Adaptation (d) Challenge (d) Withdrawal (d) 
Horse Treatment 6.28 7.2 7.9 7.12 7.16 7.19 7.23 7.26 7.30 
Matty G-
Unit 
Control 473.5 476 466.5 465 461 462.5 462 464 463 
R s  ‘s Ex 
Sodium 
Ceftiofur 
605 599 583 586.5 584 577.5 574.5 571.5 569 
Friendly 
Fella 
Trimethoprim-
sulfadiazine 
492.5 493 486.5 485 481.5 480.5 482.5 483 485 
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Block 4 – Body Weights (kg) 
 
  Adaptation (d) Challenge (d) Withdrawal (d) 
Horse Treatment 8.2 8.6 8.9 8.16 8.20 8.23 8.27 8.30 9.3 
T ‘s  u  y 
Deelite 
Control 571.5 572.5 575 600.5 611 608.5 613 619 621.5 
Menka 
Sodium 
Ceftiofur 
623 635.5 635.5 640.5 646.5 645 635 647 646 
Tonosi 
Trimethoprim-
sulfadiazine 
595.5 601.5 596 601 622 619 627 630.5 634 
 
Block 5 – Body Weights (kg) 
 
  Adaptation (d) Challenge (d) Withdrawal (d) 
Horse Treatment 9.3 9.8 9.10 9.13 9.17 9.20 9.24 9.27 10.1 
Matty G 
Whiz 
Control 587.5 593 589.5 601.5 610 611.5 609.5 608 607.5 
Quick Flite 
Sodium 
Ceftiofur 
586 588.5 588 590.5 580.5 589 589.5 594 591.5 
Rancho 
Valencia 
Trimethoprim-
sulfadiazine 
564.5 552.5 562 556.5 554.5 558.5 560 557.5 556.5 
 
Block 6 – Body Weights (kg) 
 
  Adaptation (d) Challenge (d) Withdrawal (d) 
Horse Treatment 9.27 10.1 10.4 10.8 10.11 10.15 10.18 10.22 10.25 
Smart 
Balance 
Control 561.5 566.5 577.5 569.5 576.5 571.5 589.5 589.5 592.5 
Sister 
Cashmere 
Sodium 
Ceftiofur 
578.5 575 588 584.5 600.5 596 599 586.5 599 
Windspeil 
Trimethoprim-
sulfadiazine 
544.5 535.5 545 544 556 552.5 564.5 557 562.5 
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Appendix Q: Feed Composition Raw Data 
 
1 Dairy One, Ithaca, NY 
1 Dairy One, Ithaca, NY 
1 Dairy One, Ithaca, NY 
 
 
Alfalfa Cubes1 
 
Block 
% 
DM 
DE Mcal/kg 
% 
CP 
% 
ADF 
% NDF 
% 
Ca 
% 
P 
#1 89.6 2.62 24.2 26.4 31.2 2.14 .29 
#2 90.1 2.46 21.5 30.2 37.7 2.09 .29 
#3 90.4 2.44 20.4 30.2 38.6 1.96 .31 
#4 88.8 2.42 20.1 31.8 39.2 1.87 .28 
#5 88.5 2.33 21.1 33.5 42.4 1.5 .4 
#6 89.6 2.62 24.2 26.4 31.2 2.14 .29 
 
Pelleted Concentrate1 
 
Block 
% 
DM 
DE Mcal/kg 
% 
CP 
% 
ADF 
% NDF 
% 
Ca 
% 
P 
#1 90.1 3.48 14.2 8.7 17.5 1.04 .58 
#2 90.1 3.39 13.5 11 21.2 1.15 .66 
#3 89.8 3.28 15.8 11.6 24.8 .95 .86 
#4 90.3 3.21 15.3 14.3 26.6 1.31 1.16 
#5 89.6 3.23 16.6 13.9 25.7 1.34 1.15 
#6 90.7 3.12 15.8 14.6 30.2 1.23 1.11 
 
Long Stem Grass Hay1 
 
Block 
% 
DM 
DE Mcal/kg 
% 
CP 
% 
ADF 
% NDF 
% 
Ca 
% 
P 
#1 90.4 2.04 12.6 39.3 64.0 .62 .59 
#2 92.5 1.91 13 42.5 68.4 .63 .64 
#3 92.4 1.89 12.1 43.4 68.8 .61 .67 
#4 92.4 2.00 12.1 38.7 65.3 .64 .75 
#5 91.8 2.05 11.6 38.6 64.5 .72 .75 
#6 92.0 2.05 11.4 39.4 64.3 .63 .64 
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Appendix R: Cellulolytic Bacteria Enumerations Raw Data 
 
 
 
Control – Cellulolytic Bacteria (cells / gram of feces) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Sister 
Cashmere 
106 106 107 106 106 106 106 106 
Townsend 
Lad 
106 106 107 107 106 106 106 106 
Matty G Unit 108 108 107 108 108 108 108 108 
T ‘s  u  y 
Deelite 
107 107 107 107 107 107 107 107 
Matty G 
Whiz 
106 106 106 106 106 106 106 106 
Smart 
Balance 
106 106 106 106 107 107 106 107 
Avg. d 
(d) 
1.9 x 
107 
1.9 x 107 7 x 106 2.05 x 107 2.05 x 107 2.05 x 107 1.90 x 107 2.05 x 107 
Avg. Adaptation 
Period ± SE = 
1.9 x 107 ± 
1.1 x 107 
Avg. Antibiotic 
Challenge ± SE = 
1.6 x 107 
±7.28 x 106 
Avg. Withdrawal 
Period ± SE = 
2 x 107 ± 
8.73 x 106 
 
Sodium Ceftiofur – Cellulolytic Bacteria (cells / gram of feces) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Show Me the 
Lillies 
106 106 107 105 105 105 105 104 
Downtown 
Leroy 
106 106 105 104 104 104 103 104 
R s  ‘s Ex 108 107 106 106 104 105 104 105 
Menka 107 107 105 104 105 105 104 104 
Quick Flite 106 106 104 104 104 104 104 104 
Sister 
Cashmere 
107 106 105 105 103 103 104 104 
Avg. d 
(d) 
2.05 x 107 4.0 x 106 1.89 x 106 2.05 x 105 3.85 x 104 5.35 x 104 2.35 x 104 2.5 x 104 
Avg. Adaptation 
Period ± SE = 
5.5 x 106 ± 
8.07 x 106 
Avg. Antibiotic 
Challenge ± SE = 
7.10 x 105 ± 
5.5 x 105 
Avg. Withdrawal 
Period ± SE = 
3.94 x 104 ± 
9.95 x 103 
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Trimethoprim-sulfadiazine – Cellulolytic Bacteria (cells / gram of feces) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Bingo Betty 106 106 107 106 105 105 103 103 
My Boy 
George 
106 106 105 103 104 - - - 
Friendly 
Fella 
108 108 107 107 105 105 105 104 
Tonosi 107 107 104 104 104 104 104 104 
Rancho 
Valencia 
106 106 105 105 104 104 103 104 
Windspeil 107 106 105 104 104 104 104 104 
Avg. d 
(d) 
2.05 x 107 1.9 x 107 3.39 x 106 1.85 x 106 4 x 104 4.6 x 104 2.44 x 104 8.2 x 103 
Avg. Adaptation Period 
± SE = 
1.98 x 107 ± 
1.088 x 107 
Avg. Antibiotic 
Challenge ± SE = 
1.76 x 106 ± 
8.95 x 105 
Avg. Withdrawal 
Period ± SE = 
2.62 x 104 ± 
9.91 x 103 
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Appendix S: Cellulolytic Bacteria Lag Time Raw Data 
 
 
 
 
Control – Cellulolytic Bacteria Lag Time (d) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Sister 
Cashmere 
2 2 2 2 2 2 2 2 
Townsend 
Lad 
2 2 2 2 1 1 2 2 
Matty G Unit 2 2 2 2 2 2 2 2 
T ‘s  u  y 
Deelite 
2 2 2 2 2 2 2 2 
Matty G 
Whiz 
2 2 2 2 2 2 2 2 
Smart 
Balance 
2 2 2 2 2 2 2 2 
Avg. d 
(d) 
2 2 2 2 1.83 1.83 2 2 
Avg. Adaptation 
Period ± SE = 
2 ± 0 
Avg. Antibiotic 
Challenge ± SE = 
1.94 ± 0.06 
Avg. Withdrawal 
Period ± SE = 
1.94 ± 0.06 
 
Sodium ceftiofur – Cellulolytic Bacteria Lag Time (d) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Show Me the 
Lillies 
2 2 2 2 3 3 3 2 
Downtown 
Leroy 
2 2 3 3 3 3 3 3 
R s  ‘s Ex 2 2 3 4 4 5 5 5 
Menka 2 2 5 5 4 3 4 5 
Quick Flite 2 2 3 4 4 4 4 3 
Sister 
Cashmere 
2 2 3 4 4 4 4 3 
Avg. d 
(d) 
2 2 3.167 3.67 3.67 3.67 3.83 3.5 
Avg. Adaptation 
Period ± SE = 
2 ± 0 
Avg. Treatment Period 
± SE = 
3.5 ± 0.20 
Avg. Withdrawal 
Period ± SE = 
3.67 ± 0.21 
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Trimethoprim-sulfadiazine – Cellulolytic Bacteria Lag Time (d) 
 
 Adaptation (d) Treatment (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Bingo Betty 2 2 4 3 4 4 3 3 
My Boy 
George 
2 2 2 2 2 - - - 
Friendly 
Fella 
2 2 2 3 4 5 4 4 
Tonosi 2 2 3 5 3 4 5 4 
Rancho 
Valencia 
2 2 2 3 4 4 4 4 
Windspeil 2 2 2 3 3 3 4 4 
Avg. d 
(d) 
2 2 2.5 3.17 3.33 4 4 3.8 
Avg. Adaptation 
Period ± SE = 
2 ± 0 
Avg. Antibiotic 
Challenge ± SE = 
3 ± 0.21 
Avg. Withdrawal 
Period ± SE = 
3.93 ± 0.14 
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Appendix T: Lactobacillus spp. Enumeration Raw Data 
 
 
 
Sodium Ceftiofur –  Lactobacillus spp. (Rogosa SL Agar; cfu / gram of feces) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Show Me the 
Lillies 
214000 205000 200000 105000 65000 95000 120000 110000 
Downtown 
Leroy 
85000 105000 180000 195000 170000 130000 150000 155000 
R s  ‘s Ex 815000 765000 240000 160000 60000 95000 265000 535000 
Menka 70000 90000 20000 10000 5000 25000 45000 30000 
Quick Flite 95000 70000 30000 35000 10000 5000 10000 20000 
Sister 
Cashmere 
195000 255000 140000 10000 10000 80000 75000 105000 
Avg. d 
(cfu/g) 
245666
.7 
248333.3 135000 85833.33 53333.33 71666.67 110833.3 159166.7 
Avg. Adaptation 
Period ± SE = 
247000 ±  
75547.9 
Avg. Antibiotic 
Challenge ± SE = 
91388.89 ±  
19266.81 
Avg. Withdrawal 
Period ± SE = 
113888.9 ±  
29041.20 
 
Control – Lactobacillus spp. (Rogosa SL Agar; cfu / gram of feces) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Sister 
Cashmere 
227500 160000 190000 315000 95000 80000 155000 135000 
Townsend 
Lad 
75000 115000 160000 180000 160000 145000 160000 160000 
Matty G Unit 735000 780000 660000 195000 630000 120000 220000 780000 
T ‘s Lucky 
Deelite 
160000 70000 80000 190000 130000 280000 290000 80000 
Matty G 
Whiz 
190000 60000 20000 20000 245000 35000 20000 30000 
Smart 
Balance 
270000 315000 85000 15000 230000 140000 110000 110000 
Avg. d 
(cfu/g) 
276250 250000 199166.7 152500 248333.3 290000 250000 265000 
Avg. Adaptation 
Period ± SE = 
263125 ± 
64880.74 
Avg. Antibiotic 
Challenge ± SE = 
277222.2 ± 
50192.8 
Avg. Withdrawal 
Period ± SE = 
268333.3 ± 
48028.11 
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Trimethoprim-sulfadiazine –  Lactobacillus spp. (Rogosa SL Agar; cfu / gram of feces) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Bingo Betty 227500 160000 190000 315000 135000 80000 155000 135000 
My Boy 
George 
75000 115000 160000 180000 150000 - - - 
Friendly 
Fella 
735000 780000 660000 195000 145000 120000 220000 780000 
Tonosi 160000 70000 80000 190000 100000 280000 290000 80000 
Rancho 
Valencia 
190000 60000 20000 20000 30000 35000 20000 30000 
Windspeil 270000 315000 85000 15000 20000 140000 110000 110000 
Avg. d 
(cfu/g) 
276250 250000 199166.67 152500 96666.67 131000 159000 227000 
Avg. Adaptation 
Period ± SE = 
263125 ± 
64880.74 
Avg. Antibiotic 
Challenge ± SE = 
149444.4 ± 
35642.76 
Avg. Withdrawal 
Period ± SE = 
172333.3 ± 
48284.54 
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Appendix U: Salmonella spp. Enumeration Raw Data 
 
 
 
Control – Salmonella spp. (BBLTM CHROMagarTM Salmonella; cfu / gram of feces) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Sister 
Cashmere 
0 5000 500 0 250 5000 100 50 
Townsend 
Lad 
350 450 0 50 0 0 0 0 
Matty G Unit 1000 500 50 0 0 150 100 50 
T ‘s  u  y 
Deelite 
150 50 150 0 400 0 500 0 
Matty G 
Whiz 
0 0 0 0 0 0 0 0 
Smart 
Balance 
300 550 250 150 0 200 0 0 
Avg. d 
(cfu/g) 
300 1091.67 158.33 33.33 108.33 891.67 116.67 16.67 
Avg. Adaptation 
Period ± SE = 
695.83 ±  
400.59 
Avg. Antibiotic 
Challenge ± SE = 
100 ±   
36.38 
Avg. Withdrawal 
Period ± SE = 
341.67 ±  
275.56 
 
Sodium Ceftiofur –   Salmonella spp. (BBLTM CHROMagarTM Salmonella; cfu / gram of feces) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Show Me the 
Lillies 
0 0 500 0 300 0 50 50 
Downtown 
Leroy 
350 50 200 200 150 1300 700 800 
R s  ‘s Ex 150 1000 2000 3000 1000 2000 10000 1500 
Menka 450 3500 1500 150 0 500 150 50 
Quick Flite 0 50 100 3000 5000 30000 20000 5000 
Sister 
Cashmere 
100 250 150 2000 10000 40000 6000 500 
Avg. d 
(cfu/g) 
175 808.33 741.67 1391.67 2741.67 12300 6150 1316.67 
Avg. Adaptation 
Period ± SE = 
491.67 ±  
285.70 
Avg. Antibiotic 
Challenge ± SE = 
1625 ±  
591.93 
Avg. Withdrawal 
Period ± SE = 
6588.89 ±  
2735.12 
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Trimethoprim-sulfadiazine –   Salmonella spp. (BBLTM CHROMagarTM Salmonella; cfu / gram of feces) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Bingo Betty 100 500 2000 5000 5000 5000 600 650 
My Boy 
George 
100 0 100 100 200 - - - 
Friendly 
Fella 
500 1000 1000 5000 40000 10000 6000 25000 
Tonosi 2500 150 1500 1000 1150 500 1000 600 
Rancho 
Valencia 
450 100 100 3000 2500 1500 1000 50 
Windspeil 200 100 200 100 2000 3500 300 0 
Avg. d 
(cfu/g) 
641.67 308.33 816.67 2366.67 8475 4100 1780 5260 
Avg. Adaptation 
Period ± SE = 
475 ±  
201.27 
Avg. Antibiotic 
Challenge ± SE = 
3886.11 ±  
2163.35 
Avg. Withdrawal 
Period ± SE = 
3713.33 ±  
1686.29 
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Appendix V: Clostridium difficile Enumeration Raw Data 
 
 
 
Control – Clostridium difficile (Clostridium Difficile Selective Agar; cfu / gram of feces) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Sister 
Cashmere 
0 0 0 0 0 0 0 0 
Townsend 
Lad 
0 0 0 0 0 0 0 0 
Matty G Unit 0 0 0 0 0 0 0 0 
T ‘s  u  y 
Deelite 
0 0 0 0 0 0 0 0 
Matty G 
Whiz 
0 0 0 0 0 0 0 0 
Smart 
Balance 
0 0 0 0 0 0 0 0 
Avg. d 
(cfu/g) 
0 0 0 0 0 0 0 0 
Avg. Adaptation 
Period ± SE = 
0 ± 0 
Avg. Antibiotic 
Challenge ± SE = 
0 ± 0 
Avg. Withdrawal 
Period ± SE = 
0 ± 0 
 
Sodium Ceftiofur – Clostridium difficile (Clostridium Difficile Selective Agar; cfu / gram of feces) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Show Me the 
Lillies 
0 0 10000 1000 3500 0 0 0 
Downtown 
Leroy 
0 0 135000 10000 3500 1000 0 0 
R s  ‘s Ex 0 0 450 15000 40000 20000 15000 2000 
Menka 0 0 0 0 3000 500 1000 700 
Quick Flite 0 0 2500 2000 3000 5000 5000 100 
Sister 
Cashmere 
0 0 35000 30000 5000 45000 1000 100 
Avg. d 
(cfu/g) 
0 0 30491.67 9666.67 9666.67 11916.67 3666.67 483.33 
Avg. Adaptation 
Period ± SE = 
0 ± 0 
Avg. Antibiotic 
Challenge ± SE = 
16608.3 ± 
7559.98 
Avg. Withdrawal 
Period ± SE = 
5355.56 ± 
2676.14 
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Trimethoprim-sulfadiazine – Clostridium difficile (Clostridium Difficile Selective Agar; cfu / gram of feces) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Bingo Betty 0 0 1000 950 1000 50 500 150 
My Boy 
George 
0 0 2500 5000 30000 - - - 
Friendly 
Fella 
0 0 0 2000 2000 1500 1500 500 
Tonosi 0 0 50000 30000 30000 16000 5000 5000 
Rancho 
Valencia 
0 0 2000 35000 45000 135000 20000 2000 
Windspeil 0 0 450 5000 10000 2500 350 200 
Avg. d 
(cfu/g) 
0 0 9325 12991.67 19666.67 31010 5470 1570 
Avg. Adaptation 
Period ± SE = 
0 ± 0 
Avg. Antibiotic 
Challenge ± SE = 
13994.44 ± 
4080.94 
Avg. Withdrawal 
Period ± SE = 
12683.33 ± 
8873.03 
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Appendix W: Clostridium perfringens Enumeration Raw Data 
 
 
Control – Clostridium perfringens ( Sulfite Polymyxin Sulfadiazine Agar; cfu / gram of feces) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Sister 
Cashmere 
100 150 250 150 0 0 0 0 
Townsend 
Lad 
0 0 0 0 0 0 0 0 
Matty G Unit 0 0 0 0 0 0 0 0 
T ‘s  u  y 
Deelite 
0 50 0 0 0 0 0 0 
Matty G 
Whiz 
0 0 0 0 0 0 0 0 
Smart 
Balance 
0 0 0 0 0 0 0 0 
Avg. d 
(cfu/g) 
16.67 33.33 41.67 25 0 0 0 0 
Avg. Adaptation 
Period ± SE = 
25 
 ± 14.43 
Avg. Antibiotic 
Challenge ± SE = 
22.22  
± 15.77 
Avg. Withdrawal 
Period ± SE = 
0 
 ±  0 
 
Sodium Ceftiofur – Clostridium perfringens ( Sulfite Polymyxin Sulfadiazine Agar; cfu / gram of feces) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Show Me the 
Lillies 
0 0 450 250 50 50 0 0 
Downtown 
Leroy 
0 0 0 50 0 0 0 0 
R s  ‘s Ex 0 0 0 50 0 0 50 150 
Menka 50 0 0 0 500 1000 200 0 
Quick Flite 0 0 0 0 0 0 0 0 
Sister 
Cashmere 
0 0 100 0 0 0 0 0 
Avg. d 
(cfu/g) 
8.33 0 91.67 58.33 91.67 175 41.67 25 
Avg. Adaptation 
Period ± SE = 
4.17 ± 4.17 
Avg. Antibiotic 
Challenge ± SE = 
80.56 ± 
36.85 
Avg. Withdrawal 
Period ± SE = 
80.56 ± 
55.73 
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Trimethoprim sulfadiazine – Clostridium perfringens ( Sulfite Polymyxin Sulfadiazine Agar; cfu / gram of feces) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Bingo Betty 0 50 250 150 2500 0 50 0 
My Boy 
George 
0 0 50 50 0    
Friendly 
Fella 
0 0 0 100 0 150 200 100 
Tonosi 0 50 0 0 0 150 0 0 
Rancho 
Valencia 
0 0 0 0 0 50 0 0 
Windspeil 0 0 1500 100 0 0 0 0 
Avg. d 
(cfu/g) 
0 16.67 300 66.67 416.67 70 50 20 
Avg. Adaptation 
Period ± SE = 
8.33 ± 5.62 
Avg. Antibiotic 
Challenge ± SE = 
261.11 ± 
155.31 
Avg. Withdrawal 
Period ± SE = 
46.67 ± 
17.92 
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Appendix X: Fecal pH Raw Data 
 
Sodium Ceftiofur – Fecal pH 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Show Me 
the Lillies 
6 6.24 6.43 6.61 5.94 6.18 6.21 6.28 
Downtown 
Leroy 
5.69 - 5.66 5.59 5.86 5.79 5.86 5.63 
R s  ‘s Ex 6.22 6.24 6.22 5.99 6.06 6.23 6.03 6.29 
Menka 6.7 6.71 6.63 6.33 6.57 6.55 6.23 6.37 
Quick Flite 6.48 7.04 6.61 6.82 6.91 6.18 6.36 6.78 
Sister 
Cashmere 
6.4 6.63 6.27 6.44 6.49 6.42 6.25 6.29 
Avg. d (pH) 6.25 6.57 6.3 6.3 6.31 6.23 6.15 6.27 
Avg. Adaptation 
Period ± SE = 
6.34 ± 0.17 
Avg. Antibiotic 
Challenge ± SE = 
6.30 ± 0.15 
Avg. Withdrawal 
Period ± SE = 
6.22 ± 0.10 
 
Control – Fecal pH 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Sister 
Cashmere 
5.99 6.22 6.08 6.47 6.29 6.39 
 
6.18 6.79 
Townsend 
Lad 
6.32 - 6.05 6.1 6.31 6.4 6.31 6.32 
Matty G 
Unit 
6.75 6.35 6.4 6.61 6.81 6.91 6.66 7.36 
T ‘s  u  y 
Deelite 
6.66 6.44 6.34 6.53 7.16 6.47 6.18 6.43 
Matty G 
Whiz 
6.53 6.77 6.66 6.71 6.79 6.16 6.46 6.02 
Smart 
Balance 
6.37 6.54 6.34 6.39 6.53 6.09 6.38 6.34 
Avg. d (pH) 6.44 6.46 6.31 6.47 6.65 6.4 6.36 6.54 
Avg. Adaptation 
Period ± SE = 
6.44 ± 0.08 
Avg. Antibiotic 
Challenge ± SE = 
6.48 ± 0.09 
Avg. Withdrawal 
Period ± SE = 
6.44 ± 0.11 
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Trimethoprim-sulfadiazine – Fecal pH 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Bingo Betty 6.04 6.03 5.66 5.94 6.06 5.91 5.79 5.97 
My Boy 
George 
6.31 - 6.27 6.19 6.5 - - - 
Friendly 
Fella 
6.22 5.89 6.2 6.44 6.27 6.39 6.39 6.69 
Tonosi 7 7.26 6.36 6.97 7.05 6.26 7.17 6.8 
Rancho 
Valencia 
6.78 7.28 6.71 6.30 6.6 6.67 6.56 6.81 
Windspeil 6.37 6.68 6.26 6.55 6.32 6.12 6.22 6.31 
Avg. d (pH) 6.45 6.63 6.24 6.4 6.47 6.27 6.43 6.52 
Avg. Adaptation 
Period ± SE = 
6.51 ± 0.19 
Avg. Antibiotic 
Challenge ± SE = 
6.37 ± 0.12 
Avg. Withdrawal 
Period ± SE = 
6.40 ± 0.16 
  
182 
 
Appendix Y: Fecal Dry Matter Raw Data 
 
 
 
Control – Fecal Dry Matter (DM %) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Sister 
Cashmere 
18.22 23.55 22.49 23.65 23.32 18.63 24.80 24.27 
Townsend 
Lad 
23.38 - 21.61 21.61 22.99 22.99 22.99 21.02 
Matty G 
Unit 
26.30 25.87 25.53 23.32 25.93 24.69 25.84 25.50 
T ‘s Lucky 
Deelite 
26.03 25.33 24.42 27.67 25.44 26.17 24.80 26.51 
Matty G 
Whiz 
20.90 23.92 23.87 23.96 22.66 22.51 24.77 24.30 
Smart 
Balance 
25.37 23.90 22.22 25.41 23.97 27.16 24.60 25.97 
Avg. d 
 (DM %) 
23.36 24.51 23.36 24.27 24.05 23.69 24.63 24.59 
Avg. Adaptation 
Period ± SE = 
23.84 ± 
0.82 
Avg. Antibiotic 
Challenge ± SE = 
23.89 ± 
0.54 
Avg. Withdrawal 
Period ± SE = 
24.30 ± 
0.66 
 
Sodium Ceftiofur – Fecal Dry Matter (DM %) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Show Me 
the Lillies 
20.36 21.67 21.18 25.26 23.87 24.19 24.30 23.28 
Downtown 
Leroy 
25.74 - 27.64 27.43 23.84 25.81 23.84 27.36 
R s  ‘s Ex 22.53 22.21 19.74 19.79 21.59 18.49 18.88 19.48 
Menka 21.09 19.97 26.71 22.09 20.41 23.57 22.25 23.53 
Quick Flite 21.41 23.38 25.65 23.20 21.49 23.20 26.24 22.83 
Sister 
Cashmere 
21.69 19.44 23.56 20.65 23.73 23.17 20.44 17.06 
Avg. d 
(DM %) 
22.14 21.33 24.08 23.07 22.49 23.07 22.66 22.26 
Avg. Adaptation 
Period ± SE = 
22.10  ± 
0.80 
Avg. Antibiotic 
Challenge ± SE = 
23.21 ± 
0.78 
Avg. Withdrawal 
Period ± SE = 
22.66 ± 
1.05 
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Trimethoprim-sulfadiazine – Fecal Dry Matter (DM %) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Bingo Betty 25.46 23.07 21.78 21.85 23.84 25.38 22.10 25.47 
My Boy 
George 
26.70 - 27.18 26.60 27.32 - - - 
Friendly 
Fella 
23.91 23.50 19.93 21.78 23.33 22.20 24.32 22.30 
Tonosi 22.74 23.44 26.50 21.41 22.49 24.00 20.95 23.32 
Rancho 
Valencia 
26.04 23.15 25.28 23.64 21.36 24.20 22.53 25.17 
Windspeil 20.88 24.96 23.91 23.34 21.45 22.98 25.17 23.49 
Avg. d 
(DM %) 
24.29 23.62 24.09 23.10 23.30 23.75 23.01 23.95 
Avg. Adaptation 
Period ± SE = 
24.21 ± 
0.56 
Avg. Antibiotic 
Challenge ± SE = 
23.50 ± 
0.76 
Avg. Withdrawal 
Period ± SE = 
23.57 ± 
0.31 
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Appendix Z: In vitro Dry Matter Digestibility Analysis Raw Data 
 
Control – Alfalfa Cubes In vitro Dry Matter Digestibility (IVDMD %) 
 
 Adaptation (d) Antibiotic Challenge(d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Sister 
Cashmere 
75.63 76.51 69.09 21.31 44.95 73.89 65.23 75.36 
Townsend 
Lad 
65.68 40.46 41.85 56.51 82.91 - - - 
Matty G Unit 74.20 70.69 79.64 69.75 68.20 72.77 53.90 78.79 
T ‘s  u  y 
Deelite 
62.51 58.42 60.10 63.96 46.41 64.75 70.46 67.82 
Matty G 
Whiz 
69.80 59.26 51.59 61.45 51.38 59.42 65.08 63.41 
Smart 
Balance 
65.24 33.11 34.41 19.09 34.67 55.42 27.40 62.18 
Avg. d 
(IVDMD %) 
68.84 56.41 56.11 48.68 54.75 65.25 56.42 69.51 
Avg. Adaptation 
Period ± SE = 
65.32 
±4.13 
Avg. Antibiotic 
Challenge ± SE = 
57.94 
±4.44 
Avg. Withdrawal 
Period ± SE = 
67.57 
±1.84 
 
Sodium Ceftiofur – Alfalfa Cubes In vitro Dry Matter Digestibility (IVDMD %) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Show Me the 
Lillies 
75.03 84.29 55.20 64.24 59.09 76.43 66.71 82.82 
Downtown 
Leroy 
64.27 70.55 70.66 55.61 68.16 - - - 
R s  ‘s Ex 77.42 81.94 78.24 67.40 67.46 81.07 53.66 78.71 
Menka 56.09 49.13 47.24 63.76 50.94 63.40 35.35 64.71 
Quick Flite 64.02 61.19 66.95 54.24 56.01 70.39 68.95 66.03 
Sister 
Cashmere 
71.53 62.82 71.02 48.83 61.00 43.37 52.00 36.59 
Avg. d 
(IVDMD %) 
68.06 68.32 64.88 59.01 60.44 66.93 55.33 65.77 
Avg. Adaptation 
Period ± SE = 
68.39 
±4.02 
Avg. Antibiotic 
Challenge ± SE = 
61.68 
±2.61 
Avg. Withdrawal 
Period ± SE = 
67.35 
±2.97 
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Trimethoprim sulfadiazine – Alfalfa Cubes In vitro Dry Matter Digestibility (IVDMD %) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Bingo Betty 73.52 59.61 59.89 57.66 60.60 81.03 58.59 63.80 
My Boy 
George 
28.41 68.58 49.96 53.70 69.37 - - - 
Friendly 
Fella 
70.91 70.32 75.82 62.64 78.76 78.59 72.48 77.65 
Tonosi 64.95 67.46 75.68 69.83 49.97 65.60 55.65 64.71 
Rancho 
Valencia 
53.04 60.14 59.98 65.58 59.07 65.97 67.71 65.99 
Windspeil 71.71 59.04 64.75 56.28 55.80 55.73 47.33 55.87 
Avg. d 
(IVDMD %) 
60.42 64.19 64.35 60.95 62.26 69.38 60.35 65.60 
Avg. Adaptation 
Period ± SE = 
61.69 
±5.19 
Avg. Antibiotic 
Challenge ± SE = 
63.23 
±2.90 
Avg. Withdrawal 
Period ± SE = 
68.15 
±4.52 
 
Control – Orchard Grass In vitro Dry Matter Digestibility (IVDMD %) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Sister 
Cashmere 
43.64 62.65 49.69 45.04 35.05 59.81 58.64 59.38 
Townsend 
Lad 
57.51 39.03 14.78 45.90 64.41 - - - 
Matty G Unit 55.73 57.28 60.96 51.21 56.88 53.23 51.74 56.45 
T ‘s  u  y 
Deelite 
52.15 52.80 50.72 56.15 37.50 46.62 53.90 45.80 
Matty G 
Whiz 
54.56 49.15 34.99 44.52 40.15 40.30 51.87 36.63 
Smart 
Balance 
49.36 26.11 19.26 27.17 38.45 33.63 22.62 51.60 
Avg. d 
(IVDMD %) 
52.16 47.84 38.40 45.00 45.41 46.72 47.76 49.97 
Avg. Adaptation 
Period ± SE = 
52.45 
±1.32 
Avg. Antibiotic 
Challenge ± SE = 
45.86 
±1.34 
Avg. Withdrawal 
Period ± SE = 
51.20 
±3.49 
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Sodium Ceftiofur – Orchard Grass In vitro Dry Matter Digestibility (IVDMD %) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Show Me the 
Lillies 
62.14 68.13 39.95 51.46 45.26 59.52 40.90 65.34 
Downtown 
Leroy 
48.07 55.83 57.10 46.93 48.72 - - - 
R s  ‘s Ex 63.61 63.21 62.71 50.71 62.01 59.58 59.57 60.30 
Menka 45.01 52.38 29.81 51.69 43.03 55.17 42.25 55.04 
Quick Flite 49.43 50.97 44.36 39.24 49.66 50.57 35.43 42.29 
Sister 
Cashmere 
58.95 51.50 45.48 36.35 51.28 30.82 43.60 49.79 
Avg. d 
(IVDMD %) 
54.53 57.00 46.57 46.06 49.99 51.13 44.35 54.55 
Avg. Adaptation 
Period ± SE = 
55.88 
±3.48 
Avg. Antibiotic 
Challenge ± SE = 
48.18 
±2.99 
Avg. Withdrawal 
Period ± SE = 
52.16 
±3.64 
 
Trimethoprim sulfadiazine – Orchard Grass In vitro Dry Matter Digestibility (IVDMD %) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Bingo Betty 50.83 47.55 43.77 38.39 35.81 61.30 46.10 45.34 
My Boy 
George 
40.14 53.62 33.50 54.51 56.07 - - - 
Friendly 
Fella 
58.29 57.75 56.34 57.74 60.17 61.76 52.64 56.90 
Tonosi 53.12 52.47 46.07 49.93 40.49 45.80 39.39 51.66 
Rancho 
Valencia 
38.50 38.90 40.19 45.75 38.86 52.14 47.53 45.62 
Windspeil 56.09 41.87 49.55 48.14 47.56 47.23 29.35 38.25 
Avg. d 
(IVDMD %) 
49.49 48.69 44.90 49.08 46.49 53.65 43.00 47.55 
Avg. Adaptation 
Period ± SE = 
49.12 
±3.21 
Avg. Antibiotic 
Challenge ± SE = 
46.51 
±3.36 
Avg. Withdrawal 
Period ± SE = 
50.52 
±2.45 
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Control – Tall Fescue In vitro Dry Matter Digestibility (IVDMD %) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Sister 
Cashmere 
40.17 21.18 42.74 25.57 35.04 37.54 44.91 46.86 
Townsend 
Lad 
41.81 43.49 43.85 45.16 45.34 - - - 
Matty G Unit 46.78 45.46 44.51 34.56 46.85 33.85 30.10 36.63 
T ‘s  u  y 
Deelite 
42.92 36.71 43.70 35.09 42.41 35.69 37.50 41.74 
Matty G 
Whiz 
30.63 30.53 28.36 31.50 18.27 25.75 33.92 27.07 
Smart 
Balance 
29.31 22.00 4.46 -0.72 12.65 21.72 9.03 30.35 
Avg. d 
(IVDMD %) 
38.60 33.23 34.60 28.53 33.43 30.91 31.09 36.53 
Avg. Adaptation 
Period ± SE = 
37.97 
±3.16 
Avg. Antibiotic 
Challenge ± SE = 
37.53 
±3.33 
Avg. Withdrawal 
Period ± SE = 
35.96 
±3.06 
 
Sodium Ceftiofur – Tall Fescue In vitro Dry Matter Digestibility (IVDMD %) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Show Me the 
Lillies 
43.23 54.37 29.18 23.13 30.27 36.90 31.41 44.82 
Downtown 
Leroy 
40.58 41.51 40.85 32.50 35.13 - - - 
R s  ‘s Ex 51.14 48.51 49.32 38.18 44.96 45.98 53.29 44.40 
Menka 33.12 40.19 27.73 38.22 34.19 37.52 14.83 31.52 
Quick Flite 33.19 41.88 21.64 22.03 33.38 31.29 24.96 29.60 
Sister 
Cashmere 
42.91 37.80 24.66 21.00 31.65 20.73 29.94 25.34 
Avg. d 
(IVDMD %) 
40.69 44.04 32.23 29.18 34.93 34.48 30.89 35.14 
Avg. Adaptation 
Period ± SE = 
42.77 
±2.77 
Avg. Antibiotic 
Challenge ± SE = 
33.38 
±3.30 
Avg. Withdrawal 
Period ± SE = 
35.54 
±4.68 
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Trimethoprim-sulfadiazine – Tall Fescue In vitro Dry Matter Digestibility (IVDMD %) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Bingo Betty 39.12 37.15 30.47 21.47 24.23 40.18 33.77 29.68 
My Boy 
George 
33.85 40.06 38.87 35.42 41.31 - - - 
Friendly 
Fella 
42.25 39.95 43.51 38.91 47.20 46.08 46.44 43.23 
Tonosi 38.41 39.05 37.62 31.93 37.58 43.13 40.10 36.46 
Rancho 
Valencia 
24.39 25.44 23.54 26.22 36.49 40.03 37.74 31.93 
Windspeil 44.30 27.00 32.02 26.86 28.42 39.38 17.24 31.40 
Avg. d 
(IVDMD %) 
37.05 34.77 34.34 30.14 35.87 41.76 35.06 34.54 
Avg. Adaptation 
Period ± SE = 
35.97 
±2.85 
Avg. Antibiotic 
Challenge ± SE = 
34.32 
±3.23 
Avg. Withdrawal 
Period ± SE = 
39.06 
±2.34 
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Appendix AA: In vitro Gas Production Raw Data 
 
 
 
Sodium Ceftiofur – In vitro Gas Production (mL gas / gram of substrate) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Show Me the 
Lillies 
- - - - - - - - 
Downtown 
Leroy 
43.25 - 44.36 41.53 37.88 48.59 47.07 51.97 
R s  ‘s Ex 54.67 52.47 - 50.43 54.48 50.82 48.50 52.29 
Menka 46.34 45.07 44.68 46.97 46.57 44.61 45.27 44.20 
Quick Flite 45.62 44.86 46.14 41.66 49.24 46.09 44.80 40.94 
Sister 
Cashmere 
47.66 46.52 48.72 43.82 48.58 47.14 47.69 46.13 
Avg. d 
(mL/g) 
47.51 47.23 45.98 44.88 47.35 47.45 46.67 47.11 
Avg. Adaptation 
Period ± SE = 
46.97 ± 
1.25 
Avg. Antibiotic 
Challenge ± SE = 
46.07 ± 
1.13 
Avg. Withdrawal 
Period ± SE = 
47.07 ± 
0.79 
 
Control – In vitro Gas Production (mL gas / gram of substrate) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Sister 
Cashmere 
- - - - - - - - 
Townsend 
Lad 
50.32 - 49.63 51.67 48.98 51.34 50.87 52.58 
Matty G Unit 51.23 43.23 - 50.34 44.97 47.34 51.25 45.70 
T ‘s  u  y 
Deelite 
41.41 31.28 42.30 37.76 34.74 35.86 41.42 29.60 
Matty G 
Whiz 
47.1 41.46 46.85 48.91 46.04 42.42 42.71 43.20 
Smart 
Balance 
42.57 41.95 49.81 36.34 41.62 44.00 41.06 38.16 
Avg. d 
(mL/g) 
46.53 39.48 47.15 45.00  43.27 44.19 45.46 41.85 
Avg. Adaptation 
Period ± SE = 
44.09 ± 
1.97 
Avg. Antibiotic 
Challenge ± SE = 
45.14 ± 
1.49 
Avg. Withdrawal 
Period ± SE = 
43.83 ± 
1.65 
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Trimethoprim-sulfadiazine – In vitro Gas Production (mL gas / gram of substrate) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 3 6 8 10 13 
Bingo Betty - - - - - - - - 
My Boy 
George 
53.71 - 48.26 40.04 53.03 - - - 
Friendly 
Fella 
54.30 55.07 - 52.23 54.09 53.50 51.79 54.14 
Tonosi 45.42 46.04 32.33 44.91 39.81 52.10 43.74 42.36 
Rancho 
Valencia 
37.62 43.71 37.02 43.58 47.56 44.74 44.95 44.76 
Windspeil 53.20 41.06 49.25 38.39 51.11 45.91 42.63 44.37 
Avg. d 
(mL/g) 
48.85 46.47 41.72 43.83 49.12 49.06 45.78 46.41 
Avg. Adaptation 
Period ± SE = 
48.70 ± 
2.15 
Avg. Antibiotic 
Challenge ± SE = 
44.89 ± 
1.81 
Avg. Withdrawal 
Period ± SE = 
47.08 ± 
1.28 
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Appendix BB: Volatile Fatty Acid Concentrations Raw Data 
 
Control -  Acetic Acid (mM; DM Basis) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 6 13 
Sister Cashmere 
 
258.02 
 
186.84 124.52 128.65 107.13 
Townsend Lad 
 
76.99 
 
- 249.91 226.16 271.16 
Matty G Unit 
 
125.50 
 
146.89 148.84 53.99 90.20 
T ‘s  u  y      t  
 
88.38 
 
118.44 114.66 70.77 94.30 
Matty G Whiz 
 
100.49 
 
112.90 121.51 92.67 98.78 
Smart Balance 
 
82.78 
 
117.15 126.01 237.80 177.13 
Avg. d 
(mM) 
 
122.03 
 
136.44 147.58 135.01 139.78 
 
 
Sodium ceftiofur -  Acetic Acid (mM; DM Basis) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 6 13 
Show Me the Lillies 
 
147.33 
 
119.98 80.25 108.92 94.50 
Downtown Leroy 
 
81.59 
 
- 126.61 197.11 230.28 
R s  ‘s Ex 
 
306.26 
 
189.15 116.54 240.91 323.49 
Menka 
 
80.63 
 
160.24 74.89 151.92 170.00 
Quick Flite 
 
126.11 
 
77.00 97.45 93.06 127.02 
Sister Cashmere 
 
133.70 
 
164.63 182.50 139.06 181.69 
Avg. d 
(mM) 
 
145.94 
 
142.20 113.04 155.16 187.83 
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Trimethoprim-sulfadiazine  -  Acetic Acid (mM; DM Basis) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 6 13 
Bingo Betty 
 
90.34 
 
125.71 59.70 176.19 157.07 
My Boy George 
 
56.18 
 
- 128.76 113.49 - 
Friendly Fella 
 
150.60 
 
106.41 366.37 124.33 246.69 
Tonosi 
 
109.96 
 
183.45 117.00 226.77 154.41 
Rancho Valencia 
 
76.80 
 
69.10 94.94 140.44 59.59 
Windspeil 
 
81.40 
 
212.37 158.95 130.53 195.87 
Avg. d 
(mM) 
 
94.21 
 
139.41 154.29 151.96 162.73 
 
Control -  Propionic Acid (mM; DM Basis) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 6 13 
Sister Cashmere 
 
45.02 
 
46.71 24.46 42.88 37.91 
Townsend Lad 
 
21.81 
 
- 37.95 29.14 35.20 
Matty G Unit 
 
25.48 
 
31.70 23.11 11.96 12.16 
T ‘s  u  y      t  
 
19.60 
 
26.45 14.33 16.91 14.71 
Matty G Whiz 
 
16.75 
 
14.63 24.72 18.97 17.70 
Smart Balance 
 
15.37 
 
30.96 22.95 12.93 25.80 
Avg. d 
(mM) 
 
24.01 
 
30.09 24.59 22.13 23.91 
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Sodium ceftiofur -  Propionic Acid (mM; DM Basis) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 6 13 
Show Me the Lillies 
 
40.27 
 
59.99 20.30 46.08 42.95 
Downtown Leroy 
 
31.86 
 
- 26.77 46.13 43.86 
R s  ‘s Ex 
 
48.82 
 
36.93 26.86 37.99 46.21 
Menka 
 
12.81 
 
15.52 10.11 28.91 28.47 
Quick Flite 
 
23.82 
 
14.97 13.64 16.29 15.33 
Sister Cashmere 
 
27.20 
 
28.30 28.44 19.81 25.20 
Avg. d 
(mM) 
 
30.80 
 
31.14 21.02 32.54 33.67 
 
Trimethoprim-sulfadiazine  -  Propionic Acid (mM; DM Basis) 
 
 Adaptation (d) Antibiotic Challenge  (d) Withdrawal (d) 
Horse -4 -1 1 6 13 
Bingo Betty 
 
36.92 
 
47.68 12.40 41.95 51.05 
My Boy George 
 
20.60 
 
- 24.65 24.53 - 
Friendly Fella 
 
17.99 
 
21.71 45.17 15.01 40.37 
Tonosi 
 
22.43 
 
23.46 19.25 32.90 23.59 
Rancho Valencia 
 
18.05 
 
16.84 18.59 16.38 17.08 
Windspeil 
 
14.84 
 
26.85 23.01 18.18 14.90 
Avg. d 
(mM) 
 
21.81 
 
27.31 23.85 24.83 29.40 
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Control -  Butyric Acid (mM; DM Basis) 
 
 Adaptation (d) Antibiotic Challenge  (d) Withdrawal (d) 
Horse -4 -1 1 6 13 
Sister Cashmere 
 
18.66 
 
19.53 11.56 15.87 12.36 
Townsend Lad 
 
11.12 
 
- 24.99 14.79 22.83 
Matty G Unit 
 
11.79 
 
14.30 12.14 7.71 5.10 
T ‘s  u  y      t  
 
6.53 
 
6.71 4.91 2.36 7.17 
Matty G Whiz 
 
6.70 
 
9.20 10.89 8.83 8.64 
Smart Balance 
 
5.12 
 
10.88 13.95 6.26 18.48 
Avg. d 
(mM) 
 
9.99 
 
12.12 13.07 9.30 12.43 
 
Sodium ceftiofur -  Butyric Acid (mM; DM Basis) 
 
 Adaptation (d) Antibiotic Challenge  (d) Withdrawal (d) 
Horse -4 -1 1 6 13 
Show Me the 
Lillies 
 
21.12 
 
22.61 9.44 18.85 16.75 
Downtown Leroy 
 
16.71 
 
- 13.38 27.26 21.93 
R s  ‘s Ex 
 
31.51 
 
27.02 13.17 27.80 39.54 
Menka 
 
6.64 
 
8.51 4.12 10.78 13.17 
Quick Flite 
 
10.74 
 
5.56 5.46 6.51 4.82 
Sister Cashmere 
 
8.76 
 
9.26 13.16 9.27 8.79 
Avg. d 
(mM) 
 
15.91 
 
14.59 9.79 16.75 17.50 
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Trimethoprim-sulfadiazine  -  Butyric Acid (mM; DM Basis) 
 
 Adaptation (d) Antibiotic Challenge  (d) Withdrawal (d) 
Horse -4 -1 1 6 13 
Bingo Betty 
 
12.18 
 
22.54 11.94 16.78 27.09 
My Boy George 
 
13.86 
 
- 15.82 11.35 - 
Friendly Fella 
 
10.88 
 
11.92 30.11 7.29 24.22 
Tonosi 
 
13.64 
 
14.51 8.68 19.12 17.16 
Rancho Valencia 
 
5.76 
 
4.75 5.14 7.49 5.16 
Windspeil 
 
5.75 
 
11.22 10.04 8.39 4.26 
Avg. d 
(mM) 
 
10.35 
 
12.99 13.62 11.74 15.58 
 
Control -  Phenylacetic Acid (mM; DM Basis) 
 
 Adaptation (d) Antibiotic Challenge  (d) Withdrawal (d) 
Horse -4 -1 1 6 13 
Sister Cashmere 
 
0 
 
2.55 10.67 3.43 2.47 
Townsend Lad 
 
10.69 
 
- 12.03 11.31 13.80 
Matty G Unit 
 
10.27 
 
10.44 10.58 9.64 10.20 
T ‘s  u  y      t  
 
8.84 
 
8.69 0 0 9.05 
Matty G Whiz 
 
11.01 
 
10.04 10.48 0 0 
Smart Balance 
 
0 
 
0 0 0 10.78 
Avg. d 
(mM) 
 
6.80 
 
6.34 7.29 4.06 7.72 
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Sodium ceftiofur -  Phenylacetic Acid (mM; DM Basis) 
 
 Adaptation (d) Antibiotic Challenge  (d) Withdrawal (d) 
Horse -4 -1 1 6 13 
Show Me the Lillies 
 
25.54 
 
3.69 10.86 2.51 1.72 
Downtown Leroy 
 
9.32 
 
- 0 10.48 10.23 
R s  ‘s Ex 
 
13.76 
 
12.61 0 13.43 14.38 
Menka 
 
0 
 
11.52 0 11.76 10.62 
Quick Flite 
 
11.68 
 
0 0 0 0 
Sister Cashmere 
 
0 
 
13.38 15.70 13.06 0 
Avg. d 
(mM) 
 
10.05 
 
8.24 4.43 8.54 6.16 
 
Trimethoprim-sulfadiazine  -  Phenylacetic Acid (mM; DM Basis) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 6 13 
Bingo Betty 
 
0 
 
1.30 0 2.94 2.36 
My Boy George 
 
8.99 
 
- 9.20 9.15 - 
Friendly Fella 
 
10.04 
 
10.21 15.56 10.29 22.43 
Tonosi 
 
10.56 
 
11.09 0 11.56 10.72 
Rancho Valencia 
 
0 
 
0 0 11.23 0 
Windspeil 
 
0 
 
10.02 11.29 0 0 
Avg. d 
(mM) 
 
4.93 
 
6.52 6.01 7.53 7.10 
  
197 
 
 
 
 
 
 
 
 
Control -  Total Volatile Fatty Acids (mM; DM Basis) 
 
 Adaptation (d) Antibiotic Challenge  (d) Withdrawal (d) 
Horse -4 -1 1 6 13 
Sister Cashmere 
 
321.70 
 
255.63 171.21 190.84 159.88 
Townsend Lad 
 
120.62 
 
- 324.89 281.40 343.00 
Matty G Unit 
 
173.04 
 
203.32 194.67 83.30 117.65 
T ‘s  u  y      t  
 
123.34 
 
160.28 133.91 90.03 125.24 
Matty G Whiz 
 
134.94 
 
146.76 167.60 120.47 125.13 
Smart Balance 
 
103.27 
 
159.00 162.92 256.99 232.19 
Avg. d 
(mM) 
 
162.82 
 
185.00 192.53 170.51 183.85 
 
Sodium ceftiofur -  Total Volatile Fatty Acids (mM; DM Basis) 
 
 Adaptation (d) Antibiotic Challenge  (d) Withdrawal (d) 
Horse -4 -1 1 6 13 
Show Me the Lillies 
 
234.25 
 
206.28 120.84 176.36 155.92 
Downtown Leroy 
 
139.48 
 
- 166.76 280.99 306.31 
R s  ‘s Ex 
 
400.36 
 
265.71 156.57 320.13 423.62 
Menka 
 
100.07 
 
195.79 89.12 203.38 222.27 
Quick Flite 
 
172.34 
 
97.54 116.55 115.86 147.17 
Sister Cashmere 
 
169.66 
 
215.56 239.79 181.20 215.69 
Avg. d 
(mM) 
 
206.03 
 
196.18 148.27 212.99 245.16 
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Trimethoprim-sulfadiazine  -  Total Volatile Fatty Acids (mM; DM Basis) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 6 13 
Bingo Betty 
 
139.44 
 
197.24 84.04 237.86 237.56 
My Boy George 
 
99.62 
 
- 178.42 158.52 - 
Friendly Fella 
 
189.50 
 
150.24 457.21 156.91 333.71 
Tonosi 
 
156.59 
 
232.51 144.93 290.35 205.88 
Rancho Valencia 
 
100.61 
 
90.70 118.67 175.54 81.84 
Windspeil 
 
101.99 
 
260.45 203.29 157.10 215.03 
Avg. d 
(mM) 
 
131.29 
 
186.23 197.76 196.05 214.80 
 
Control -  Acetate : Propionate Ratio (mM; DM Basis) 
 
 Adaptation (d) Antibiotic Challenge  (d) Withdrawal (d) 
Horse -4 -1 1 6 13 
Sister Cashmere 
 
5.73 
 
4 5.09 3 2.83 
Townsend Lad 
 
3.53 
 
- 6.59 7.76 7.70 
Matty G Unit 
 
4.93 
 
4.63 6.44 4.52 7.42 
T ‘s  u  y      t  
 
4.51 
 
4.48 8 4.19 6.41 
Matty G Whiz 
 
6 
 
7.71 4.92 4.88 5.58 
Smart Balance 
 
5.38 
 
3.78 5.49 18.39 6.87 
Avg. d 
(mM) 
 
5.01 
 
4.92 6.09 7.12 6.14 
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Sodium ceftiofur -  Acetate : Propionate Ratio (mM; DM Basis) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 6 13 
Show Me the 
Lillies 
 
3.66 
 
2 3.95 2.36 2.2 
Downtown Leroy 
 
2.56 
 
- 4.73 4.27 5.25 
R s  ‘s Ex 
 
6.27 
 
5.12 4.34 6.34 7 
Menka 
 
6.30 
 
10.32 7.41 5.25 5.97 
Quick Flite 
 
5.29 
 
5.14 7.14 5.71 8.29 
Sister Cashmere 
 
4.92 
 
5.82 6.42 7.02 7.21 
Avg. d 
(mM) 
 
4.83 
 
5.68 5.67 5.16 5.99 
 
Trimethoprim-sulfadiazine  -  Acetate : Propionate Ratio (mM; DM Basis) 
 
 Adaptation (d) Antibiotic Challenge (d) Withdrawal (d) 
Horse -4 -1 1 6 13 
Bingo Betty 
 
2.45 
 
2.64 4.81 4.20 3.08 
My Boy George 
 
2.73 
 
- 5.22 4.63 - 
Friendly Fella 
 
8.37 
 
4.90 8.11 8.29 6.11 
Tonosi 
 
4.90 
 
7.82 6.08 6.89 6.55 
Rancho Valencia 
 
4.26 
 
4.10 5.11 8.57 3.49 
Windspeil 
 
5.48 
 
7.91 6.91 7.18 13.14 
Avg. d 
(mM) 
 
4.70 
 
5.47 6.04 6.63 6.47 
  
 
2
0
0
 
Appendix CC: PCR-DGGE Raw Data 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Control - PCR-DGGE Dice’s Analysis Percent Similarities  (sample day vs. .sample day) 
 
Horse -4 vs.-1 -4 vs. 1 -4 vs. 6 .4 vs.13 -1 vs. 1 -1 vs. 6 -1 vs. 13 1 vs. 6 1 vs. 13 6 vs. 13 
Sister Cashmere 
 
47.1 
 
54.1 59.3 52.6 56.5 79.4 75.8 53.1 53.8 84.1 
Townsend Lad 
 
73.1 
 
62.9 64.2 36.8 63.6 71.7 42.1 70.4 35.7 46.2 
Matty G Unit 
 
57.1 
 
59.5 44.4 64.3 59.5 62.5 57.7 51.6 62.7 43.5 
T ‘s  u  y 
Deelite 
 
59.5 
 
50 61.9 51.2 71.7 62.7 57.7 62.7 61.2 55.3 
Matty G Whiz 
 
55.6 
 
52.8 63.5 42.9 59.7 65.7 47.8 66.7 53.3 50.9 
Smart Balance 
 
72.1 
 
65.4 60.9 74.2 69.1 61.2 76.9 75 61.5 60 
Avg,. % 
Similarity 
(% ± SE) 
 
60.75 ± 4.12 
 
57.45 ± 2.49 59.03 ± 3.01 53.67 ± 5.60 63.35 ± 2.44 67.2 ± 2.88 59.67 ± 5.81 63.25 ± 3.83 54.7 ± 4.15 56.67 ± 6.00 
  
 
2
0
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sodium Ceftiofur - PCR-DGGE Dice’s Analysis Percent Similarities  (sample day vs. .sample day) 
 
Horse -4 vs.-1 -4 vs. 1 -4 vs. 6 .4 vs.13 -1 vs. 1 -1 vs. 6 -1 vs. 13 1 vs. 6 1 vs. 13 6 vs. 13 
Show Me the 
Lillies 
 
58.6 
 
65.5 65.6 71.4 62.5 66.7 52.2 78.4 56.5 53.1 
Downtown Leroy 
 
53.7 
 
40 25.6 44.4 60 70.4 73.3 54.2 55.6 65.5 
R s  ‘s Ex 
 
63.2 
 
75.8 68.9 60 71.6 64.5 62.3 78.9 65.7 58.5 
Menka 
 
64.9 
 
39.1 50 61.5 35.6 57.1 70.6 63.6 60 48 
Quick Flite 
 
45.5 
 
41 54.5 35.9 71.1 62.5 62.2 46.5 55 60.5 
Sister Cashmere 
 
56. 
 
47.1 58.8 58.8 67.8 74.6 61 70 70 70 
Avg,. % 
Similarity 
(% ± SE) 
 
 
56.98 ± 2.87 
 
 
51.42 ± 6.33 53.9 ± 6.33 55.33 ± 5.25 61.43 ± 5.50 65.97 ± 2.50 63.6 ± 3.07 65.27 ± 5.35 60.47 ± 2.50 59.27 ± 3.27 
  
 
2
0
2
 
 
 
 
 
Trimethoprim-sulfadiazine - PCR-DGGE Dice’s Analysis Percent Similarities  (sample day vs. .sample day) 
 
Horse -4 vs.-1 -4 vs. 1 -4 vs. 6 .4 vs.13 -1 vs. 1 -1 vs. 6 -1 vs. 13 1 vs. 6 1 vs. 13 6 vs. 13 
Bingo Betty 
 
50.6 
 
49 56.6 50 62.1 61.3 62.3 71.9 66.7 71.6 
My Boy 
George 
 
54.1 
 
42.1 44.4 - 59.5 68.6 - 50 - - 
Friendly Fella 
 
34 
 
38.5 37.8 40 45.3 59.4 59.7 55.8 50 51.1 
Tonosi 
 
70 
 
65.6 72.2 65.7 64.3 62.5 67.8 70.6 66.7 84.5 
Rancho 
Valencia 
 
68 
 
59.1 56.4 65.5 60.4 68.1 64.4 69.6 72.4 57.7 
Windspeil 
 
60.9 
 
59.1 51.2 54.2 75 69.1 73.3 64.2 75.9 70.2 
Avg,. % 
Similarity 
(% ± SE) 
 
 
56.27 ± 5.42 
 
 
52.23 ± 4.38 53.1 ± 4.84 55.08 ± 4.88 61.1 ± 3.90 64.83 ± 1.74 65.5 ± 2.36 63.68 ± 3.65 66.34 ± 4.45 67.02 ± 5.82 
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